<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Mol Biomed</journal-id><journal-id journal-id-type="iso-abbrev">Mol Biomed</journal-id><journal-title-group><journal-title>Molecular Biomedicine</journal-title></journal-title-group><issn pub-type="epub">2662-8651</issn><publisher><publisher-name>Springer Nature Singapore</publisher-name><publisher-loc>Singapore</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39998776</article-id><article-id pub-id-type="pmc">PMC11861501</article-id>
<article-id pub-id-type="publisher-id">251</article-id><article-id pub-id-type="doi">10.1186/s43556-025-00251-0</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Cancer brain metastasis: molecular mechanisms and therapeutic strategies</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Lu</surname><given-names>Yu</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Huang</surname><given-names>Yunhang</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Zhu</surname><given-names>Chenyan</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Zhidan</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Bin</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Sheng</surname><given-names>Hui</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Haotai</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Xixi</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Xu</surname><given-names>Zhongwen</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Wen</surname><given-names>Yi</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Jing</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0009-0002-0730-6291</contrib-id><name><surname>Zhang</surname><given-names>Liguo</given-names></name><address><email>liguozhang2021@scu.edu.cn</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/007mrxy13</institution-id><institution-id institution-id-type="GRID">grid.412901.f</institution-id><institution-id institution-id-type="ISNI">0000 0004 1770 1022</institution-id><institution>Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, </institution><institution>West China Hospital, Sichuan University, </institution></institution-wrap>Chengdu, 610041 China </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00726et14</institution-id><institution-id institution-id-type="GRID">grid.461863.e</institution-id><institution-id institution-id-type="ISNI">0000 0004 1757 9397</institution-id><institution>Center for Translational Medicine, Key Laboratory of Birth Defects and Related Disease of Women and Children of MOE, </institution><institution>West China Second University Hospital, Sichuan University, </institution></institution-wrap>Chengdu, 610041 China </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/007mrxy13</institution-id><institution-id institution-id-type="GRID">grid.412901.f</institution-id><institution-id institution-id-type="ISNI">0000 0004 1770 1022</institution-id><institution>Department of Neurosurgery, </institution><institution>West China Hospital, Sichuan University, </institution></institution-wrap>Chengdu, 610041 China </aff></contrib-group><pub-date pub-type="epub"><day>25</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>25</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2025</year></pub-date><volume>6</volume><elocation-id>12</elocation-id><history><date date-type="received"><day>18</day><month>9</month><year>2024</year></date><date date-type="rev-recd"><day>6</day><month>1</month><year>2025</year></date><date date-type="accepted"><day>6</day><month>2</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><p id="Par1">Brain metastases (BMs) are the most common intracranial tumors in adults and the major cause of cancer-related morbidity and mortality. The occurrence of BMs varies according to the type of primary tumors with most frequence in lung cancer, melanoma and breast cancer. Among of them, lung cancer has been reported to have a higher risk of BMs than other types of cancers with 40&#x02009;~&#x02009;50% of such patients will develop BMs during the course of disease. BMs lead to many neurological complications and result in a poor quality of life and short life span. Although the treatment strategies were improved for brain tumors in the past decades, the prognosis of BMs patients is grim. Poorly understanding of the molecular and cellular characteristics of BMs and the complicated interaction with brain microenvironment are the major reasons for the dismal prognosis of BM patients. Recent studies have enhanced understanding of the mechanisms of BMs. The newly identified potential therapeutic targets and the advanced therapeutic strategies have brought light for a better cure of BMs. In this review, we summarized the mechanisms of BMs during the metastatic course, the molecular and cellular landscapes of BMs, and the advances of novel drug delivery systems for overcoming the obstruction of blood&#x02013;brain barrier (BBB). We further discussed the challenges of the emerging therapeutic strategies, such as synergistic approach of combining targeted therapy with immunotherapy, which will provide vital clues for realizing the precise and personalized medicine for BM patients in the future.</p></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Brain metastasis</kwd><kwd>Lung cancer</kwd><kwd>Therapy</kwd><kwd>Prognosis</kwd><kwd>Blood&#x02013;brain barrier</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source><award-id>82273012</award-id><award-id>82472674</award-id><principal-award-recipient><name><surname>Zhang</surname><given-names>Liguo</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution>1&#x000b7;3&#x000b7;5 project for disciplines of excellence, West China Hospital, Sichuan University</institution></funding-source><award-id>ZYYC22003</award-id><principal-award-recipient><name><surname>Zhang</surname><given-names>Liguo</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Sichuan International Medical Exchange &#x00026; Promotion Association 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par82">Brain metastases (BMs) are the most common intracranial tumors, which exhibit more than ten times of incidence than that of primary brain tumors [<xref ref-type="bibr" rid="CR1">1</xref>]. Around 20% of cancer patients will develop BMs with lung cancer is the most frequent tumor type that metastasizes to brain [<xref ref-type="bibr" rid="CR2">2</xref>]. Almost half of lung cancer develop into BMs, followed by breast cancer (20%) and melanoma (15%) [<xref ref-type="bibr" rid="CR3">3</xref>]. Lung cancer is divided into non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) based on the histopathology [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>]. Among NSCLC patients, lung adenocarcinoma (LUAD,&#x02009;~&#x02009;58.6%) and large cell carcinoma (~&#x02009;17.7%) carry a higher frequency for BMs compared to squamous cell carcinoma (~&#x02009;9.9%) [<xref ref-type="bibr" rid="CR5">5</xref>]. For SCLC, approximately 10% of patients have BMs at the time of diagnosis and 40&#x02013;50% will develop BMs during the course of disease [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref>]. Lung cancer brain metastasis (LCBM) frequently occurs in patients with advanced stage and leads to poor overall survival (OS) [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>].</p><p id="Par83">&#x0201c;Seed and soil&#x0201d; hypothesis posits that BMs are resulted from the interaction between disseminated cancer cells (DCCs) and brain microenvironment. Tumor cells disseminate from primary lung cancer, enter the blood circulation system and become the circulating tumor cells (CTCs). After spreading throughout the circulatory system to the brain microvasculature, CTCs extravasate the BBB and locate into brain, where it is a complex organ and favorable soil for DCCs. To successfully outgrow in brain, DCCs interact with brain resident cellular and acellular components to adapt the brain microenvironment. Brain resident cells include neurons, astrocytes, oligodendrocytes, immune cells and vascular-related cells. Of note, the blood&#x02013;brain barrier (BBB), composed of endothelial cells, pericytes and astrocyte endfeets, presents a formidable structure for tumor cells to penetrate. Once formation of BMs, blood-tumor barrier (BTB) gradually replaces the BBB, exhibiting different permeability and characteristics [<xref ref-type="bibr" rid="CR10">10</xref>]. The distinctive microenvironment of brain contains resident cell populations, structural composition, and immune processes [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR12">12</xref>], which means that cancer cells seeding into the brain need possess the capacities to not only penetrate the BBB but also to survive and proliferate in the metastatic niche. Gain of unique driver mutations and metabolic reprogramming are critical for BM tumor cells to adapt the brain microenvironment. Current therapeutic approaches of BMs include surgical resection, radiotherapy, targeted therapy, immunotherapy or a combination of several modalities [<xref ref-type="bibr" rid="CR13">13</xref>&#x02013;<xref ref-type="bibr" rid="CR15">15</xref>]. Although systemic therapies exhibit promising effects for BMs treatment, the impermeable property of BBB limits the transport of therapeutic agents to the brain, making systemic therapies less effective in treating BMs than in treating other types of cancers. Current biomaterial-based nanodrugs have been developed and applied in preclinical studies and clinical trials of cancer immunotherapies to overcome the obstruction of BBB.</p><p id="Par84">BM patients exhibit significant neurological complications, resulting in a poor quality of life and short life span. Despite undergoing rough treatment, BM patients still exhibit very grim prognosis. Therefore, understanding the underlying mechanisms of BMs is an urgent need to develop effective therapeutic strategies. Recent studies have enhanced understanding of the mechanisms of BMs. The newly identified potential therapeutic targets and the advanced therapeutic strategies have brought light for a better cure of BMs. In this review, we comprehensively described the major steps of metastatic spreading of cancer cells to brain and addressed the influence of brain microenvironment and the molecular determinants of progression. Furthermore, we summarized the current treatment approaches and discussed the challenges of the emerging therapeutic strategies that may improve the prognosis of BM patients.</p></sec><sec id="Sec2"><title>Molecular mechanisms of brain metastases</title><p id="Par85">Cancer BMs is complex and contains multiple steps, including epithelial-mesenchymal transition (EMT), detachment from the primary lung cancer, intravasation of blood vessels, hematogenous dissemination, penetrating the BBB, and finally adaption of brain microenvironment and colonization in the brain niche. Each step of BM is tightly regulated by crucial molecular and cellular mechanisms.</p><sec id="Sec3"><title>Tumor cell intravasation and extravasation</title><sec id="Sec4"><title>The role of EMT for brain metastases initiation and intravasation</title><p id="Par86">Detachment from primary tumor and intravasation of blood vessels is the first step of distal metastasis of cancer cells to the brain. The process is characterized by gain of EMT feature for cancer cells to break through the basement membrane at the primary tumor sites [<xref ref-type="bibr" rid="CR16">16</xref>&#x02013;<xref ref-type="bibr" rid="CR18">18</xref>]. Primary tumor cells are immotile and tightly bound to each other and to the neighboring extracellular matrix (ECM). EMT is the trans-differentiation process through which primary tumor cells can be transformed to develop the ability to detach from primary tumor and invade into surrounding tissues. EMT can drive tumor cell to gain a mesenchymal phenotype, 13 which is crucial for tumor progression and metastasis [<xref ref-type="bibr" rid="CR19">19</xref>].</p><p id="Par87">EMT in primary tumor cells shifts between different intermediate stages with different invasive, metastatic, and differentiation characteristics [<xref ref-type="bibr" rid="CR20">20</xref>]. These various stages possess diverse cellular characteristics, chromatin landscapes, and gene expression profiles that are regulated by distinct transcription factors and signaling pathways. EMT can be induced by activation of various growth factor receptor tyrosine kinases and cellular signaling pathways, including the TGF-&#x003b2;, Wnt and Notch pathways [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR22">22</xref>]. TWIST and SNAIL, the markers of EMT, are overexpressed in LCBM tumors [<xref ref-type="bibr" rid="CR8">8</xref>]. During the EMT process, LCBM cells exhibit high expression level of CD44 and stem cell-like properties. Driver mutations have been reported to enhance EMT transformation and contribute to the LCBM. EMT is often driven by transcription factors, which trend to repress epithelial genes and activate mesenchymal genes [<xref ref-type="bibr" rid="CR23">23</xref>]. Epigenetic and post-translational modulators also play a vital role in controlling the EMT process. Moreover, stromal cells within tumor microenvironments (TME) can induce EMT of tumor cells. It has been reported that metastatic tumor cells with mesenchymal phenotype usually proliferate near endothelial and inflammatory cells. Metastasis tumor cells release chemokines to attract immune cells and stimulate angiogenesis, thus promoting the development of a unique inflammatory and highly vascularized niche [<xref ref-type="bibr" rid="CR20">20</xref>]. Cancer-associated fibroblasts (CAFs) have been reported to enhance EMT and drive primary tumor cells migration [<xref ref-type="bibr" rid="CR24">24</xref>]. In addition, other TME factors, such as hypoxia, metabolic stressors, and matrix stiffness also could trigger the EMT process in primary tumor cells [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR26">26</xref>].</p></sec><sec id="Sec5"><title>Interactions with the vasculature and the blood&#x02013;brain barrier</title><p id="Par88">The BBB is a tight barrier structure between blood and brain tissue, which ensures the stability of brain microenvironment. BBB is composed of endothelial cells, pericytes and astrocyte endfeets and functions as a highly selective semipermeable border in brain to avoid the damage of biological agents and other risk factors [<xref ref-type="bibr" rid="CR27">27</xref>]. BBB destruction by tumor cells is a key step during the formation of BM, but the cellular and molecular mechanisms involved in lung cancer cells penetrating BBB have not been fully understood. BBB is the first obstacle for metastatic cancer cells to colonize in brain and limited information about CTCs extravasating BBB has been demonstrated (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). Due to the brain tumor burden, the tight junctions of BBB should be extended and the permeability of BBB increases at the site where CTCs extravasate into brain [<xref ref-type="bibr" rid="CR28">28</xref>].<fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>Molecular mechanisms of CTCs to penetrate the BBB during BM. Cancer cells expressed PLGF can active VEGFR1 and the downstream ROCK-ERK1/2 pathway and leads to the disassembly of the tight junction. Pathologically decrease of astrocyte-derived TGF&#x003b2;/bFGF can also disassemble the tight junction by downregulation of Nfsd2a. In additiona, lung cancer cell-derived Cd-pericytes enhance BM formation through GPR124-mediated TEM and L1CAM-YAP/MRTF pathway-mediated spreading along brain capillaries. The figure was generated using Biorender.com</p></caption><graphic xlink:href="43556_2025_251_Fig1_HTML" id="MO1"/></fig></p><p id="Par89">Disruption of BBB by cancer cells is linked to BM initiation and progression. However, the mechanisms of driving these events remain poorly understood. Li et al. have uncovered that SCLC patients with high levels of placental growth factor (PLGF) were prone to BM by promoting SCLC cell trans-endothelial migration (TEM) [<xref ref-type="bibr" rid="CR29">29</xref>]. PLGF derived from SCLC cells triggers VEGFR1-ROCK-ERK1/2 axis activation and leads to disassembly of tight junctions in BBB. Downregulation of PLGF suppresses SCLC cell metastasis to brain in an experimental BM model. Tiwary et al. have demonstrated that BBB was disrupted in BM by downregulation of major facilitator superfamily domain 2a (Mfsd2a), the endothelial cell-expressed docosahexaenoic acid (DHA) transporter [<xref ref-type="bibr" rid="CR30">30</xref>]. Pathologically diminished TGF&#x003b2; and bFGF pathways in endothelium cells leads to downregulation of Mfsd2a accompanied with reduced DHA transport and altered lipid metabolism, suggesting that restoring DHA metabolism may be a novel therapeutic strategy to block BM. Previous studies revealed that breast cancer cells dysregulated the action dynamics of brain endothelial cells and destructed BBB by releasing miRNA-181c-containing extracellular vesicles to facilitated BM of breast cancer [<xref ref-type="bibr" rid="CR31">31</xref>]. Whether the same mechanism occurs in lung cancer cells is needed to be further verified. It has been reported that dynamic extravasation of CTCs in the small holes of brain vascular wall was essential for LCBM [<xref ref-type="bibr" rid="CR32">32</xref>]. Another way of CTCs passing through the BBB may be by disrupting the endothelium to gain entry [<xref ref-type="bibr" rid="CR33">33</xref>]. Two studies performed by Er et al. and Huang et al. have highlighted the importance of pericyte-like spreading during extravasation and co-option with brain capillaries. Er et al. indicated that mechano-transduction signaling triggered by the pericyte-like spreading of DCCs on brain capillaries was critical for metastatic colonization [<xref ref-type="bibr" rid="CR34">34</xref>]. DCCs employed L1 cell adhesion molecule (L1CAM) to spread on capillaries and displaced resident pericytes. In addition, L1CAM activated mechano-transduction effectors YAP and MRTF by engaging &#x003b2;1 integrin and integrin-linked kinase to enhance the outgrowth of BM initiating cells both immediately following infiltration and after exiting from a period of latency. Huang et al. revealed that CD44<sup>+</sup> lung cancer stem cell-derived pericyte-like cells (Cd-pericytes) enhanced BM formation through GPR124-mediated TEM [<xref ref-type="bibr" rid="CR35">35</xref>]. Cd-pericytes exhibit remarkable TEM capacity to effectively intravasate into the vessel lumina, survive in the circulation, extravasate into the brain parenchyma, and then de-differentiate into cancer stem cells to form BM. Cd-pericytes expressed GPR124 mediates the activation of Wnt7b-catenin signaling to enhance TEM capacity for intravasation and extravasation, two critical steps during LCBM. Furthermore, selective disruption of Cd-pericytes, GPR124, or the Wnt7b-catenin signaling markedly reduced LCBM. Xia et al. have uncovered that Mesothelin (MSLN) expression was significantly elevated in both serum and tumor tissue from NSCLC-BM patients and was correlated with a poor clinical prognosis [<xref ref-type="bibr" rid="CR36">36</xref>]. MSLN significantly enhanced the BM abilities of NSCLC cells by facilitating the expression and activation of MET through the c-Jun N-terminal kinase signaling pathway, which allowed tumor cells to disrupt tight junctions and the integrity of the BBB. Drugs targeting MSLN and MET effectively blocked the development of BM and prolonged the survival in mice model.</p></sec></sec><sec id="Sec6"><title>Survival and colonization of circulating tumour cells in brain</title><sec id="Sec7"><title>Survival of circulating tumour cells</title><p id="Par90">Tumor progression is often accompanied by new blood vessel formation, which allows tumor cells to access the blood circulation and long-distance metastasis [<xref ref-type="bibr" rid="CR37">37</xref>]. Tumor cells at the primary site acquire invasive properties, break away from the primary tumor, and intravasate to blood vessels to become CTCs. Blood vessel density is one of the most import factors for lung cancer intravasation [<xref ref-type="bibr" rid="CR38">38</xref>]. Donnem et al. revealed that tumor cells hijacked the host vasculature to obtain blood supply and migrate to distinct locations along the vessels. Approximately 20% of NSCLC patients exhibit vessel co-option [<xref ref-type="bibr" rid="CR39">39</xref>]. Upon entering the circulation, CTCs derived from primary lung cancer are exposed to tremendous physical and biochemical stresses, such as high oxygen tension, fluid shear stress, immune surveillance and apoptosis. These stresses lead to extreme oxidative stress characterized by increased reactive oxygen species (ROS) in CTCs, hindering the survival of the vast majority of CTCs.</p><p id="Par91">Although current advances in enriching and analyzing rare cells in the blood stream have allowed to further characterize CTCs [<xref ref-type="bibr" rid="CR40">40</xref>], the mechanism by which CTCs escape immune surveillance and survive in the circulation remain poorly understood (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>). By performing single-cell RNA-seq (scRNA-seq) of CTCs from lung cancer patients, Zheng et al. have revealed that increased intracellular ROS in CTCs could consistently induct the production of &#x003b2;-globin, which in turn efficiently suppresses the level of ROS and mediates the survival of CTCs [<xref ref-type="bibr" rid="CR41">41</xref>]. CTCs develop strategies, such as interacting with neutrophils, platelets and CAFs to escape immune surveillance in the blood vascular system. CTCs can also travel as clusters to provide coagulation and adherence to endothelial cells, resulting in reducing the speed of blood flow, facilitating the roll-over on endothelial cells and finally extravasating from the circulation. Duda et al. have uncovered that BMs from LUAD and other carcinomas in patients contained CAFs in contrast to primary brain tumors or normal brain tissue [<xref ref-type="bibr" rid="CR42">42</xref>]. Fibroblasts carried over from the primary tumor increase the efficiency of lung metastasis. Ao et al. have reported that circulated CAFs (cCAFs) were found in the peripheral blood of breast cancer patients with metastatic disease using microfilter technology [<xref ref-type="bibr" rid="CR43">43</xref>]. The presence of cCAFs was associated with clinical metastasis, indicating that cCAFs may complement CTCs as a clinically relevant biomarker for metastatic cancers. On the other hand, CAFs can generate gaps in the basement membrane to promote CTCs migration by applying mechanical pulling forces on ECM fibers [<xref ref-type="bibr" rid="CR44">44</xref>]. In addition, CAFs derived collagen modifying enzymes, such as PLOD2 and LOXL2, can mediate ECM remodeling and stiffness to enhance CTCs invasion and metastasis [<xref ref-type="bibr" rid="CR45">45</xref>]. Furthermore, CAFs can protect CTCs from antitumor immune response by secretion of TGF-&#x003b2; and interleukin 6 (IL-6) [<xref ref-type="bibr" rid="CR46">46</xref>, <xref ref-type="bibr" rid="CR47">47</xref>].<fig id="Fig2"><label>Fig.&#x000a0;2</label><caption><p>The interactions between CTCs and the blood cells, with a focus on the main molecules involved in these interactions. Platelets derived TGF-&#x003b2; binds to Smad of CTCs to promote the invasion of CTCs. The expression of PECAM-1, P-selectin, VEGF, PDGF and &#x003b1;IIb&#x003b2;3 integrin, as well as the release of microvesicle and granules are furthermore beneficial for the migration, anti-apoptosis, angiogenesis and immune evasion of CTCs. CTCs can express &#x003b2;-globin to promote itself survival. CTCs derived adhesion molecules VCAM-1 and ICAM-1 bind to LFA-1/MAC-1 receptors on neutrophils to promote the migration of the CTCs. CXCL5/7-CXCR2 signaling enhances the formation of neutrophils-platelets-CTCs aggregates to promote the proliferation of CTCs. CAFs can promote CTCs migration through mechanical pulling forces on ECM fibers and facilitate invasion and immune evasion of CTCs through releasing PLOD2, LOXL2, TGF-&#x003b2; and other cytokines. Platelets-CTCs aggregates can protect CTCs from recognition by NK cells and T cells. The figure was generated using Biorender.com</p></caption><graphic xlink:href="43556_2025_251_Fig2_HTML" id="MO2"/></fig></p><p id="Par92">In the circulation, CTCs are no longer protected by the primary TME and are more exposed to immune cells, including circulating T lymphocytes and natural killer (NK) cells [<xref ref-type="bibr" rid="CR48">48</xref>]. CTCs can interact with and co-opt other circulating cell types to evade the immune system and drive metastasis. Recent studies have provided insights into the mechanism of the increased metastatic potential mediated by platelets. The platelets play a vital role in promoting survival, escape from immune surveillance in the bloodstream, and ultimately support metastasis of CTCs [<xref ref-type="bibr" rid="CR49">49</xref>, <xref ref-type="bibr" rid="CR50">50</xref>]. The platelets can release adhesion molecules and growth factors, including integrins (&#x003b1;IIb&#x003b2;3), selectins (P-selectin), immunoglobulin superfamily proteins (PECAM-1), platelet-derived growth factor (PDGF), and vascular endothelial growth factor (VEGF), to form platelet-CTC aggregates to promote the anti-apoptosis, angiogenesis and immune evasion of CTCs [<xref ref-type="bibr" rid="CR51">51</xref>, <xref ref-type="bibr" rid="CR52">52</xref>]. In addition, platelets exhibit anti-apoptosis behaviors of CTCs by secreting platelet microvesicles, or releasing of platelet granules [<xref ref-type="bibr" rid="CR53">53</xref>]. Based on NanoString analysis of CTCs RNAs and plasma cell-free RNAs, Beck et al. have identified platelet-associated genes, such as platelet factor 4<italic>, </italic><italic>&#x0feff;CLU</italic>, serglycin secreted protein acidic and rich in cysteine <italic>and</italic> serglycin, in LCBM that could predict OS in LCBM patients, suggesting an important role that platelets play in LCBM [<xref ref-type="bibr" rid="CR54">54</xref>]. The function of these platelet-associated genes for LCBM still need to be confirmed in the future. Furthermore, platelet-derived TGF-&#x003b2; can activate the TGF&#x003b2;-Smad and NF-&#x003ba;B pathways in cancer cells, resulting in their transition to an invasive mesenchymal-like phenotype and enhanced metastasis [<xref ref-type="bibr" rid="CR50">50</xref>]. Platelets also can recruit neutrophils by CXCL5/7-CXCR2 signaling to form neutrophil-platelet-CTC aggregates to enhance early metastatic niches formation and significantly enhance metastatic seeding and progression [<xref ref-type="bibr" rid="CR49">49</xref>].</p><p id="Par93">Szczerba et al. have isolated and characterized CTCs associated white blood cells (WBCs), as well as corresponding cancer cells within each CTCs-WBCs cluster from patients with breast cancer [<xref ref-type="bibr" rid="CR55">55</xref>]. By performing scRNA-seq, they revealed that CTCs were associated with neutrophils in the majority of these cases. In addition, a number of cell cycle progression associated genes were highly expressed in CTCs associated with neutrophils against those of CTCs alone. Furthermore, cell&#x02013;cell junctions and cytokine-receptor pairs that define CTCs-neutrophils clusters were identified, representing key vulnerabilities of the metastatic process. Thus, the association between neutrophils and CTCs drives cell cycle progression within the bloodstream and expands the metastatic potential of CTCs, providing a rationale for targeting this interaction in treatment of LCBM.</p></sec><sec id="Sec8"><title>Metabolic reprogramming and colonization in brain</title><p id="Par94">The BM cells depend not only on the extravasation of blood vessels, but also on the post metastatic survival and colonization in brain. Once lung cancer cells extravasate and settle in brain, they must overcome the impact of brain microenvironment. While normal brain cells depend on glucose for energy production, BM cells in brain undergo metabolic reprogramming and depend not only on glucose, but also on glutamine for energy [<xref ref-type="bibr" rid="CR56">56</xref>]. These metabolic adaptations are the result of interactions between BM cells and brain cells including astrocytes and neurons, which promote rapid metastatic colonization in brain [<xref ref-type="bibr" rid="CR57">57</xref>, <xref ref-type="bibr" rid="CR58">58</xref>].</p><p id="Par95">Recent studies have revealed that metabolic reprogramming enhanced the adaption of brain microenvironment and colonization of BM cells. By performing multi&#x02011;omic molecular profiling, Fukumura et al. have demonstrated that enhanced oxidative phosphorylation (OXPHOS) was found in LCBM and other BM types compared to patient-matched primary or extracranial metastatic tissues, which might be resulted from PI3K-AKT pathway activation [<xref ref-type="bibr" rid="CR59">59</xref>]. Ngo et al. have highlighted metabolic constraints imposed by the serine-limited brain environment restricted metastatic tumor growth [<xref ref-type="bibr" rid="CR60">60</xref>]. 3-phosphoglycerate dehydrogenase (PHGDH), a catalyst in the serine synthesis pathway, was identified as a major determinant of BM for NSCLC and other cancer types. Genetic suppression or pharmacologic inhibition of PHGDH attenuated BM rather than extracranial tumor growth. Zeng et al. have uncovered that BM breast cancer cells expressed N-methyl-d-aspartate receptors (NMDARs) and utilized the glutamate secreted by glutamatergic neurons to promote metastatic colonization in the brain [<xref ref-type="bibr" rid="CR61">61</xref>]. BM cells can form pseudo-tripartite synapses with glutamatergic neurons to obtain the glutamate. Autocrine secretion of glutamate by neurons stimulates NMDARs on the member of BM cells, which is transduced via the cytoplasmic adaptor protein guanylate kinase-associated protein to enhance the outgrowth and colonization. Mitochondrial metabolism can generate energy, regulate redox homeostasis, and provide key metabolites for macromolecule synthesis. Recently, targeting mitochondrial metabolism has emerged as a treatment option for LCBM patients. Luttman et al. revealed that abelson (ABL) tyrosine kinases promoted lung cancer cells metastases and the ABL kinase allosteric inhibitors could impair mitochondrial integrity, decrease OXPHOS and lead to apoptosis of LCBM cells [<xref ref-type="bibr" rid="CR62">62</xref>]. By utilizing a clustered regularly interspaced short palindromic repeats loss-of-function screen, they further identified HMG-CoA reductase, the target of statin therapies, as a top-scoring sensitizer to ABL inhibition. Metabolic combination treatment with ABL allosteric inhibitors and statins decreases LCBM cells survival in a synergistic manner. Cheng et al. have modified the antiglycolytic drug lonidamine (LND) to mitochondria-targeted mito-lonidamine (Mito-LND), which showed 100-fold more potent [<xref ref-type="bibr" rid="CR63">63</xref>]. The Mito-LND exhibits a tumor-selective inhibition of OXPHOS and inhibits mitochondrial bioenergetics in lung cancer cells, leads to reduced LCBM in mice model. In summary, metabolism targeted therapy maybe effective to decrease metastatic outgrowth, leading to increased survival for LCBM patients.</p></sec><sec id="Sec9"><title>Dormancy in brain</title><p id="Par96">Once extravasating BBB and settling in brain, most lung cancer cells die or enter a dormant state. Dormant lung cancer cells can remain unaffected by standard chemotherapy and may develop to tumor burden years after surgical resection. Dormancy may be the result of an adaptive response that allows DCCs to pause the proliferation and avoid stress imposed by microenvironment or treatment. There are two different types of metastatic dormancy, including solitary dormant tumor cells and preangiogenic dormant micrometastases (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>). Both these two kinds of dormant cells can remain dormant for months or years, leading to uncertainty in the prognosis for BM patients. The solitary dormant tumor cells spread the distant site with the characteristics of neither proliferation nor apoptosis. While the preangiogenic dormant micrometastases function as a potential contributor to metastatic dormancy of the small tumor cells clusters with a balanced rate of cell proliferation and death [<xref ref-type="bibr" rid="CR64">64</xref>].<fig id="Fig3"><label>Fig.&#x000a0;3</label><caption><p>The dormant patterns of DCCs in the site of LCBM. There are two types of metastatic dormancy that help DCCs to avoid apoptosis and immune surveillance. Solidary dormant tumor cells exhibit stem cell signature with upregulation of SOX2, SOX9, KISS1, KAI1, and avoid NK cell clearance by DKK1-mediated WNT pathway inhibition. Preangiogenic dormant micrometastases are characterized by upregulated expression of VEGFA, MKK4, MKK7 AND Nm23-H1. The figure was generated using Biorender.com</p></caption><graphic xlink:href="43556_2025_251_Fig3_HTML" id="MO3"/></fig></p><p id="Par97">Different mechanisms have been reported to responsible for metastatic dormancy. Malladi et al. have demonstrated that dormant lung cancer cells expressed SOX2 and SOX9 transcription factors and imparted themselves the cancer stem cell identity, which was essential for their survival under immune surveillance and for metastatic outgrowth [<xref ref-type="bibr" rid="CR65">65</xref>]. Through expression of the WNT inhibitor DKK1, these dormant cells exhibit a slow-cycling state with downregulation of UL16-binding proteins (ULBP) to evade the NK-cell-mediated clearance. Thus, once acquiring stem-like state and silencing WNT signaling, metastatic lung cancer cells can enter quiescence and evade innate immunity to remain latent for extended periods. By using multiphoton laser scanning technology, Kienast et al. imaged the single step of metastasis formation in real time and revealed that long&#x000ad;term dormant cells were all solitary or in tiny clusters of up to three cells in strict perivascular localization. Furthermore, early angiogenesis is essential for lung cancer cell metastasis and vascular endothelial growth factor A (VEGFA) inhibition induces long-term dormancy of lung cancer micrometastases by preventing angiogenic growth [<xref ref-type="bibr" rid="CR32">32</xref>]. Horak et al. revealed that several metastasis suppressor genes, such as <italic>KISS1, KAI1, MKK4/7</italic> and <italic>Nm23-H1</italic> could induce dormancy of cancer cells during metastases [<xref ref-type="bibr" rid="CR66">66</xref>]. KISS1 triggers dormancy in solitary metastatic tumor cells by causing growth arrest at the secondary site. KAI1 induces growth arrest prior to extravasation by binding a vascular endothelial cell surface marker. MKK4, MKK7 and Nm23-H1 appear to promote dormancy of micrometastatic colonies, after disseminated tumor cells have undergone several rounds of proliferation. In summary, dormancy should be a result of an adaptive response that allows DCCs to pause the proliferation and avoid stress imposed by microenvironment or treatment.</p></sec></sec><sec id="Sec10"><title>Interactions with brain microenvironment</title><sec id="Sec11"><title>Crosstalk with astrocytes</title><p id="Par98">When DCCs reach brain, they encounter a complex microenvironment that is different from the primary site. Since the brain microenvironment is a vital aspect that affect the progression of BM, dissecting the mechanisms of the interactions between DCCs and different components of the brain microenvironment will facilitate the understanding of biological behavior of BM. The brain microenvironment consists of specialized cell types, such as neuron, microglia, oligodendrocyte, astrocyte, and endothelial cell. Among them, astrocyte is the most abundant parenchymal cell type and possesses the biological function of supporting and maintenance of brain homeostasis. However, in a state of metastases, astrocytes are reactivated and interact with extravasated tumor cells to reconstruct a BM microenvironment (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>).<fig id="Fig4"><label>Fig.&#x000a0;4</label><caption><p>Crosstalk between lung cancer cells and astrocytes in the BM site. Astrocytes secrete PA to generate plasmin to promote cancer cell apoptosis through secreting sFasL and inhibiting L1CAM function. Whereas cancer cells express high level of anti-PA serpins to prevent above process. Astrocytes transfer the <italic>TRPA1</italic>-targeting exosomal miRNA-142-3p to deplete <italic>TRPA1</italic> in LCBM cells and in turn inhibit TRPA1-mediated activation of FGFR2 to hinder the metastatic process. Cancer cells express PCDH7 to promote the assembly of carcinoma-astrocyte gap junctions to transfer cGAMP to astrocytes, which in turn activates STING pathway in astrocytes and then produce cytokines to support LCBM. STAT3<sup>+</sup> reactive astrocytes produce cytokines to generate immune suppressive TME to enhance LCBM. Cancer cells secrete Reelin to recruit reactive astrocytes to the TME and in turn astrocytes release SERPINE1 to promote cancer cells survival and outgrowth. Astrocytes secreted CXCL1 and TGF-&#x003b1; can induce S100A9 production in cancer cells to promote radiation resistance. Astrocytes derived Wnt5a induces mGluR1 expression in cancer cells, which directly interacts with and stabilizes EGFR to activate the downstream MAPK pathway to promote BM progression. The figure was generated using Biorender.com</p></caption><graphic xlink:href="43556_2025_251_Fig4_HTML" id="MO4"/></fig></p><p id="Par99">As the first brain cellular component that contact with lung cancer cells after extravasation, astrocytes play an important role for the formation of LCBM. Valiente et al. have illustrated that reactive astrocytes could release plasminogen activator (PA) in the presence of extravasated BM cells [<xref ref-type="bibr" rid="CR67">67</xref>]. PA generates plasmin from neuron-derived plasminogen to mobilize FasL from astrocytes to kill extravasated BM cells. In addition, astrocytes produced plasmin can cleave and inactivate BM cells secreted L1CAM to prevent BM cells from spreading along brain capillaries and metastatic outgrowth. On the other hand, LCBM cells express high levels of anti-PA serpins to prevent plasmin generation and the metastasis-suppressive effects. Berrout et al. revealed that upon metastasis to the brain, astrocytes could transfer the <italic>TRPA1</italic>-targeting exosomal miRNA-142-3p to deplete <italic>TRPA1</italic> in LCBM cells and in turn inhibit TRPA1-mediated activation of FGFR2 to hinder the metastatic process [<xref ref-type="bibr" rid="CR68">68</xref>]. Chen et al. demonstrated that astrocytes could promote LCBM by forming carcinoma-astrocyte gap junctions [<xref ref-type="bibr" rid="CR69">69</xref>]. LCBM cells express PCDH7 to promote the assembly of carcinoma-astrocyte gap junctions and use these channels to transfer 2&#x02032;3&#x02032;-cyclic GMP-AMP (cGAMP) to astrocytes, which in turn activating the stimulator of interferon genes (STING) pathway in astrocytes. Activated astrocytes then product cytokines such as IFN-&#x003b1; and TNF to active STAT1 and NF-&#x003ba;B pathways in lung cancer cells, thereby supporting LCBM tumor growth and chemoresistance. Priego et al. revealed that a subpopulation of STAT3<sup>+</sup> reactive astrocytes were required for LCBM by both promoting the expansion of CD74<sup>+</sup> tumor associated macrophages (TAMs) and negatively regulating the activation of CD8<sup>+</sup> T cells, which could produce immunosuppressive microenvironment to enhance LCBM [<xref ref-type="bibr" rid="CR70">70</xref>]. Monteiro et al. have identified the astrocytes-released cytokines such as CXCL1 and TGF-&#x003b1; that could induce S100A9 secretion in LCBM cells [<xref ref-type="bibr" rid="CR71">71</xref>]. The activation of the S100A9-RAGE-NF-&#x003ba;B-JUNB pathway in LCBM cells functions as a potential mediator for radiotherapy-resistance. Inhibition of this pathway can increase the therapeutic benefits in vivo at lower doses of radiation. Qu et al. have demonstrated that SCLC cells could secrete Reelin to recruit reactive astrocytes to the TME [<xref ref-type="bibr" rid="CR72">72</xref>]. Reactivated astrocytes in turn secrete neuronal pro-survival factors such as SERPINE1 to promote SCLC cells survival and outgrowth. Ishibashi et al. revealed that astrocytes-derived Wnt5a induced mGluR1 expression in LCBM cells, which directly interacted with and stabilized EGFR in a glutamate-dependent manner, leading to activation of the mitogen-activated protein kinase (MAPK) pathway and progression of LCBM [<xref ref-type="bibr" rid="CR73">73</xref>]. Collectively, reciprocal interactions between LCBM cells and astrocytes facilitate the adaption of lung cancer cells to brain microenvironment and acquire the therapeutic resistance.</p></sec><sec id="Sec12"><title>Modulation by immune microenvironment</title><p id="Par100">Brain is generally considered as an immune-privileged organ for DCCs to escape systemic chemotherapy and immunotherapy. To successfully outgrow in the brain, DCCs must overcome immune surveillance by interacting with both brain resident and infiltrated immune cells. Microglia, the brain resident macrophages, is the major immune cell type in brain that modulates the DCCs to adapt the brain immune microenvironment. The infiltrated bone-marrow-derived myeloid cells (BMDMs) cooperate with microglia to regulate brain immunity for LCBM. Lower programmed death ligand 1 (PD-L1) expression and less CD8<sup>+</sup> T-cell infiltration was found in LCBM tumors compared with matched primary lung tumors, suggesting an immunosuppressive microenvironment for LCBM.</p><p id="Par101">The heterogeneity and specific roles of immune cells in shaping brain niche to regulate LCBM cells outgrowth were uncovered recently (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>a). Guldner et al. have demonstrated that brain resident microglia rather than BMDMs promoted BM outgrowth [<xref ref-type="bibr" rid="CR74">74</xref>]. CX3CR1 downregulation in microglia led to an enriched interferon response signature and CXCL10 upregulation, which in turn recruited VISTA<sup>Hi</sup>PD-L1<sup>+</sup> immunosuppressive microglia to BM lesions and finally promoted BM outgrowth. Correspondingly, inhibiting VISTA and PD-L1 signaling relieved immune suppression and reduced BM burden. Bejarano et al. have performed single-cell and bulk RNA-seq of vascular cells from human LCBM and healthy brain respectively. CD276 was identified as a potential immunotherapeutic target for BM [<xref ref-type="bibr" rid="CR75">75</xref>]. Upregulation of CD276 in the BM vasculature can inhibit the infiltration of cytotoxic T cells. Anti-CD276 blocking antibodies treatment increased infiltrating CD8<sup>+</sup> T cells in BM lesions and prolonged survival. Wang et al. revealed that upregulation of HSP47 in primary lung cancer cells could drive metastatic colonization and outgrowth in brain by creating an immunosuppressive microenvironment [<xref ref-type="bibr" rid="CR76">76</xref>]. HSP47-mediated collagen deposition in the metastatic niche promotes microglia polarization to the M2 phenotype via the &#x003b1;2&#x003b2;1 integrin/NF-kB pathway, which upregulates the anti-inflammatory cytokines and represses CD8<sup>+</sup> T cell mediated anti-tumor responses. Blocking the HSP47-collagen axis represents a promising therapeutic strategy against BM.<fig id="Fig5"><label>Fig.&#x000a0;5</label><caption><p>Interactions between lung cancer cells and immune cells in BM microenvironment. <bold>a</bold> Downregulation of CXCR1 in brain homeostasis macrophages lead to CXCL10 secretion and recruitment of VISTA<sup>Hi</sup>PD-L1<sup>+</sup> immunosuppressive macrophages to BM lesions, which inhibit cytotoxic T cells and promote BM outgrowth. Upregulation of HSP47 in cancer cells can mediate collagen deposition, which in turn promotes macrophages polarization to M2 phenotype and represses CD8<sup>+</sup> T cell mediated anti-tumour responses. Highly expressed CD276 in endothelial cells and mural cells of BM vasculature can lead to increased BBB leakiness and decreased CD8<sup>+</sup> T cell infiltration. <bold>b</bold> The main immune cells in the TME of LCBM and glioma. The figure was generated using Biorender.com</p></caption><graphic xlink:href="43556_2025_251_Fig5_HTML" id="MO5"/></fig></p></sec></sec></sec><sec id="Sec13"><title>Molecular and cellular landscapes of lung cancer brain metastasis</title><sec id="Sec14"><title>Genetic and molecular drivers of lung cancer brain metastasis</title><p id="Par102">Activation of epidermal growth factor receptor (EGFR) or anaplastic-lymphoma-kinase (ALK) is particularly important for lung cancer cells to survive and outgrowth in brain [<xref ref-type="bibr" rid="CR3">3</xref>]. Inhibitors for EGFR and ALK have been used for targetable treatment in LCBM therapeutic practice (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>) [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR11">11</xref>]. EGFR mutant NSCLC patients have longer OS and more likely to develop BM than patients with wild type EGFR [<xref ref-type="bibr" rid="CR77">77</xref>]. Since EGFR mutant NSCLC patients had a higher incidence of BM at the time of diagnosis, an inherent propensity for BM should be exist in EGFR mutant NSCLC patients [<xref ref-type="bibr" rid="CR78">78</xref>]. Shih et al. have performed whole-exome sequencing (WES) of 73 LCBM specimens and compared the mutations with that of primary lung cancers. Amplification of <italic>MYC, YAP1, MMP3</italic> and deletion of <italic>CDKN2A/B</italic> were identified among the highest frequency of driver mutations for BM [<xref ref-type="bibr" rid="CR79">79</xref>]. Enhanced LCBM by overexpression of <italic>MYC, YAP1 or MMP13</italic> was confirmed in xenograft mouse models. Skakodub et al. have reported a cohort of 233 patients with sequenced NSCLC-BM cases and analyzed metastatic specimens with matched primary tumors. <italic>&#x0feff;CDKN2A/B</italic> alterations and cell cycle pathway alterations were found more common in the BM samples compared to primary tumors [<xref ref-type="bibr" rid="CR80">80</xref>]. Alterations for genes of <italic>TP53, MYC, SMARCA4, RB1, ARID1A,</italic> and <italic>FOXA1</italic>, also exhibited significant enrichment in primary tumor specimens from patients who developed BM compared to those who did not have BM. Other driver mutations, such as ROS proto-oncogene 1 (<italic>ROS1</italic>) rearrangement, amplification or exon 14 mutations of mesenchymal-to-epithelial transition (<italic>MET</italic>), Neurotrophic tropomyosin receptor kinase (<italic>NTRK</italic>) fusion, and rearranged during transfection (<italic>RET</italic>) fusion were also identified in LCBM patients. Only a few studies have been reported for molecular characteristics of SCLC-BM patients so far. c-Kit overexpression, EGFR mutation, VEGF overexpression, PI3K activation, PTEN mutation, and Myc activation are among the most frequent molecular drivers for SCLC-BM [<xref ref-type="bibr" rid="CR81">81</xref>]. These molecular abnormalities represent potentially actionable targets for drug development to treat aggressive LCBM.
<table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>Driver mutations in patients with lung cancer brain metastasis</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Driver mutations</th><th align="left">Incidence of BM (%)</th><th align="left">Mutation types</th><th align="left">Encoded Protein</th><th align="left">Function</th><th align="left">Targeted drugs</th></tr></thead><tbody><tr><td align="left"><italic>EGFR</italic></td><td align="left"><p>40 [<xref ref-type="bibr" rid="CR82">82</xref>]</p><p>50.3 [<xref ref-type="bibr" rid="CR83">83</xref>]</p><p>&#x0feff;23&#x02009;~&#x02009;32 [<xref ref-type="bibr" rid="CR84">84</xref>]</p><p>44 [<xref ref-type="bibr" rid="CR85">85</xref>]</p></td><td align="left">Exon 19 deletion or point mutation in exon 21</td><td align="left">Epidermal growth factor receptor tyrosine kinase</td><td align="left">Regulate cell proliferation, migration, survival and differentiation</td><td align="left"><p>Erlotinib;</p><p>Gefitinib;</p><p>Rociletinib, Osimertinib and Zorifertinib</p></td></tr><tr><td align="left"><italic>ALK</italic></td><td align="left"><p>20&#x02009;~&#x02009;40 [<xref ref-type="bibr" rid="CR84">84</xref>]</p><p>39.1 [<xref ref-type="bibr" rid="CR86">86</xref>]</p><p>35&#x02009;~&#x02009;50 [<xref ref-type="bibr" rid="CR87">87</xref>]</p></td><td align="left">Chromosomal rearrangement</td><td align="left">A member of the insulin receptor protein-tyrosine kinase superfamily</td><td align="left">Regulate brain development and specific neurons formation in CNS</td><td align="left"><p>Crizotinib;</p><p>Alectinib, Ceritinib;</p><p>Brigatinib;</p><p>Lorlatinib;</p><p>Ropotrectinib</p></td></tr><tr><td align="left"><italic>KRAS</italic></td><td align="left"><p>32 [<xref ref-type="bibr" rid="CR80">80</xref>]</p><p>6.7 [<xref ref-type="bibr" rid="CR82">82</xref>]</p></td><td align="left">Fusion</td><td align="left">A member of small GTPase superfamily</td><td align="left">Regulate cell proliferation</td><td align="left">Sotorasib, Adagrasib</td></tr><tr><td align="left"><italic>ROS1</italic></td><td align="left"><p>19 [<xref ref-type="bibr" rid="CR84">84</xref>]</p><p>19.4 [<xref ref-type="bibr" rid="CR86">86</xref>]</p></td><td align="left">Chromosomal rearrangement</td><td align="left">A type I integral membrane protein with tyrosine kinase activity</td><td align="left">Promote cell proliferation and differentiation</td><td align="left"><p>Crizotinib;</p><p>Lorlatinib;</p><p>Entrectinib, Ropotrectinib</p></td></tr><tr><td align="left"><italic>TP53</italic></td><td align="left"><p>66.7 [<xref ref-type="bibr" rid="CR82">82</xref>]</p><p>41 [<xref ref-type="bibr" rid="CR83">83</xref>]</p></td><td align="left">Missense mutation</td><td align="left">A tumor suppressor protein</td><td align="left">Induce cell cycle arrest, apoptosis, senescence and DNA repair</td><td align="left">NA</td></tr><tr><td align="left"><italic>RET</italic></td><td align="left"><p>46 [<xref ref-type="bibr" rid="CR84">84</xref>]</p><p>25 [<xref ref-type="bibr" rid="CR88">88</xref>]</p></td><td align="left">Fusion or rearrangement</td><td align="left">A transmembrane receptor and member of the tyrosine protein kinase family</td><td align="left">Promote cell differentiation, migration, survival and the development of CNS</td><td align="left"><p>Pralsetinib, selpercatinib;</p><p>Cabozantinib, Vandetanib and Sunitinib</p></td></tr><tr><td align="left"><italic>MET</italic></td><td align="left">20 [<xref ref-type="bibr" rid="CR84">84</xref>]</td><td align="left">Genomic amplification or exon 14 skipping mutation</td><td align="left">The receptor tyrosine kinase family</td><td align="left">Regulates cell survival, migration and invasion</td><td align="left"><p>Capmatinib;</p><p>Tepotinib, Savolitinib</p></td></tr><tr><td align="left"><italic>MYC</italic></td><td align="left">12&#x02009;~&#x02009;21 [<xref ref-type="bibr" rid="CR79">79</xref>]</td><td align="left">Amplification or rearrangement</td><td align="left">A proto-oncogene that encodes a transcription factor</td><td align="left">Regulate cell cycle progression and cellular transformation</td><td align="left">NA</td></tr><tr><td align="left"><italic>YAP1</italic></td><td align="left">7&#x02009;~&#x02009;9 [<xref ref-type="bibr" rid="CR79">79</xref>]</td><td align="left">Amplification</td><td align="left">A downstream nuclear effector of the Hippo signaling pathway</td><td align="left">Regulate cell cycle, proliferation, EMT process and metastasis</td><td align="left">NA</td></tr><tr><td align="left"><italic>MMP13</italic></td><td align="left">9&#x02009;~&#x02009;10 [<xref ref-type="bibr" rid="CR79">79</xref>]</td><td align="left">Somatic copy-number alteration</td><td align="left">A member of matrix metalloproteinase family</td><td align="left">Promote the degradation of extracellular matrix proteins</td><td align="left">NA</td></tr><tr><td align="left"><italic>CDKN2A/B</italic></td><td align="left"><p>27 [<xref ref-type="bibr" rid="CR79">79</xref>]</p><p>34 [<xref ref-type="bibr" rid="CR80">80</xref>]</p></td><td align="left">Copy number loss</td><td align="left">The cyclin-dependent kinase inhibitor 2A/B</td><td align="left">Inhibit cell cycle progression</td><td align="left">NA</td></tr><tr><td align="left"><italic>NTRK</italic></td><td align="left">22 [<xref ref-type="bibr" rid="CR84">84</xref>]</td><td align="left">Fusion</td><td align="left">Neurotrophic tropomyosin receptor kinase</td><td align="left">Regulate the MAPK, PI3K, and PKC pathways</td><td align="left"><p>Larotrectinib;</p><p>Ropotrectinib</p></td></tr></tbody></table><table-wrap-foot><p><italic>NA</italic> not applicable</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec15"><title>Role of non-coding RNAs in lung cancer brain metastasis</title><p id="Par103">Besides the driver mutations of protein-coding genes, non-coding RNAs (ncRNAs), which are essential in regulating pre-and post-transcriptional steps in protein synthesis [<xref ref-type="bibr" rid="CR89">89</xref>&#x02013;<xref ref-type="bibr" rid="CR91">91</xref>], were also considered to play important roles for LCBM. NcRNAs play potential roles in determining BMs prognosis, chemo- and radio-resistance and may work as potential therapeutic targets for BMs treatment (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). NcRNAs with more than 200 nucleotides are named as long ncRNAs (lncRNAs), while ncRNAs with less than 200 nucleotides are called small ncRNAs [<xref ref-type="bibr" rid="CR91">91</xref>]. MicroRNAs are considered as small ncRNAs for regulating messenger RNA translation by binding to them and inhibiting protein production [<xref ref-type="bibr" rid="CR92">92</xref>]. A series of microRNAs have been reported to play important roles for BM. MicroRNA-590 was found to downregulated in NSCLC cell lines with high metastatic potential and induced expression of microRNA-590 inhibited tumor cell proliferation, migration, and invasion [<xref ref-type="bibr" rid="CR93">93</xref>]. Another study performed by Chen et al. uncovered that microRNA-375 was significantly downregulated in patients with BMs compared to NSCLC patients without BMs. Further analysis revealed that high level of microRNA-375 led to poor prognosis in patients through downregulation of matrix metalloproteinase-9 (MMP9) and VEGF [<xref ref-type="bibr" rid="CR94">94</xref>]. Additionally, Singh et al. revealed that STAT3 knocking down could reduce lung cancer cell migration by its direct effect on microRNA-21 [<xref ref-type="bibr" rid="CR95">95</xref>], suggesting STAT3 is a potential therapeutic target to prevent BMs.
<table-wrap id="Tab2"><label>Table&#x000a0;2</label><caption><p>Summary of brain metastases-associated ncRNAs</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">ncRNAs</th><th align="left">Type</th><th align="left">Expression pattern in BMs</th><th align="left">Related signaling pathways</th><th align="left">Function for BMs</th><th align="left">Reference</th></tr></thead><tbody><tr><td align="left">miR-590</td><td align="left">microRNA</td><td align="left">Downregulation in NSCLC-BM</td><td align="left">Directly targeting ADAM9</td><td align="left">Enhancing the migration and invasion of NSCLC cell lines with high metastatic potential</td><td align="left"> [<xref ref-type="bibr" rid="CR81">81</xref>]</td></tr><tr><td align="left">miR-375</td><td align="left">microRNA</td><td align="left">Downregulation in NSCLC-BM</td><td align="left">Promoting the overexpression of VEGF and MMP9</td><td align="left">Significantly shorten the OS of patients</td><td align="left"> [<xref ref-type="bibr" rid="CR89">89</xref>]</td></tr><tr><td align="left">miR-21</td><td align="left">microRNA</td><td align="left">Overexpression in LCBM</td><td align="left">As a direct downstream target of STAT3 and binds to STAT3</td><td align="left">Promoting migration and self-renewal of tumor stem cell populations, tumor cell proliferation, survival and migration</td><td align="left"> [<xref ref-type="bibr" rid="CR90">90</xref>]</td></tr><tr><td align="left">lnc-MMP2-2</td><td align="left">lncRNA</td><td align="left">Overexpression in NSCLC-BM</td><td align="left">As a microRNA sponge or a competing endogenous RNA for miR-1207-5p</td><td align="left">Increasing BBB permeability</td><td align="left"> [<xref ref-type="bibr" rid="CR9">9</xref>]</td></tr><tr><td align="left"><italic>SLNCR</italic></td><td align="left">lncRNA</td><td align="left">Overexpression in melanoma-BM</td><td align="left">Binding to Brn3a and AR to transcriptional activation of MMP9</td><td align="left">Promoting invasion and leading to an overall lower survival</td><td align="left"> [<xref ref-type="bibr" rid="CR91">91</xref>]</td></tr><tr><td align="left">MALAT1</td><td align="left">lncRNA</td><td align="left">Overexpression in NSCLC-BM</td><td align="left">Inducing EMT process</td><td align="left">Promoting migration</td><td align="left"> [<xref ref-type="bibr" rid="CR92">92</xref>]</td></tr><tr><td align="left">RP11-355I22.7</td><td align="left">lncRNA</td><td align="left">Overexpression in BCBM</td><td align="left">Increasing JAK2 kinase activity to mediate OSM- and IL-6-triggered STAT3 phosphorylation</td><td align="left">Promoting BCBM by mediating communication between cancer cells and the brain microenvironment</td><td align="left"> [<xref ref-type="bibr" rid="CR93">93</xref>]</td></tr><tr><td align="left">BMOR</td><td align="left">lncRNA</td><td align="left">Overexpression in BCBM</td><td align="left">Inactivating IRF3</td><td align="left">Promoting BCBM by evading immune-mediated killing in the brain microenvironment</td><td align="left"> [<xref ref-type="bibr" rid="CR94">94</xref>]</td></tr><tr><td align="left">LGALS8-AS1</td><td align="left">lncRNA</td><td align="left">Overexpression in NSCLC-BM</td><td align="left">Targeting miR-885-3p to mediate FSCN1 expression</td><td align="left">Promoting cancer cell growth, angiogenesis</td><td align="left"> [<xref ref-type="bibr" rid="CR95">95</xref>]</td></tr></tbody></table><table-wrap-foot><p><italic>ADAM9</italic> a disintegrin and metalloproteinase 9, <italic>AR</italic> androgen receptor, <italic>BBB</italic> blood&#x02013;brain barrier, <italic>BCBM</italic> breast cancer brain metastases, <italic>BM</italic> brain metastasis, <italic>Brn3a</italic> brain-specific homeobox protein 3a, <italic>EMT</italic> epithelial-mesenchymal transition, <italic>FSCN1</italic> fascin actin-bundling protein 1, <italic>IRF3</italic> interferon regulatory Factor 3, <italic>JAK2</italic> janus kinase-2, <italic>LCBM</italic> lung cancer brain metastasis, <italic>lncRNA</italic> long non-coding RNA, <italic>miR</italic> microRNA, <italic>MMP9</italic> matrix metalloproteinase 9, <italic>ncRNA</italic> non-coding RNA, <italic>NSCLC</italic> non-small cell lung cancer, <italic>OSM</italic> oncostatin M, <italic>STAT3</italic> signal transducers and activators of transcription 3</p></table-wrap-foot></table-wrap></p><p id="Par104">Similar to microRNAs, the lncRNAs also have been reported to play important roles for LCBM progression. High level of lncRNA-MMP2-2 increases BBB permeability and subsequently induces NSCLC metastases. Inhibition of lncRNA-MMP2-2 reduces BMs formation in vivo [<xref ref-type="bibr" rid="CR9">9</xref>]. Another study performed by Schmidt et al. revealed that lncRNA-SLNCR1 interacted with androgen receptor and transcription factor Brn3a to form a complex to increase MMP9 expression and then induced melanoma cell invasion and migration [<xref ref-type="bibr" rid="CR96">96</xref>]. LncRNA metastasis associated lung adenocarcinoma transcript 1&#x000a0;(MALAT1) was significantly upregulated in BMs than that in non-BM samples and the level of MALAT1 was associated with patients&#x02019; survival [<xref ref-type="bibr" rid="CR97">97</xref>]. Increased level of MALAT1 promotes LCBM by inducing EMT, which may be a promising prognosis factor and therapeutic target to treat LCBM in future. Wang et al. have uncovered that lncRNA associated with BCBM (lnc-BM) was prognostic of the progression of BM in breast cancer patients [<xref ref-type="bibr" rid="CR98">98</xref>]. Elevated lnc-BM expression drove BM and depletion of lnc-BM with nanoparticle encapsulated siRNAs effectively inhibited BM in preclinical mice model. Lnc-BM increased JAK2 activity to mediate oncostatin M and IL-6 triggered STAT3 phosphorylation to enhance BM. Liu et al. have revealed that a brain-enriched long noncoding RNA (BMOR) was expressed in breast cancer metastatic cells and was required for colonization of tumor cells in brain [<xref ref-type="bibr" rid="CR99">99</xref>]. BMOR enables cancer cells to evade immune-mediated killing in the brain microenvironment by binding and inactivating interferon regulatory factor 3. Zhou et al. have revealed that NSCLC-BM patients exhibited higher level of LGALS8-AS1 than NSCLC patients without BMs [<xref ref-type="bibr" rid="CR100">100</xref>]. Depleting LGALS8-AS1 prevented NSCLC cell proliferation, migration and angiogenesis in vitro and also inhibited NSCLC tumorigenesis and BM in vivo. LGALS8-AS1 may be a useful biomarker for identifying NSCLC with metastatic potential. Thus, the ncRNAs regulate BM formation and progression through different mechanisms and maybe served as potential therapeutic targets for BM treatment.</p></sec><sec id="Sec16"><title>Genomic and transcriptomic changes in lung cancer brain metastasis</title><p id="Par105">Genomic sequencing of a large cohort of metastatic tumors and matched primary tumors has revealed previously unknown genomic aberrance of BMs. Skakodub et al. have uncovered that the tumor mutational burden, the fraction genome altered and the copy-number alterations were significantly higher in BM specimens compared to either primary tumor or extracranial metastases samples [<xref ref-type="bibr" rid="CR80">80</xref>]. Additionally, genomic alterations of <italic>CDKN2A/B</italic>, <italic>TP53</italic>, <italic>KRAS</italic>, and <italic>EGFR</italic>, were more common in the BM samples compared to primary tumor samples. Using paired whole-exome and RNA-seq data, Mart&#x000ed;nez-Ruiz et al. have described the genomic-transcriptomic evolution in lung cancer and metastases [<xref ref-type="bibr" rid="CR101">101</xref>]. They characterized the transcriptomes of primary-metastatic tumor pairs by combining multiple machine-learning approaches to link metastasis-seeding potential to the evolutionary context of mutations and increased proliferation within primary tumor regions. By performing WES of 40 samples from 12 LUAD-BM patients, Jiang et al. have observed significant higher intertumoral heterogeneity in BMs compared to pair-matched primary tumors [<xref ref-type="bibr" rid="CR102">102</xref>]. Phylogenetic analysis revealed that BM-competent clones genetically diverged from their primary tumors at relatively early stage, suggesting a parallel progression model of genetic evolution trajectory. Saunus et al. have investigated the genomic and transcriptomic landscapes of 36 BMs from breast, lung, melanoma and esophageal cancers [<xref ref-type="bibr" rid="CR103">103</xref>]. Using DNA copy-number analysis and exome- and RNA-sequencing, they identified novel candidates with possible roles in BM development, including the significantly mutated genes <italic>DSC2, ST7, PIK3R1</italic> and <italic>SMC5</italic>, and the DNA repair, ERBB-HER signalling, axon guidance and protein kinase-A signaling pathways. Treatment with tyrosine kinase inhibitors (TKIs) osimertinib that targeting activated EGFR can prolong the survival of patients with EGFR mutant lung cancer. However, patients often develop metastatic relapses to the brain. Using metastatic mouse models of EGFR mutant lung cancer, Biswas et al. have demonstrated that overexpression of S100A9 could escape osimertinib treatment and initiate BM [<xref ref-type="bibr" rid="CR104">104</xref>]. S100A9 upregulates Aldehyde dehydrogenase 1A1 (ALDH1A1) expression and activates the retinoic acid (RA) signaling pathway in osimertinib-refractory cancer cells. Targeting S100A9-ALDH1A1-RA signaling could suppress BMs in EGFR mutant lung cancer patients. Wang et al. have performed WES and RNA-seq on 30 LUAD-BM patients and revealed that genomic drivers required for BMs often occur early in the primary lung tumor. In addition, they uncovered that genetic intratumor heterogeneity remodeled the immune microenvironment and induced immune evasion in LCBM [<xref ref-type="bibr" rid="CR105">105</xref>]. Wei et al. have revealed that lysophosphatidylcholine acyltransferase 1 (LPCAT1) could promote LCBM by upregulating the PI3K/AKT/MYC pathway and maybe a promising target for treating LCBM patients [<xref ref-type="bibr" rid="CR106">106</xref>]. Jiang et al. have silenced LPCAT1 using an exosome-based delivery system to efficiently arrest tumor growth and inhibit malignant progression of BM in vivo [<xref ref-type="bibr" rid="CR107">107</xref>]. Thus, the genomic evolution and transcriptomic changes promote the transformation of primary lung cancer cells to more malignant forms for BMs and may provide potential therapeutic targets.</p></sec><sec id="Sec17"><title>Heterogeneity of lung cancer brain metastasis at single cell and spatial resolution</title><p id="Par106">LCBM tumors have great intra- and intertumoral heterogeneity among patients. Despite aggressive treatment, the LCBM patients still exhibit dismal prognosis. Tumor heterogeneity, including malignant cell hierarchy and TME diversity, is assumed to responsible for the failure of treatment. Thus, comprehensively understanding the heterogeneity of LCBM tumors may provide the potential for improving therapeutic effects. The recent advantages of scRNA-seq technology have extended our insights into the molecular and cellular mechanisms of BM at single cell resolution (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>).
<table-wrap id="Tab3"><label>Table&#x000a0;3</label><caption><p>Single-cell studies for lung cancer brain metastasis discussed in this review</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Assay</th><th align="left">Tissues profiled</th><th align="left">Organism</th><th align="left">Accession</th><th align="left">Key findings</th><th align="left">References</th></tr></thead><tbody><tr><td align="left">scRNA-seq</td><td align="left">LUAD</td><td align="left">Human</td><td align="left"><p>GSE131907</p><p>EGAD00001005054</p></td><td align="left">LUAD-BM exists a special cancer cell subtype that dominates the late-stage and metastatic stage; normal myeloid cell populations of the metastasis site are gradually replaced with monocyte-derived macrophages.</td><td align="left"> [<xref ref-type="bibr" rid="CR108">108</xref>]</td></tr><tr><td align="left">scRNA-seq</td><td align="left">LUAD</td><td align="left">Human</td><td align="left">GSE131907</td><td align="left">S100A9 is specially expressed in a subgroup of BM original cells and its high expression level is positively associated with poor survival.</td><td align="left"> [<xref ref-type="bibr" rid="CR109">109</xref>]</td></tr><tr><td align="left">scRNA-seq</td><td align="left">Lung cancer and other cancers</td><td align="left">Human</td><td align="left"><p>GSE131907</p><p>GSE186344</p></td><td align="left">Metastatic tumor cells were divided into eight subtypes and further identified two major categories: highly proliferative or highly inflammation.</td><td align="left"> [<xref ref-type="bibr" rid="CR110">110</xref>]</td></tr><tr><td align="left">CyTOF</td><td align="left">NSCLC</td><td align="left">Human</td><td align="left"><ext-link ext-link-type="uri" xlink:href="https://data.mendeley.com/datasets/jk8c3c3nmz/draft?a=c0a9d8dc-8ac2-4942-baf9-208de7a8c310">https://data.mendeley.com/datasets/jk8c3c3nmz/draft?a=c0a9d8dc-8ac2-4942-baf9-208de7a8c310</ext-link></td><td align="left">&#x0feff;Leukocyte invasion was higher in BM than that in brain resident tumours. BM tumors harbored a high frequency of regulatory T cells and monocyte-derived macrophages.</td><td align="left"> [<xref ref-type="bibr" rid="CR111">111</xref>]</td></tr><tr><td align="left"><p>&#x0feff;Flow cytometry</p><p>&#x0feff;RNA-seq</p><p>&#x0feff;Protein arrays</p></td><td align="left">Lung cancer and other cancers</td><td align="left">Human</td><td align="left"><ext-link ext-link-type="uri" xlink:href="https://joycelab.shinyapps.io/braintime/">https://joycelab.shinyapps.io/braintime/</ext-link></td><td align="left">BM and IDH mutation types shape the brain TME; microglia and monocyte-derived macrophages exhibit multifaceted activation.</td><td align="left"> [<xref ref-type="bibr" rid="CR112">112</xref>]</td></tr><tr><td align="left">IMC</td><td align="left">Lung cancer and other cancers</td><td align="left">Human</td><td align="left"><p>GSE154795</p><p>GSE162631</p></td><td align="left">BM tumors have increased frequency and density of NK cells, neutrophils, macrophages, classical monocytes, T cells and decreased dendritic cells and non-classical monocytes compared with glioblastoma,</td><td align="left"> [<xref ref-type="bibr" rid="CR113">113</xref>]</td></tr><tr><td align="left">scRNA-seq</td><td align="left">Lung cancer and breast cancers</td><td align="left">Human</td><td align="left"><p>GSE234832</p><p>GSE186344</p></td><td align="left">LCBM components include tumor cells, fibroblasts, myeloid cells, stromal cells, oligodendrocytes and T cells. Tumor-associated fibroblasts secreting type I collagen are the key mediators of TME.</td><td align="left"> [<xref ref-type="bibr" rid="CR114">114</xref>]</td></tr></tbody></table><table-wrap-foot><p><italic>scRNA-seq</italic> single-cell RNA- sequencing, <italic>LUAD</italic> lung adenocarcinoma, <italic>LCBM</italic> lung cancer brain metastases, <italic>NSCLC</italic> non-small cell lung cancer, <italic>CyTOF</italic> cytometry by time-of-flight, <italic>IMC</italic> imaging mass cytometry, <italic>TME</italic> tumour microenvironment</p></table-wrap-foot></table-wrap></p><sec id="Sec18"><title>Malignant heterogeneity and cellular origin of lung cancer brain metastasis</title><p id="Par107">Recently, utilizing of scRNA-seq technology has revealed novel insights for the malignant heterogeneity and cellular origin of LCBM tumors, which has not been uncovered before using conventional technologies, such as bulk profiling. Kim et al. have performed single-cell transcriptome profiling of primary and metastatic LUAD and identified a special cancer cell subtype that deviated from normal differentiation trajectory and dominated the late-stage and metastatic stage [<xref ref-type="bibr" rid="CR108">108</xref>]. Survival analysis revealed that this special cancer cell subtype associated gene sets could predict poor survival in LUAD patients. Furthermore, the normal resident myeloid cell populations were found gradually replaced with monocyte-derived macrophages and dendritic cells, along with T-cell exhaustion, which led to an immunosuppressive microenvironment. While endothelial cells and fibroblasts orchestrated tissue remodeling and angiogenesis to promote tumor progression and metastases. By analyzing the single-cell transcriptomic profiles of primary LUAD and LUAD-BM samples, Wang et al. demonstrated that LUAD-BM was derived from a subclones of primary LUAD with a gain of chromosome 7 and identified S100A9 as a biomarker of the cellular origins [<xref ref-type="bibr" rid="CR109">109</xref>]. Expression level of S100A9 was strongly correlated with BM and prognosis. In addition, targeting these cellular origins by lapatinib could inhibit LUAD-BM. Gonzalez et al. have performed integrative analysis of single-cell transcriptomics and mass cytometry for malignant and non-malignant cells from 15 human BM tumors, including LCBM samples [<xref ref-type="bibr" rid="CR110">110</xref>]. Eight functional cell programs that coexist or anticorrelated were delineated to two functional archetypes, one proliferative and the other inflammatory, which were shaped by tumor-immune interactions. Combining scRNA-seq and spatial transcriptomic analyses, Xiao et al. have identified a special early metastatic epithelial cell cluster (EMEC), which was enriched in OXPHOS and coagulation, was related to clinical prognosis [<xref ref-type="bibr" rid="CR115">115</xref>]. In addition, EMEC cells invaded from the peripheral region to the central regions of the tumor with the progress of invasion. Thus, the heterogeneity and cellular origin of LCBM uncovered by scRNA-seq and spatial transcriptomics provide potential therapeutic targets for LCBM patients.</p></sec><sec id="Sec19"><title>Heterogeneity of lung cancer brain metastasis microenvironment</title><p id="Par108">Comprehensively defining the specific immunological signature of BM tumors can facilitate the rational design of immunotherapy strategies. Recently, two parallel studies performed by Friebel et al. and Klemm et al. have uncovered the distinct immunological microenvironment of BMs compared to brain resident tumors (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>b). By single-cell profiling analyses, Friebel et al. have revealed that leukocyte invasion was higher in BMs than that in brain resident tumors. BM tumors harbored a high frequency of regulatory T cells and monocyte-derived macrophages, whereas glioma was characterized by brain resident reactive microglia [<xref ref-type="bibr" rid="CR111">111</xref>]. By high-dimensional multi-omics characterization of the brain TME, Klemm et al. found that BM types and glioma isocitrate dehydrogenase mutation status shaped the brain TME [<xref ref-type="bibr" rid="CR112">112</xref>]. Microglia and monocyte-derived macrophages exhibited multifaceted activation in BM tumors and altering the multifaceted phenotypes of TAMs rather than simply depletion of these cells should be considered as an effective therapeutic strategy. Karimi et al. have applied imaging mass cytometry to characterize the single-cell spatial immune landscapes of high-grade glioma and BM tumors [<xref ref-type="bibr" rid="CR113">113</xref>]. Compared to glioblastoma, increased frequency and density of NK cells, neutrophils, macrophages, classical monocytes, T cells and decreased in dendritic cells and non-classical monocytes were found in BM tumors. Additionally, increased monocytes and microglia were found in BM-cores of patients without leptomeningeal disease, suggesting a putative protective role for these cells. Furthermore, endothelial cells were found to have a high tendency to interact with Ki67-expressing tumor cells in both cores and margins of BM. However, within BM cores, rather than margins, tumor-adjacent endothelial cells exhibited lower claudin-5 expression compared with tumor-avoiding endothelial cells, supporting a model of vascular co-option during BM colonization. Song et al. have revealed the landscape of the human BM microenvironment by single-cell profiling and uncovered various intratumoral components, including tumor cells, fibroblasts, myeloid cells, stromal cells, oligodendrocytes and T cells [<xref ref-type="bibr" rid="CR114">114</xref>]. Among them, type I collagen-secreting CAFs were identified as key mediators for remodeling the TME in BM tumors and associated with patient survival. By digital spatial transcriptomic profiling of lung tumors and metastases, Zhang et al. have provided a whole transcriptome map of LCBM resolved with morphological markers for the tumor core, tumor immune microenvironment, and tumor brain microenvironment [<xref ref-type="bibr" rid="CR116">116</xref>]. They revealed that the brain TME was undergone extensive remodeling to create an immunosuppressive and fibrogenic niche for the BMs. Specifically, the brain TME is characterized with reduced antigen presentation, dysfunction of B cells and T cells, increased neutrophils and M2-type macrophages, immature microglia, and reactive astrocytes. Differential gene expression and network analysis identified fibrosis and immune regulation as the major functional modules disrupted in brain TME. In summary, the extensive single-cell and spatial analysis of TME of BM tumors enhances our understanding of the cellular dynamics and intercellular interactions and reveals the potential diagnostic and therapeutic targets.</p></sec></sec></sec><sec id="Sec20"><title>Therapeutic strategies</title><sec id="Sec21"><title>Current treatment modalities</title><p id="Par109">Current treatment approaches of BM include surgical resection, whole-brain radiation therapy (WBRT), stereotactic radiosurgery (SRS), targeted therapy, immunotherapy or a combination of several modalities [<xref ref-type="bibr" rid="CR13">13</xref>&#x02013;<xref ref-type="bibr" rid="CR15">15</xref>]. Since the intro- and inter-heterogeneity of BMs, there is no definitive consensus of the sequence of treatment and the outcomes are often volatile. Thus, the treatment for BM patients should be in a flexible way. Here, we summarized the current therapeutic strategies for BMs (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>).<fig id="Fig6"><label>Fig.&#x000a0;6</label><caption><p>Current treatment strategies of BMs, including traditional and emerging therapy. The figure was generated using Biorender.com</p></caption><graphic xlink:href="43556_2025_251_Fig6_HTML" id="MO6"/></fig></p><sec id="Sec22"><title>Surgery, radiation therapy, and systemic treatments</title><p id="Par110">Surgical resection should be considered for patients with large tumors and with minimal intracranial disease. BM patients usually have a better survival after surgical resection if they have a single and accessible BM lesion [<xref ref-type="bibr" rid="CR117">117</xref>, <xref ref-type="bibr" rid="CR118">118</xref>]. For multiple brain lesions and recurrent metastases, the current advances in surgical techniques have further resulted in safer resections and promoted the benefit [<xref ref-type="bibr" rid="CR118">118</xref>]. After surgical resection of both primary lesion and BM lesions, the long-term survival of LCBM patients is improved [<xref ref-type="bibr" rid="CR119">119</xref>]. However, elevation of the serum carcinoembryonic antigen (CEA) level in NSLC-BM patients after surgical resection for solitary BM lesion may lead to postoperative recurrence. NSCLC-BM patients with normal CEA level, small primary tumor size, and node-negative status will be significantly benefit to local control and with improved survival rates after surgical resection of the primary tumor and synchronous BM [<xref ref-type="bibr" rid="CR120">120</xref>]. A retrospective multicenter study proved the safety and importance of surgical treatment in NSCLC-BM patients without molecular driver alterations [<xref ref-type="bibr" rid="CR121">121</xref>].</p><p id="Par111">Patients with single or multiple BM lesions could be considered for WBRT or SRS strategy, which could also be considered for patients with karnofsky performance status&#x02009;&#x0003c;&#x02009;70 or with comorbidities impeding neurosurgery. One study showed a median OS of 6&#x000a0;months treated with WBRT alone in 229 SCLC-BM patients [<xref ref-type="bibr" rid="CR122">122</xref>]. Recently, it has been reported that WBRT was more recommended for NSCLC-MB patients with good status of performance and were unsuitable for SRS treatment, whereas not for patients with a poor prognosis [<xref ref-type="bibr" rid="CR123">123</xref>]. Additionally, WBRT treatment has clear survival advantages for NSCLC patients with leptomeningeal metastasis and wildtype EGFR [<xref ref-type="bibr" rid="CR124">124</xref>]. However, WBRT should be prudently used in the NSCLC-BM patients, due to therapeutic effect may be accompanied by worse cognitive decline [<xref ref-type="bibr" rid="CR123">123</xref>].</p><p id="Par112">As a safer and more effective technique, SRS has gradually replaced WBRT and represented a cornerstone of BM management. SRS exerts therapeutic effects by delivering high doses of radiation to tumor lesions, and its benefits include quick treatment, low rate of complications and less deterioration of neurocognitive functions [<xref ref-type="bibr" rid="CR125">125</xref>]. It has been reported that SCLC-BM patients treated with upfront SRS exhibited favorable outcomes, including 1-year control of 80% and median survival time of approximately 8&#x000a0;months [<xref ref-type="bibr" rid="CR126">126</xref>]. A meta-analysis has also demonstrated that upfront SRS produced favorable lesion control and survival outcomes when used for SCLC-BM patients with limited BM lesions [<xref ref-type="bibr" rid="CR127">127</xref>]. Small retrospective case series have indicated that 189 NSCLC-BM patients with fewer than 4 BM lesions and less than 4&#x000a0;cm in size had longer survival after treated with SRS alone than those treated with WBRT [<xref ref-type="bibr" rid="CR128">128</xref>]. In oligometastatic NSCLC-BM patients, treatment for both lung primary lesion and BM lesions with lung synchronous thoracic stereotactic body radiation therapy and brain SRS achieved good local control rates and led to improved OS [<xref ref-type="bibr" rid="CR129">129</xref>]. Previous studies suggested that SRS could be as a promising salvage treatment after WBRT for SCLC-BM patients [<xref ref-type="bibr" rid="CR130">130</xref>, <xref ref-type="bibr" rid="CR131">131</xref>]. Andrews et al. reported significant better survival for combination of WBRT with SRS group in single BM patients compared to WBRT only group [<xref ref-type="bibr" rid="CR132">132</xref>]. However, given the combination of SRS with WBRT is associated with potential adverse effects, such as higher rate of cognitive impairment, hippocampal avoidance or administration of memantine is necessary to decrease neurological toxicity.</p><p id="Par113">Surgical resection and radiotherapy are the major local treatment approaches for BM patients currently. However, the advanced cancer patients usually cannot benefit from local therapies as multiple tumor lesions in the brain and other parts of the body. On the other hand, patients with asymptomatic BM have increased over the last decade. Recent clinical trials for systemic treatment, such as immune and targeted therapies, exhibited promising intracranial responses especially in asymptomatic status. Current available systemic therapies for BM patients include chemotherapy, targeted therapy, endocrine therapy, immunotherapy, and novel therapies that may be available in the future. Systemic treatments are often used to complement local strategies to achieve optimal control of BM [<xref ref-type="bibr" rid="CR133">133</xref>]. With the emergence of various new targetable drugs, the systematic therapies have shown promising clinical results recently. Several next-generation TKIs and immune checkpoint inhibitors have shown significant intracranial efficacies. Osimertinib and afatinib have exhibited remarkable intracranial response rates for asymptomatic NSCLC-BM patients. Immune-related therapy and next-generation TKIs have been applied for in advanced cancer patients with BM in the last decades. However, systemic therapies may come with some side effects, patients need to be closely monitored and manage these side effects during the treatment process.</p></sec><sec id="Sec23"><title>Challenges in drug delivery across the blood&#x02013;brain barrier</title><p id="Par114">Although systemic therapies exhibit promising effects for BM treatment, the chemotherapy and targeted therapy are challenged for administering in BM patients&#x02019; treatment because of the BBB. The BBB is composed of endothelium cells, vascular basement membrane, pericytes, and astrocyte endfeets [<xref ref-type="bibr" rid="CR134">134</xref>, <xref ref-type="bibr" rid="CR135">135</xref>]. Endothelial cells form the impermeable BBB by surrounding astrocytes and the basement membrane. BBB can separate circulating blood and brain tissue. The BBB is both a physiological and biochemical obstacle that protects the brain from potentially hazardous chemicals while also maintains the brain homeostasis [<xref ref-type="bibr" rid="CR136">136</xref>]. However, the impermeable property of BBB also limits the transport of therapeutic agents to the brain, making systemic therapies less effective in treating BMs than in treating other types of cancers. As BMs formed in the brain, the BBB is disrupted and replaced by BTB [<xref ref-type="bibr" rid="CR137">137</xref>]. Although the structure is damaged to a certain degree, BTB can impede the transport of anticancer agents to brain tumors, leading to poor treatment effect. Since the BBB and BTB are impediments for drug delivery to brain, disruption techniques are needed to improve the permeability of drugs to metastatic tumors in the brain. Invasive and noninvasive techniques for improving antitumor agent delivery across the BBB and BTB are being developed. Recent advances have confirmed the systemic delivery of therapeutic agents via transporter systems, nanoparticle-based systems, molecular trojan horse technology, and engineered stem cells, which are promising approaches for treating BMs. Identifying the molecular mechanisms and signaling pathways underlying BBB and BTB formation may lead to the discovery of new strategies for BMs treatment.</p></sec></sec><sec id="Sec24"><title>Targeted therapies</title><p id="Par115">Driver mutation identifications have greatly promoted the targeted therapies for lung cancer and LCBM (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). Most targeted therapies for LCBM are those targeting driver mutations of <italic>EGFR</italic>, <italic>ALK</italic>, <italic>ROS1</italic>, <italic>RET</italic>, and <italic>MET</italic>, as well as these driver mutation-associated signaling pathways, such as RAS/RAF, PI3K/AKT/mTOR, WNT/&#x003b2;-catenin, and JAK/STAT, which also provide new strategies for the treatment of LCBM [<xref ref-type="bibr" rid="CR79">79</xref>, <xref ref-type="bibr" rid="CR80">80</xref>, <xref ref-type="bibr" rid="CR82">82</xref>&#x02013;<xref ref-type="bibr" rid="CR84">84</xref>, <xref ref-type="bibr" rid="CR86">86</xref>, <xref ref-type="bibr" rid="CR88">88</xref>, <xref ref-type="bibr" rid="CR138">138</xref>]. In light of this, there are ongoing targetable clinical trials enrolling patients based on the molecular characteristics [<xref ref-type="bibr" rid="CR85">85</xref>, <xref ref-type="bibr" rid="CR87">87</xref>, <xref ref-type="bibr" rid="CR139">139</xref>&#x02013;<xref ref-type="bibr" rid="CR148">148</xref>].</p><sec id="Sec25"><title>Inhibitors of key molecules</title><p id="Par116">Genetic and genomic analyses have identified driver mutations for the development of LCBM. Among these drivers, mutations in <italic>EGFR</italic> activation and <italic>ALK</italic> gene rearrangement are of particularly important owing to the high prevalence in BM patients and the clinical availability of targeted inhibitors [<xref ref-type="bibr" rid="CR149">149</xref>&#x02013;<xref ref-type="bibr" rid="CR152">152</xref>]. LCBM is heterogeneous and associated with specific driver oncogenes. Around 15&#x02009;~&#x02009;20% of non-squamous NSCLC patients have <italic>EGFR</italic> mutations at diagnosis [<xref ref-type="bibr" rid="CR153">153</xref>]. In clinical practice of TKIs treatment, erlotinib, the first-generation EGFR-TKI, is the first-line systemic option for metastatic patients with activated <italic>EGFR</italic> mutations and exhibits significant response for LCBM with objective response rate (ORR) of 51.8% [<xref ref-type="bibr" rid="CR140">140</xref>]. Afatinib is the second-generation EGFR-TKI that has been shown to improve progression free survival (PFS) of <italic>EGFR</italic>-mutated NSCLC-BM patients with ORR of 70&#x02009;~&#x02009;75% and PFS of 8.2&#x000a0;months [<xref ref-type="bibr" rid="CR85">85</xref>]. The data from a retrospective study indicated that patients with <italic>EGFR</italic> mutations treated with TKIs gefitinib or afatinib have better outcomes [<xref ref-type="bibr" rid="CR87">87</xref>]. However, both the first and second generation EGFR-TKIs finally resulted in acquired treatment resistance [<xref ref-type="bibr" rid="CR154">154</xref>]. Recently, it has been reported that the third-generation EGFR-TKIs osimertinib could overcome the most common resistance and exhibited more effective BBB penetration than previous generation TKIs in preclinical and early clinical studies with ORR of 40&#x02009;~&#x02009;70% and PFS of 18.9&#x000a0;months [<xref ref-type="bibr" rid="CR141">141</xref>, <xref ref-type="bibr" rid="CR155">155</xref>].</p><p id="Par117"><italic>ALK</italic> rearrangements were detected in around 5% of newly diagnosed patients with non-squamous NSCLC [<xref ref-type="bibr" rid="CR153">153</xref>]. ALK inhibitors are small molecule targeted drugs and the clinical trials of first-generation ALK-TKI crizotinib showed a better disease control rate of 18&#x02009;~&#x02009;62% and extended PFS and OS with the median intracranial time to progression is 7&#x02009;~&#x02009;13.2&#x000a0;months [<xref ref-type="bibr" rid="CR142">142</xref>, <xref ref-type="bibr" rid="CR143">143</xref>]. The second-generation ALK-TKIs alectinib (brain response rate, 52.4%) and ceritinib (brain response rate, 42.1%) were used to treat NSCLC-BM patients with <italic>ALK</italic> active mutation and crizotinib resistance. However, these inhibitors exhibited adverse CNS effect [<xref ref-type="bibr" rid="CR143">143</xref>]. Brigatinib (ORR, 42&#x02009;~&#x02009;67%; median PFS, 9.2&#x02009;~&#x02009;12.9&#x000a0;months) is a third-generation ALK-TKI and was applied to crizotinib-resistant NSCLC-BM patients [<xref ref-type="bibr" rid="CR144">144</xref>, <xref ref-type="bibr" rid="CR156">156</xref>]. Another third generation ALK inhibitor lorlatinib is still in the phase 3 CROWN study, which can improve PFS (median duration of follow-up for PFS, 36.7&#x000a0;months), ORR (76&#x02009;~&#x02009;82%), duration of response (&#x02265;&#x02009;2&#x000a0;years, 74%), and time to intracranial progression (&#x02265;&#x02009;2&#x000a0;years, 81%) of advanced NSCLC patients [<xref ref-type="bibr" rid="CR157">157</xref>]. In presence of asymptomatic BMs, deeper CNS ORR and better brain penetrance were observed for upfront treatment with second (alectinib) or third (brigatinib and lorlatinib) generation ALK inhibitors compared to crizotinib [<xref ref-type="bibr" rid="CR151">151</xref>, <xref ref-type="bibr" rid="CR158">158</xref>, <xref ref-type="bibr" rid="CR159">159</xref>]. Among these TKIs, lorlatinib exhibited the highest cerebral spinal fluid (CSF)-plasma ratio and preserved intra-cranial activity compared to alectinib and brigatinib, with a CNS ORR of 59% and PFS of 24.6&#x000a0;months [<xref ref-type="bibr" rid="CR145">145</xref>, <xref ref-type="bibr" rid="CR160">160</xref>]. Several other targetable driver mutations were identified in NSCLC-BM, including <italic>NTRK</italic>, <italic>RET</italic>, and <italic>neuregulin 1</italic> (<italic>NRG1</italic>) [<xref ref-type="bibr" rid="CR161">161</xref>]. Among these targetable driver mutations, TKI is the main therapy strategy for targeting <italic>NTRK</italic> and <italic>RET</italic> active mutations. A clinical trial indicated that a novel bispecific HER2/3 antibody (MCLA-128) led to intracranial response in NSCLC-BM patients with NRG1 fusion [<xref ref-type="bibr" rid="CR162">162</xref>].</p></sec><sec id="Sec26"><title>Pathway inhibitors</title><p id="Par118">&#x0feff;In addition to genomic driver mutations, molecular analyses have identified signaling pathways that dysregulated and associated with BMs. A topic of clinical interest is whether these pathways offer effective therapeutic targets for BMs treatment. Bohn et al. have indicated that combinatorial inhibition of VEGF and Angiopoietin-2 (Ang2) decreased lesion permeability and reduced BMs of breast cancer burden in animal model [<xref ref-type="bibr" rid="CR163">163</xref>]. Another study performed by Kovalchuk et al. also have revealed that VEGF pathway inhibitor nintedanib and dual anti&#x02011;VEGF/Ang2 nanobody selectively prevented BM of LUAD cells [<xref ref-type="bibr" rid="CR164">164</xref>]. Both compounds were able to normalize cerebral blood vessels within BMs lesions, indicating a brain specific effect of antiangiogenic compounds BI836880 with respect to metastasis treatment. Nintedanib and BI836880 are promising candidates for future BM preventive study concepts in LUAD patients. Brastianos et al. have presented a clinical trial for cyclin-dependent kinase (CDK) inhibitor by a small cohort of BM patients with CDK alterations and met the primary endpoint [<xref ref-type="bibr" rid="CR165">165</xref>]. They evaluated the intracranial efficacy of CDK inhibition and demonstrated a 53% intracranial benefit rate at 8&#x000a0;weeks with palbociclib in a pretreated population of patients with progressive BM and CDK alterations. Aberrant activation of the PI3K-AKT-mTOR signaling pathway is frequently observed in many cancers, including primary tumors and BMs [<xref ref-type="bibr" rid="CR166">166</xref>]. Agents targeting key components of this pathway have demonstrated antitumor activity in diverse cancers and may represent a new treatment strategy for BMs. Several inhibitors of this pathway have been demonstrated to penetrate the BBB and down-regulate PI3K signaling in preclinical studies, indicating that these agents may be potential therapies for BMs. The PI3K inhibitor buparlisib and the mTOR inhibitor everolimus are currently under evaluation in combination with trastuzumab in patients with HER2<sup>+</sup> breast cancer BMs.</p></sec></sec><sec id="Sec27"><title>Immunotherapies and their challenges in the brain metastases context</title><p id="Par119">Recent clinical guidelines agree that NSCLC patients with asymptomatic BMs and without oncogenic drivers should be treated with immune checkpoint inhibitors (ICIs) [<xref ref-type="bibr" rid="CR139">139</xref>]. The usage of ICIs is an attractive strategy to stimulate immune response of the immunosuppressed TME [<xref ref-type="bibr" rid="CR57">57</xref>, <xref ref-type="bibr" rid="CR167">167</xref>]. ICIs are now commonly used in the management of NSCLC patients, particularly for patients without molecularly targetable mutations. The ICIs targeting programmed death receptor 1 (PD-1) (pembrolizumab and nivolumab) and PD-L1 (atezolizumab) as well as cytotoxic T lymphocyte-associated antigen-4 (CTLA4) (ipilimumab) have been developed and evaluated in LCBM patients [<xref ref-type="bibr" rid="CR168">168</xref>]. Treatment recommendations for tumors with a PD-L1 expression 0&#x02009;~&#x02009;49% include platinum-based chemotherapy with anti&#x02013;PD-1/PD-L1. Tumors with a PD-L1 expression&#x02009;&#x02265;&#x02009;50% benefit from the prior mentioned regimens or anti-PD-1/PD-L1 agents in monotherapy. Clinical trials have demonstrated that patients with asymptomatic BM benefited from the nivolumab-ipilimumab combination, reporting an intracranial benefit of 57%, and an OS at 3&#x000a0;years of 71.9% [<xref ref-type="bibr" rid="CR169">169</xref>&#x02013;<xref ref-type="bibr" rid="CR171">171</xref>]. A multicenter retrospective analysis including 100 NSCLC-BM patients treated with upfront ICIs showed a CNS ORR of 27% among evaluable patients and rates of 35.7% in PD-L1-positive and 11.1% in PD-L1-negative tumors [<xref ref-type="bibr" rid="CR172">172</xref>].</p><p id="Par120">Since NSCLC-BM patients treated with ICIs alone usually exhibited low-to-modest response, combination of ICIs with radiotherapy or/and chemotherapy is needed to be further investigated [<xref ref-type="bibr" rid="CR173">173</xref>, <xref ref-type="bibr" rid="CR174">174</xref>]. A meta-analysis of 19 studies in NSCLC patients reported that combination of ICIs and radiation was associated with prolonged OS and with no significant increase in neurologic adverse events in comparison with radiation alone [<xref ref-type="bibr" rid="CR175">175</xref>]. Other studies also indicated that PD-1 or PD-L1 antibody alone or in combination with chemotherapy or radiotherapy exhibited activity for both NSCLC- and SCLC-BM patients [<xref ref-type="bibr" rid="CR176">176</xref>, <xref ref-type="bibr" rid="CR177">177</xref>]. A series of prospective trials with the regimens of testing combinations of ICIs and SRS are ongoing or in development. Chang et al. have demonstrated that immunotherapy improved the OS and intracranial PFS of SCLC-BM patients [<xref ref-type="bibr" rid="CR178">178</xref>]. At least four cycles of ICIs should be applied for SCLC patients with BMs and cross-line treatment with ICIs is recommended. Given the low survival rates of SCLC patients, the use of ICIs should be as early as possible. They also showed that immunotherapy plus chemotherapy and radiotherapy for BMs exhibited promising efficacy for SCLC-BM patients.</p><p id="Par121">With the widespread application of immunotherapy, a series of challenges had emerged during the treatment process. One of the issues is the penetration and efficiency of activation of immune cells for the immune checkpoint inhibitors. Another issue that requires resolution is that of pseudo-progression, a potentially fatal intense inflammatory response that can mimic rapid tumor progression [<xref ref-type="bibr" rid="CR179">179</xref>]. Although the optimal diagnosis and management strategies for pseudo-progression remain active areas of study, immune depression with a course of steroids is often pursued. Systemic toxicity with immunotherapies is also a concern, with mild toxicity rates as high as 50%, although rates of grade 3 or 4 toxicities were less than 10%. To overcome the challenges of immunotherapies, a better understanding of the regulatory mechanisms underlying immune infiltration and activation is necessary, which will lead to improve the incorporation of immunotherapies into the therapeutic landscape for BMs.</p></sec></sec><sec id="Sec28"><title>Emerging therapies and future directions</title><sec id="Sec29"><title>Novel drug delivery systems</title><sec id="Sec30"><title>Nanoparticles and other blood&#x02013;brain barrier-penetrating strategies</title><p id="Par122">Cancer therapy has been remarkably improved over the past few years because of the development of antitumor agents at the nanoscale. More recently, biomaterial-based nanodrugs have been developed and applied in preclinical studies and clinical trials of cancer immunotherapies [<xref ref-type="bibr" rid="CR180">180</xref>, <xref ref-type="bibr" rid="CR181">181</xref>]. Nanoparticles used in targeted drug delivery systems exhibit unique advantages, such as reliable delivery, sufficient loading capacity, nanosized, and drug-loading plasticity [<xref ref-type="bibr" rid="CR182">182</xref>]. Nanodrugs have increased the efficacy and reduced the toxicity of parent drugs in clinical trials of BMs treatment [<xref ref-type="bibr" rid="CR183">183</xref>]. Nanoparticle-mediated targeted delivery of chemotherapeutic drugs to BMs is currently among the most frequently used approaches. BBB can prevent macromolecules and nanoparticles from shuttling freely between the blood system and BM tumors. However, the interactions between nanoparticles and BBB, including biological interactions and physicochemical interactions, can be utilized to delivery of nanoparticles to BM tumors. The biological interactions include receptor-mediated transcytosis (RMT) and transporter-mediated transcytosis (TMT), while the physicochemical interactions contain absorption-mediated transcytosis (AMT) and BBB opening.</p><p id="Par123">RMT is considered as the most promising method and is widely used for delivery of nanoparticles with the characterization of high specificity, selectivity, and affinity for brain tumors [<xref ref-type="bibr" rid="CR180">180</xref>, <xref ref-type="bibr" rid="CR181">181</xref>]. Most endogenous macromolecules are transported into brain parenchyma via RMT. RMT-based transport is usually energy-dependent and with relatively high efficiency. To achieve a best delivery efficiency of therapeutic to a brain tumor, the target receptor should be highly expressed in the endothelial cells of the brain tumor, whereas minimally expressed in other vascular endothelial cells to minimize the off-target effect. The typical receptors utilized in nanoparticle-based drug delivery for brain tumors includes transferrin receptor mediated transcytosis, low-density lipoprotein receptor-mediated transcytosis, insulin receptor-mediated transcytosis and nicotinic acetylcholine receptor-mediated transcytosis. TMT is also known as carrier-mediated transcytosis, which is a vital strategy for transporting low molecular weight nutrients from the bloodstream into the brain [<xref ref-type="bibr" rid="CR180">180</xref>, <xref ref-type="bibr" rid="CR184">184</xref>]. Many transporters have been discovered on the BBB. Among them, glucose transporter and glutathione transporter are the two most explored transporters for facilitating nanoparticles crossing the BBB in brain tumor treatment. AMT is another widely explored approach for delivering drugs across the BBB. AMT is triggered by the electrostatic interaction between positively charged agents and negatively charged luminal membranes of brain endothelial cells [<xref ref-type="bibr" rid="CR181">181</xref>]. Cationic bovine serum albumin and cell-penetration peptides are two kinds of the most frequently used moieties conjugated on nanoparticles to trigger nanoparticles across the BBB through AMT [<xref ref-type="bibr" rid="CR185">185</xref>]. Notably, although the travel route of AMT is similar to RMT, there is a significant difference between these two pathways. The prominent feature of AMT is its high binding capacity to BBB cells and associated with poor tissue selectivity due to non-special binging.</p><p id="Par124">Temporary opening and disruption of BBB by using biochemical reagents or physical approaches is another straightforward and effective strategy for agent brain delivery [<xref ref-type="bibr" rid="CR186">186</xref>, <xref ref-type="bibr" rid="CR187">187</xref>]. Different from interaction mediated nanoparticle transport, which is nearly not influence the integrity of BBB, the disruption of BBB by physicochemical method usually compromises the integrity of BBB to a certain degree temporarily and reversibly. Therapeutic agents then transport into the brain parenchyma by diffusion after temporary opening the BBB. The commonly adopted disruption methods include hyperosmotic agents induced osmotic disruption, ultrasound disruption, magnetic disruption, and their orthogonal combination.</p></sec><sec id="Sec31"><title>Regional delivery strategies</title><p id="Par125">Besides the nanoparticle delivery, regional drug delivery strategies, such as direct injections, convection enhanced delivery (CED), administration of implants, and intranasal delivery (IN), have been developed to bypass the BBB and enhance the therapeutic efficacy of treatment agents. Although these strategies are invasive, site-specific delivery of the therapeutics with high bioavailability and minimal drug loss can be achieved. Drugs can be directly injected or infused into the brain tumor sites. This strategy is less toxic and much effective than systemic administration. However, this method exhibits high risk of side effects such as edema and infection [<xref ref-type="bibr" rid="CR188">188</xref>].</p><p id="Par126">CED is developed to prevent the backflow of drugs and improve the drug distribution in brain tumor site [<xref ref-type="bibr" rid="CR189">189</xref>]. In this method, the catheter is introduced stereotactically while the constant pressure from the pump maintains a convection flow of the drug solution into the delivery site. In addition, the convective flow allows the drug solution to cover longer distance in the brain compared to direct injection/infusion [<xref ref-type="bibr" rid="CR190">190</xref>]. CED has been widely tested for the delivery of a broad spectrum of therapeutic agents, including small molecules, macromolecules, nanocarriers, and immunotoxins [<xref ref-type="bibr" rid="CR191">191</xref>&#x02013;<xref ref-type="bibr" rid="CR195">195</xref>]. Despite the significant promise, invasiveness and the common side effects of infusion methods are limitations for CED strategies. Polymeric implants, including wafers, gels, microspheres and nanospheres, have been tested for regional delivery of therapeutic agents in brain tissue. Wafers are drug loaded polymeric implants and are implanted in the remaining cavity of post-surgical resection of a tumor where they act as a platform for sustained drug release [<xref ref-type="bibr" rid="CR196">196</xref>]. The major drawback of wafers as standard delivery platform for treating invasive brain tumors is lack of deep tissue penetration. Unlike wafers and other large implants, gels and microsphere- and nanosphere-based or polymeric microchips have been tested as alternate drug delivery implants. However, due to the common limitation of lack of deep tissue penetration, none of these are clinically approved [<xref ref-type="bibr" rid="CR188">188</xref>]. IN is another non-invasive approach to circumvent the BBB. Although the mechanism of intranasal drug delivery to brain is not well understood, the olfactory and trigeminal pathway is presumed to be the significant route for nose-to-brain drug delivery [<xref ref-type="bibr" rid="CR197">197</xref>]. Some clinical trials of IN for the brain disease treatment are ongoing.</p></sec></sec><sec id="Sec32"><title>Combination therapies and multimodal treatments</title><sec id="Sec33"><title>Synergistic approaches combining targeted therapies with immunotherapies</title><p id="Par127">Targeted therapies can be more effective and less harmful than traditional chemotherapy or radiotherapy [<xref ref-type="bibr" rid="CR198">198</xref>]. However, cancer cells can activate alternative signaling pathways to bypass the blocked pathways targeted by special inhibitors and gain an adaptive resistance. Immunotherapies activate the body&#x02019;s immune cells against cancer cells and represent the most promising strategy for cancer therapy. However, cancer cells also become resistant to immunotherapies through the downregulation of antigens that immune cells recognize, making themselves less visible to the immune system [<xref ref-type="bibr" rid="CR199">199</xref>]. In addition, the presence of immunosuppressive TME also contributes to the low efficacy of immunotherapies [<xref ref-type="bibr" rid="CR200">200</xref>, <xref ref-type="bibr" rid="CR201">201</xref>]. To address the adaptation of cancer cells to targeted therapy and resistance to immunotherapy, scientists have explored combination strategies that targeted therapies combined with immunotherapies based on the complementary mechanisms of action and potential for synergistic interaction [<xref ref-type="bibr" rid="CR202">202</xref>, <xref ref-type="bibr" rid="CR203">203</xref>].</p><p id="Par128">Small-molecule targeted therapies have been reported to exert specific effects on antitumor immune response in mouse models and in the clinical trials. Inhibitors of v-Raf murine sarcoma viral oncogene homolog B (BRAF), CDK4/6 and poly ADP-ribose polymerase 1/2 (PARP1/2) are currently being tested in combination with immune checkpoint blockades (ICBs) in clinical trials and have shown promising potential. Treatment with BRAF inhibitors has been shown to increase NK-cell infiltration and reduce Treg and MDSC levels in mouse models of BRAF-mutant melanoma [<xref ref-type="bibr" rid="CR204">204</xref>&#x02013;<xref ref-type="bibr" rid="CR206">206</xref>]. Furthermore, BRAF inhibition with dabrafenib in combination with the MEK inhibitor trametinib also enhanced CD8<sup>+</sup> T-cell infiltration and improved response to PD-1 blockade in animal model [<xref ref-type="bibr" rid="CR207">207</xref>]. In vitro small-molecule screen has identified CDK4/6 inhibitors as capable of directly enhancing T-cell activation via NFAT signaling, which was required for proper activation and function of T cells [<xref ref-type="bibr" rid="CR208">208</xref>]. CDK4/6 inhibition by palbociclib or trilaciclib has been reported to potentiate PD-1 blockade to stimulate antitumor T-cell function and inhibit tumor growth in preclinical studies. In vivo treatment with CDK4/6 inhibitors increased PD-L1 levels of tumor cells and sensitized ICBs, resulting in tumor regression in mice receiving combined palbociclib and anti-PD-1. It has been reported that the therapeutic efficacy of PARP inhibitors (PARPis) required not only the direct cytotoxicity, but also the coordinated activation of robust local and systemic antitumor immune response [<xref ref-type="bibr" rid="CR209">209</xref>, <xref ref-type="bibr" rid="CR210">210</xref>]. PARPis have also been shown to induce expression of PD-L1 in tumor cells [<xref ref-type="bibr" rid="CR211">211</xref>&#x02013;<xref ref-type="bibr" rid="CR214">214</xref>], which could promote the adaptative immune suppression. Preclinical studies have shown that PD-1/PD-L1 blockade further augmented PARPi-triggered immune response, leading to more durable suppression of tumor growth and prolonged survival.</p><p id="Par129">Recent studies have revealed that PD&#x02011;L1 and VEGF dual blockade enhanced anti&#x02011;tumor effect on BMs in animal model. The combination of anti-PD-L1 antibody and anti-VEGF antibody showed a stronger anti-tumor effect than each single agent [<xref ref-type="bibr" rid="CR215">215</xref>]. Anti-PD-L1 antibody alone enhanced CD8<sup>+</sup> T cell priming in regional lymph nodes and increased the density of CD8<sup>+</sup> cells in the brain tissue. Anti-VEGF antibody alone decreased microvessel density in BM lesions. PD-L1 blockade combined with VEGF blockade increased the antitumor effect by increasing the infiltration of activated CD8<sup>+</sup> T cell and decreasing microvessel density. LCBM have posed a significant clinical challenge due to acquired resistance to TKI treatment. Fu et al. have revealed that TKI treatment elevated the immune checkpoint CTLA4 expression in T&#x000a0;cells, promoting an immune-suppressive microenvironment [<xref ref-type="bibr" rid="CR216">216</xref>]. Combination of CTLA4 blockade with TKI treatment enhanced efficacy over TKI monotherapy, highlighting the potential of CTLA4 blockade in effectively overcoming TKI resistance in LCBM.</p></sec><sec id="Sec34"><title>Metabolic reprogramming as a therapeutic target</title><p id="Par130">Metabolic alterations observed in BMs provides potential targets for new therapeutics. Since cancer cells have higher nutrient consumption than normal cells, targeting metabolism represents a potential therapeutic perspective. The enzymes that participate in biochemical reactions during metabolism provide many target-specific targets that can be exploited pharmacologically. Given that normal brain cells use the same metabolic pathways as BMs, it is important to account for the potential off-target toxicities of metabolic-targeted therapeutics. Some metabolic interventions have already exhibited minimal toxicity profiles. </p><p id="Par131">Ferraro et al. have revealed that fatty acid synthesis was required for breast cancer BMs [<xref ref-type="bibr" rid="CR217">217</xref>]. Fatty acid synthesis was elevated in BCBM, which was an adaptation to decreased lipid availability in the brain relative to other tissues. Genetic or pharmacological inhibition of fatty acid synthase reduces breast tumor growth in the brain, demonstrating that differences in nutrient availability across metastatic sites can result in targetable metabolic dependencies. Furthermore, both primary brain tumors and metastatic tumors show upregulated glycolysis and OXPHOS for which many potential drugs, including&#x000a0;metformin&#x000a0;and&#x000a0;phenformin, that target bioenergetic pathways have been identified as therapeutic alternatives in the clinical setting [<xref ref-type="bibr" rid="CR218">218</xref>&#x02013;<xref ref-type="bibr" rid="CR221">221</xref>]. The treatment of cancer cells with dichloroacetate, an inhibitor of mitochondrial pyruvate dehydrogenase kinase, led to normalize glucose oxidation, making the cancer cells susceptible to apoptosis while normal cells are unaffected [<xref ref-type="bibr" rid="CR222">222</xref>]. Dichloroacetate is also well tolerated in mice and in humans [<xref ref-type="bibr" rid="CR223">223</xref>, <xref ref-type="bibr" rid="CR224">224</xref>]. These studies demonstrate the potential benefit of targeting metabolic liability and flexibility to treat BMs. On the other hand, inhibition of key metabolic factors in brain tumor cells is challenging, as neurons and&#x000a0;glial cells&#x000a0;are metabolically active, and their inhibition can lead to&#x000a0;CNS toxicity. Furthermore, many drugs fail to penetrate brain tissue due to the presence of formidable BBB, making the design of BM-targeting therapies very challenging. Effective drug delivery methods combined with metabolic targets may provide advances in the treatment of BMs.</p></sec></sec><sec id="Sec35"><title>Personalized medicine and precision medicine</title><sec id="Sec36"><title>Biomarker-driven treatment strategies</title><p id="Par132">Biomarker testing is recommended for patients diagnosed with NSCLC and already implemented in diagnostic and therapeutic routine workups. Patients with targetable mutations are associated with a higher incidence of BMs, but also with a prolonged survival prognosis, particularly after the introduction to targeted therapy [<xref ref-type="bibr" rid="CR225">225</xref>]. Approximately 15&#x02009;~&#x02009;20% of non-squamous NSCLC patients present with an EGFR mutation and routine testing of EGFR mutation is recommended in metastatic NSCLC with non-squamous histology [<xref ref-type="bibr" rid="CR226">226</xref>, <xref ref-type="bibr" rid="CR227">227</xref>]. EGFR mutations predict response to therapy with TKIs. Specifically, the third-generation EGFR-TKI osimertinib presented remarkable intracranial response rates of over 80% in patients with EGFR-mutated metastatic lung cancer and asymptomatic BMs.</p><p id="Par133">The ALK rearrangements occur in 2&#x02009;~&#x02009;9% of LUAD patients [<xref ref-type="bibr" rid="CR228">228</xref>]. Therefore, ALK testing is recommended in patients with non-squamous histology if EGFR mutations were not detected [<xref ref-type="bibr" rid="CR229">229</xref>]. ALK rearrangements predict response to ALK-TKIs. The next-generation ALK inhibitors, including alectinib, lorlatinib, and brigatinib, were associated with considerable intracranial response rates over 65% [<xref ref-type="bibr" rid="CR230">230</xref>&#x02013;<xref ref-type="bibr" rid="CR232">232</xref>]. Importantly, ALK-TKIs are further effective in BM patients with ROS1 rearrangement. ROS1 gene rearrangements are present in approximately 1&#x02009;~&#x02009;2% of non-squamous NSCLC patients and serve as a predictive biomarker for response to ALK-TKIs [<xref ref-type="bibr" rid="CR233">233</xref>]. Considering the remarkable intracranial response rates in ROS1-altered LUAD patients treated with TKIs, regularly testing for ROS1 in clinical setting should be evaluated [<xref ref-type="bibr" rid="CR234">234</xref>]. BRAF V600E mutation is detected in 2&#x02009;~&#x02009;4% of NSCLC patients, therefore, routine testing for this biomarker in BMs from NSCLC are currently not generally recommended. However, recent phase II clinical trials have postulated the clinical efficacy of BRAF inhibitor dabrafenib in combination with the MAPK kinase inhibitor trametinib as a therapeutic approach in metastatic BRAF V600E-mutated NSCLC. Moreover, considering the success of dual inhibition in BRAF V600E-mutated melanoma BMs, further clinical trials focusing on the intracranial efficacy of dabrafenib and trametinib in BRAF-mutated NSCLC BM are warranted.</p></sec><sec id="Sec37"><title>Patient-derived xenograft (PDX) models for personalized therapy</title><p id="Par134">Establishment of a disease model that adequately reflects the characteristics of BM tumors is crucial to the development of novel therapeutics. PDX models have a high clinical relevance, offering the potential for individualized patient treatment. Previous research demonstrated that successful PDX modeling can be achieved by direct intracranial implantation of metastatic cells or tissue into the lateral ventricle and frontal cortex. Orthotopic intracranial implants allow cancer cells to more closely resemble their original patient tumors both phenotypically and genotypically given the influence of the brain microenvironment.</p><p id="Par135">Antitumor activity against BMs can be assessed in PDX models, which may be especially relevant when implanted orthotopically into the brain to more closely reproduce the anatomic situation of the original tumor. Baschnagel et al. have reported on the development and characterization of a cohort of NSCLC-BM PDX models, including both flank and orthotopic intracranial xenografts [<xref ref-type="bibr" rid="CR235">235</xref>]. These PDXs models have been assessed their response to radiation and selumetinib in <italic>KRAS</italic> mutated xenografts and savolitinib in a <italic>MET</italic> exon 14 mutated xenograft. Friese-Hamim et al. have investigated the brain penetration and efficacy of tepotinib in orthotopic PDX models of <italic>MET</italic>-driven NSCLC-BM [<xref ref-type="bibr" rid="CR236">236</xref>]. Guillen et al. have established a human breast cancer-derived xenograft and organoid platform for drug discovery and precision oncology [<xref ref-type="bibr" rid="CR237">237</xref>]. They leveraged PDXs and PDX-derived organoids for drug screening and demonstrated the feasibility of using these models for precision oncology in real time with clinical care in a case of triple-negative breast cancer. A FDA-approved drug eribulin with high efficacy against the models was identified and treatment with this therapy resulted in a complete response for the individual.</p><p id="Par136"> Faria et al. have established a library of 23 PDXs of BMs from eight primary tumors that resembled the disseminated disease of the patients [<xref ref-type="bibr" rid="CR238">238</xref>]. These PDXs and their matched BMs have similar gene expression profiles and recapitulate the dissemination pattern of patient tumors. These PDXs were tested in preclinical studies for anticancer therapies, such as the FDA-approved drugs of pan-PI3K inhibitor buparlisib and mTOR inhibitor everolimus. Sun et al. have made comprehensive characterization of 536 PDX models and prioritized candidates for targeted treatment [<xref ref-type="bibr" rid="CR239">239</xref>]. These studies uncovered that development of candidate cancer treatments was a resource-intensive process, with the research community continuing to investigate options beyond static genomic characterization. Compared with human tumors, PDXs typically have higher purity and fit to investigate dynamic driver events and molecular properties via multiple time points from same case PDXs. These PDX models of BMs recapitulate the biology of human metastatic disease and provide valuable methods and resources for functional precision medicine and drug development for human BMs.</p></sec></sec></sec><sec id="Sec38"><title>Conclusion</title><p id="Par137">BM is the leading cause of death in lung cancer patients with 40% of NSCLC patients and 40&#x02013;50% of SCLC patients develop BMs during their disease course, leading to high morbidity and mortality rates. Despite the advances of therapeutic strategies in the past decades, the prognosis is still grim and the molecular and cellular mechanisms of BMs have not been fully elucidated. Current LCBM trials predominantly target NSCLC and tyrosine kinase inhibitors emerged as promising treatments for brain parenchymal and leptomeningeal NSCLC metastases (Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>). For example, a phase II trial of atezolizumab combined with carboplatin and pemetrexed showed activity in advanced and untreated NSCLC-BM patients with an acceptable safety profile [<xref ref-type="bibr" rid="CR240">240</xref>]. BM is a complex process involves a series of pathological stages, which can be divided into three major stages according to the location of incident: primary lung cancer stage, CTCs stage, and BM stage. Each step of the BM process is tightly regulated by distinct molecular and cellular mechanisms. However, most of the current studies focused on the third stage of the interaction between tumours cells and brain microenvironment. Due to the lack of animal models, the intrinsic signature of dissociated cancer cells and molecular changes before entering brain are usually less studied. Thus, a deeper understanding of the BM process for both before and after entering the brain may help to develop more and effective potential therapeutic strategies.
<table-wrap id="Tab4"><label>Table&#x000a0;4</label><caption><p>Clinical trials directed towards brain metastases in recent years</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Identifier</th><th align="left">Phase</th><th align="left">BM Type</th><th align="left">Patients included</th><th align="left">Treatment</th><th align="left">Started year</th><th align="left">Status</th></tr></thead><tbody><tr><td align="left">NCT03297788</td><td align="left">II</td><td align="left">SCLC</td><td align="left">SCLC patients with BM</td><td align="left">SRS or WBRT</td><td align="left">2017</td><td align="left">Completed</td></tr><tr><td align="left">NCT04824079</td><td align="left">II</td><td align="left">NSCLC</td><td align="left">Advanced NSCLC patients with BM after treatment with EGFR inhibitors</td><td align="left">Keynatinib</td><td align="left">2020</td><td align="left">Recruiting</td></tr><tr><td align="left">NCT05012254</td><td align="left">II</td><td align="left">NSCLC</td><td align="left">Stage IV or recurrent, NSCLC patients with synchronous BM</td><td align="left">Treatment with two cycles of Platinum-based chemotherapy (Carboplatin or Cisplatin) plus Nivolumab and Ipilimumab; then maintain with Nivolumab and Ipilimumab</td><td align="left">2021</td><td align="left">Active, not recruiting</td></tr><tr><td align="left">NCT04631029</td><td align="left">I</td><td align="left">SCLC</td><td align="left">Extensive stage SCLC patients with BM</td><td align="left">Entinostat in combination with Atezolizumab/Carboplatin/Etoposide</td><td align="left">2021</td><td align="left">Completed</td></tr><tr><td align="left">NCT05104281</td><td align="left">III</td><td align="left">NSCLC</td><td align="left">NSCLC patients with BM and <italic>EGFR</italic> mutation</td><td align="left">Osimertinib combined with Bevacizumab</td><td align="left">2021</td><td align="left">Recruiting</td></tr><tr><td align="left">NCT06128148</td><td align="left">I</td><td align="left">NSCLC</td><td align="left">NSCLC patients with BM and <italic>ROS1</italic> fusion</td><td align="left">JYP0322 (an orally available inhibitor of ROS1)</td><td align="left">2022</td><td align="left">Recruiting</td></tr><tr><td align="left">NCT04967417</td><td align="left">II</td><td align="left">NSCLC</td><td align="left">Stage IV NSCLC patients with BM</td><td align="left">Pemetrexed, Carboplatin and Pembrolizumab or Paclitaxel, Carboplatin and Pembrolizumab</td><td align="left">2022</td><td align="left">Recruiting</td></tr><tr><td align="left">NCT05948813</td><td align="left">II</td><td align="left">NSCLC</td><td align="left">Patients with EGFR-mutated NSCLC with BM</td><td align="left">TY-9591; Osimertinib</td><td align="left">2023</td><td align="left">Recruiting</td></tr><tr><td align="left">NCT06238882</td><td align="left">not applicable</td><td align="left">NSCLC</td><td align="left">Patients with stage IV NSCLC with <italic>EGFR</italic> mutations and BM</td><td align="left">Total CRT plus concomitant transdermal nitroglycerin</td><td align="left">2023</td><td align="left">Recruiting</td></tr><tr><td align="left">NCT06476093</td><td align="left">not applicable</td><td align="left">NSCLC</td><td align="left">NSCLC patients with BM resistant to treatment</td><td align="left">SRT combined with Anlotinib (a novel TKI)</td><td align="left">2024</td><td align="left">Recruiting</td></tr><tr><td align="left">NCT06501391</td><td align="left">II</td><td align="left">NSCLC</td><td align="left">Stage IV NSCLC patients with BM and without driver gene mutations</td><td align="left">PD-L1/PD-1 inhibitor and chemotherapy combined with SRT or WBRT</td><td align="left">2024</td><td align="left">Recruiting</td></tr><tr><td align="left">NCT06676917</td><td align="left">II</td><td align="left">NSCLC</td><td align="left">Non-squamous NSCLC with BM</td><td align="left">Datopotamab Deruxtecan (Dato-DXd; a tumor-associated calcium signal transducer 2 (TROP2)-directed antibody drug conjugate)</td><td align="left">2025</td><td align="left">Not yet recruiting</td></tr><tr><td align="left">NCT03696030</td><td align="left">I</td><td align="left">BC</td><td align="left">HER2 positive BC patients with BM</td><td align="left">Autologous HER2-targeted chimeric antigen receptor (HER2-CAR) T cells</td><td align="left">2018</td><td align="left">Recruiting</td></tr><tr><td align="left">NCT05781633</td><td align="left">II</td><td align="left">BC</td><td align="left">BC patients with BM</td><td align="left">A regimen of eutidrone, etoposide and bevacizumab</td><td align="left">2022</td><td align="left">Recruiting</td></tr><tr><td align="left">NCT06152822</td><td align="left">II</td><td align="left">BC</td><td align="left">HER2 positive BC patients with BM</td><td align="left">Pyrotinib combined with capecitabine and bevacizumab</td><td align="left">2023</td><td align="left">Recruiting</td></tr><tr><td align="left">NCT05872347</td><td align="left">II</td><td align="left">BC</td><td align="left">HR-positive, HER2-negative BC patients with BM</td><td align="left">SPH4336 (a novel highly selective oral CDK4/6 inhibitor)</td><td align="left">2023</td><td align="left">Recruiting</td></tr><tr><td align="left">NCT06088056</td><td align="left">II</td><td align="left">BC</td><td align="left">HER2 positive BC patients with BM</td><td align="left">SRT combined with Trastuzumab-Deruxtecan (T-DXd)</td><td align="left">2023</td><td align="left">Not yet recruiting</td></tr><tr><td align="left">NCT06418594</td><td align="left">II</td><td align="left">BC</td><td align="left">HER2-negative BC patients with BM</td><td align="left">Adebrelimab plus apatinib and etoposide</td><td align="left">2024</td><td align="left">Recruiting</td></tr><tr><td align="left">NCT06462079</td><td align="left">II</td><td align="left">BC</td><td align="left">HER2-negative BC patients with BM</td><td align="left">Sacituzumab Govitecan combined with intracranial radiotherapy</td><td align="left">2024</td><td align="left">Not yet recruiting</td></tr><tr><td align="left">NCT06210438</td><td align="left">II</td><td align="left">BC</td><td align="left">Triple-negative BC patients with BM</td><td align="left">SHR-A1921 (an antibody conjugated drug targeting Trop-2) combined with bevacizumab</td><td align="left">2024</td><td align="left">Not yet recruiting</td></tr><tr><td align="left">NCT03563729</td><td align="left">II</td><td align="left">Melanoma</td><td align="left">Melanoma patients with BM and in need of steroid treatment</td><td align="left">Pembrolizumab alone or ipilimumab and nivolumab in combination</td><td align="left">2018</td><td align="left">Recruiting</td></tr><tr><td align="left">NCT03898908</td><td align="left">II</td><td align="left">Melanoma</td><td align="left">Patients with BRAF mutant melanoma metastatic to the brain</td><td align="left">Encorafenib and binimetinib</td><td align="left">2019</td><td align="left">Active, not recruiting</td></tr><tr><td align="left">NCT04074096</td><td align="left">II</td><td align="left">Melanoma</td><td align="left">BRAFV600 mutation-positive melanoma patients with BM</td><td align="left">Adding upfront SRS to binimetinib-encorafenib-pembrolizumab combination therapy</td><td align="left">2022</td><td align="left">Active, not recruiting</td></tr><tr><td align="left">NCT05704933</td><td align="left">I</td><td align="left">Melanoma</td><td align="left">Melanoma patients with BM</td><td align="left">A single dose of nivolumab with ipilimumab or relatlimab</td><td align="left">2023</td><td align="left">Active, not recruiting</td></tr><tr><td align="left">NCT06712927</td><td align="left">II</td><td align="left">Melanoma</td><td align="left">Melanoma patients with BM</td><td align="left">Relatlimab, nivolumab, and ipilimumab</td><td align="left">2025</td><td align="left">Not yet recruiting</td></tr></tbody></table><table-wrap-foot><p>All information comes from <ext-link ext-link-type="uri" xlink:href="https://classic.clinicaltrials.gov">https://classic.clinicaltrials.gov</ext-link></p><p><italic>BC</italic> breast cancer, <italic>CRT</italic> cranial radiation therapy, <italic>EGFR</italic> Epidermal Growth Factor Receptor, <italic>SRT</italic> stereotactic radiotherapy, <italic>SRS</italic> stereotactic radiotherapy, <italic>WBRT</italic> whole brain radiation therapy</p></table-wrap-foot></table-wrap></p><p id="Par138">Over the past decades, advancements in cancer therapeutics have markedly improved patient outcomes, resulting in longer survival and subsequently a potential rise in the incidence of BMs. Although novel therapies such as immunotherapies and targeted therapies exhibit promising results in controlling extracranial disease, the efficacy of systemic therapies for intracranial metastases is still grim and treatment options for BMs remain limited. This is partly attributed to the special structure of the brain, especially the obstruction of BBB that can impede the antitumor agents delivery into brain. To solve this issue, biomaterial-based nanodrugs have been developed and applied in preclinical studies and clinical trials of BMs. Nanoparticles used in targeted drug delivery systems exhibited unique advantages and have increased the efficacy and reduced the toxicity of parent drugs in clinical trials of BMs treatment.</p><p id="Par139">Despite the advances in treatment have significantly increased life span of BM patients, the incidence of BMs has been steadily increasing and the prognosis for BM patients remains poor. In addition, the current therapeutic strategies often lead to serious adverse. BM patients are often accompanied with extracranial metastases, which must be addressed along with BMs. Since the tumoral heterogeneity of BM patients, the treatment strategies for BM patients should be in a flexible way. Therefore, fully understanding the molecular and cellular mechanisms of BMs, as well as the development of new effective therapeutic interventions based on the newly identified targets, will ultimately change the dismal prognosis of BM patients.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>ABL</term><def><p id="Par2">Abelson</p></def></def-item><def-item><term>ALDH1A1</term><def><p id="Par3">Aldehyde dehydrogenase 1A1</p></def></def-item><def-item><term>ALK</term><def><p id="Par4">Anaplastic-lymphoma-kinase</p></def></def-item><def-item><term>AMT</term><def><p id="Par5">Absorption-mediated transcytosis</p></def></def-item><def-item><term>Ang2</term><def><p id="Par6">Angiopoietin-2</p></def></def-item><def-item><term>BBB</term><def><p id="Par7">Blood&#x02013;brain barrier</p></def></def-item><def-item><term>BM</term><def><p id="Par8">Brain metastases</p></def></def-item><def-item><term>BMDMs</term><def><p id="Par9">Bone-marrow-derived myeloid cells</p></def></def-item><def-item><term>BMOR</term><def><p id="Par10">Brain-enriched long noncoding RNA</p></def></def-item><def-item><term>BRAF</term><def><p id="Par11">V-Raf murine sarcoma viral oncogene homolog B</p></def></def-item><def-item><term>CAFs</term><def><p id="Par12">Cancer-associated fibroblasts</p></def></def-item><def-item><term>cCAFs</term><def><p id="Par13">Circulated CAFs</p></def></def-item><def-item><term>CDK</term><def><p id="Par14">Cyclin-dependent kinase</p></def></def-item><def-item><term>Cd-pericytes</term><def><p id="Par15">Cell-derived pericyte-like cells</p></def></def-item><def-item><term>CEA</term><def><p id="Par16">Carcinoembryonic antigen</p></def></def-item><def-item><term>CED</term><def><p id="Par17">Convection enhanced delivery</p></def></def-item><def-item><term>cGAMP</term><def><p id="Par18">2&#x02032;3&#x02032;-cyclic GMP-AMP</p></def></def-item><def-item><term>CITE-seq</term><def><p id="Par19">cellular indexing of transcriptomes and epitopes by sequencing</p></def></def-item><def-item><term>CTCs</term><def><p id="Par20">Circulating tumour cells</p></def></def-item><def-item><term>CTLA4</term><def><p id="Par21">Cytotoxic T lymphocyte-associated antigen-4</p></def></def-item><def-item><term>CyTOF</term><def><p id="Par22">cytometry by time-of-flight</p></def></def-item><def-item><term>DCCs</term><def><p id="Par23">Disseminated cancer cells</p></def></def-item><def-item><term>DHA</term><def><p id="Par24">Docosahexaenoic acid</p></def></def-item><def-item><term>ECM</term><def><p id="Par25">Extracellular matrix</p></def></def-item><def-item><term>EGFR</term><def><p id="Par26">Epidermal growth factor receptor</p></def></def-item><def-item><term>EMEC</term><def><p id="Par27">Early metastatic epithelial cell cluster</p></def></def-item><def-item><term>EMT</term><def><p id="Par28">Epithelial-mesenchymal transition</p></def></def-item><def-item><term>ICBs</term><def><p id="Par29">Immune checkpoint blockades</p></def></def-item><def-item><term>ICIs</term><def><p id="Par30">Immune checkpoint inhibitors</p></def></def-item><def-item><term>IL-6</term><def><p id="Par31">Interleukin 6</p></def></def-item><def-item><term>IN</term><def><p id="Par32">Intranasal delivery</p></def></def-item><def-item><term>L1CAM</term><def><p id="Par33">L1 cell adhesion molecule</p></def></def-item><def-item><term>LCBM</term><def><p id="Par34">Lung cancer brain metastasis</p></def></def-item><def-item><term>lnc-BM</term><def><p id="Par35">LncRNA associated with BCBM</p></def></def-item><def-item><term>lncRNAs</term><def><p id="Par36">Long ncRNAs</p></def></def-item><def-item><term>LND</term><def><p id="Par37">Lonidamine</p></def></def-item><def-item><term>LPCAT1</term><def><p id="Par38">Lysophosphatidylcholine acyltransferase 1</p></def></def-item><def-item><term>LUAD</term><def><p id="Par39">Lung adenocarcinoma</p></def></def-item><def-item><term>MALAT1</term><def><p id="Par40">Metastasis associated lung adenocarcinoma transcript 1</p></def></def-item><def-item><term>MAPK</term><def><p id="Par41">Mitogen-activated protein kinase</p></def></def-item><def-item><term>MET</term><def><p id="Par42">Mesenchymal-to-epithelial transition</p></def></def-item><def-item><term>Mfsd2a</term><def><p id="Par43">Major facilitator superfamily domain 2a</p></def></def-item><def-item><term>Mito-LND</term><def><p id="Par44">Mito-lonidamine</p></def></def-item><def-item><term>MMP9</term><def><p id="Par45">Matrix metalloproteinase-9</p></def></def-item><def-item><term>MSLN</term><def><p id="Par46">Mesothelin</p></def></def-item><def-item><term>ncRNAs</term><def><p id="Par47">Non-coding RNAs</p></def></def-item><def-item><term>NK cell</term><def><p id="Par48">Natural killer cell</p></def></def-item><def-item><term>NMDARs</term><def><p id="Par49">N-methyl-d-aspartate receptors</p></def></def-item><def-item><term>NRG1</term><def><p id="Par50">Neuregulin 1</p></def></def-item><def-item><term>NSCLC</term><def><p id="Par51">Non-small cell lung cancer</p></def></def-item><def-item><term>NTRK</term><def><p id="Par52">Neurotrophic tropomyosin receptor kinase</p></def></def-item><def-item><term>ORR</term><def><p id="Par53">Objective response rate</p></def></def-item><def-item><term>OS</term><def><p id="Par54">Overall survival</p></def></def-item><def-item><term>OXPHOS</term><def><p id="Par55">Oxidative phosphorylation</p></def></def-item><def-item><term>PA</term><def><p id="Par56">Plasminogen activator</p></def></def-item><def-item><term>PARP 1/2</term><def><p id="Par57">Poly ADP-ribose polymerase 1/2</p></def></def-item><def-item><term>PARPis</term><def><p id="Par58">PARP inhibitors</p></def></def-item><def-item><term>PD-1</term><def><p id="Par59">Programmed death receptor 1</p></def></def-item><def-item><term>PDGF</term><def><p id="Par60">Platelet-derived growth factor</p></def></def-item><def-item><term>PD-L1</term><def><p id="Par61">Programmed death ligand 1</p></def></def-item><def-item><term>PFS</term><def><p id="Par62">Progression free survival</p></def></def-item><def-item><term>PHGDH</term><def><p id="Par63">Phosphoglycerate Dehydrogenase</p></def></def-item><def-item><term>PLGF</term><def><p id="Par64">Placental growth factor</p></def></def-item><def-item><term>RA</term><def><p id="Par65">Retinoic acid; RET: rearranged during transfection</p></def></def-item><def-item><term>RMT</term><def><p id="Par66">Receptor-mediated transcytosis</p></def></def-item><def-item><term>ROS</term><def><p id="Par67">Reactive oxygen species</p></def></def-item><def-item><term>ROS1</term><def><p id="Par68">ROS proto-oncogene 1</p></def></def-item><def-item><term>SCLC</term><def><p id="Par69">Small cell lung cancer</p></def></def-item><def-item><term>scRNA-seq</term><def><p id="Par70">Single-cell RNA- sequencing</p></def></def-item><def-item><term>SRS</term><def><p id="Par71">Stereotactic radiosurgery</p></def></def-item><def-item><term>STING</term><def><p id="Par72">stimulator of interferon genes</p></def></def-item><def-item><term>TAM</term><def><p id="Par73">Tumor associated macrophages</p></def></def-item><def-item><term>TEM</term><def><p id="Par74">Trans-endothelial migration</p></def></def-item><def-item><term>TKIs</term><def><p id="Par75">Tyrosine kinase inhibitors</p></def></def-item><def-item><term>TME</term><def><p id="Par76">Tumour microenvironment</p></def></def-item><def-item><term>TMT</term><def><p id="Par77">Transporter-mediated transcytosis</p></def></def-item><def-item><term>ULBP</term><def><p id="Par78">UL16-binding proteins</p></def></def-item><def-item><term>VEGFA</term><def><p id="Par79">Vascular endothelial growth factor A</p></def></def-item><def-item><term>WBCs</term><def><p id="Par80">White blood cells</p></def></def-item><def-item><term>WBRT</term><def><p id="Par81">Whole-brain radiation therapy</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Publisher&#x02019;s Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>Thanks to all authors for their contributions to the manuscript. Figures were created with the help of an online drawing tool website named &#x0201c;Biorender&#x0201d;.</p></ack><notes notes-type="author-contribution"><title>Authors&#x02019; contributions</title><p>LZ and YL conducted the literature search, drafted the manuscript, and prepared all figures and tables. YH, CZ, ZL, BZ, HS, HL, XL, ZX, YW and JZ provided critical feedback and contributed to revisions of the manuscript. All authors have read and&#x000a0;approved the final version of the manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>The study was supported by the National Natural Science Foundation of China (82273012 and 82472674) and the 1&#x000b7;3&#x000b7;5 project for disciplines of excellence, West China Hospital, Sichuan University (ZYYC22003).</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>Not applicable.</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par140">Not applicable.</p></notes><notes id="FPar2"><title>Consent for publication</title><p id="Par141">Not applicable.</p></notes><notes id="FPar3" notes-type="COI-statement"><title>Competing interests</title><p id="Par142">All authors state that there is no conflict of interests.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name><surname>Maher</surname><given-names>EA</given-names></name><name><surname>Mietz</surname><given-names>J</given-names></name><name><surname>Arteaga</surname><given-names>CL</given-names></name><name><surname>DePinho</surname><given-names>RA</given-names></name><name><surname>Mohla</surname><given-names>S</given-names></name></person-group><article-title>Brain metastasis: opportunities in basic and translational research</article-title><source>Cancer Res</source><year>2009</year><volume>69</volume><fpage>6015</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-08-4347</pub-id><pub-id pub-id-type="pmid">19638593</pub-id>
</element-citation><mixed-citation id="mc-CR1" publication-type="journal">Maher EA, Mietz J, Arteaga CL, DePinho RA, Mohla S. Brain metastasis: opportunities in basic and translational research. Cancer Res. 2009;69:6015&#x02013;20. 10.1158/0008-5472.CAN-08-4347.<pub-id pub-id-type="pmid">19638593</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>Nayak</surname><given-names>L</given-names></name><name><surname>Lee</surname><given-names>EQ</given-names></name><name><surname>Wen</surname><given-names>PY</given-names></name></person-group><article-title>Epidemiology of brain metastases</article-title><source>Curr Oncol Rep</source><year>2012</year><volume>14</volume><fpage>48</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1007/s11912-011-0203-y</pub-id><pub-id pub-id-type="pmid">22012633</pub-id>
</element-citation><mixed-citation id="mc-CR2" publication-type="journal">Nayak L, Lee EQ, Wen PY. Epidemiology of brain metastases. Curr Oncol Rep. 2012;14:48&#x02013;54. 10.1007/s11912-011-0203-y.<pub-id pub-id-type="pmid">22012633</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Achrol</surname><given-names>AS</given-names></name><name><surname>Rennert</surname><given-names>RC</given-names></name><name><surname>Anders</surname><given-names>C</given-names></name><name><surname>Soffietti</surname><given-names>R</given-names></name><name><surname>Ahluwalia</surname><given-names>MS</given-names></name><name><surname>Nayak</surname><given-names>L</given-names></name><etal/></person-group><article-title>Brain metastases</article-title><source>Nat Rev Dis Primers</source><year>2019</year><volume>5</volume><fpage>5</fpage><pub-id pub-id-type="doi">10.1038/s41572-018-0055-y</pub-id><pub-id pub-id-type="pmid">30655533</pub-id>
</element-citation><mixed-citation id="mc-CR3" publication-type="journal">Achrol AS, Rennert RC, Anders C, Soffietti R, Ahluwalia MS, Nayak L, et al. Brain metastases. Nat Rev Dis Primers. 2019;5:5. 10.1038/s41572-018-0055-y.<pub-id pub-id-type="pmid">30655533</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Thandra</surname><given-names>KC</given-names></name><name><surname>Barsouk</surname><given-names>A</given-names></name><name><surname>Saginala</surname><given-names>K</given-names></name><name><surname>Aluru</surname><given-names>JS</given-names></name><name><surname>Barsouk</surname><given-names>A</given-names></name></person-group><article-title>Epidemiology of lung cancer</article-title><source>Contemp Oncol (Pozn)</source><year>2021</year><volume>25</volume><fpage>45</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.5114/wo.2021.103829</pub-id><pub-id pub-id-type="pmid">33911981</pub-id>
</element-citation><mixed-citation id="mc-CR4" publication-type="journal">Thandra KC, Barsouk A, Saginala K, Aluru JS, Barsouk A. Epidemiology of lung cancer. Contemp Oncol (Pozn). 2021;25:45&#x02013;52. 10.5114/wo.2021.103829.<pub-id pub-id-type="pmid">33911981</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Andratschke</surname><given-names>N</given-names></name><name><surname>Kraft</surname><given-names>J</given-names></name><name><surname>Nieder</surname><given-names>C</given-names></name><name><surname>Tay</surname><given-names>R</given-names></name><name><surname>Califano</surname><given-names>R</given-names></name><name><surname>Soffietti</surname><given-names>R</given-names></name><etal/></person-group><article-title>Optimal management of brain metastases in oncogenic-driven non-small cell lung cancer (NSCLC)</article-title><source>Lung Cancer</source><year>2019</year><volume>129</volume><fpage>63</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1016/j.lungcan.2018.12.009</pub-id><pub-id pub-id-type="pmid">30797493</pub-id>
</element-citation><mixed-citation id="mc-CR5" publication-type="journal">Andratschke N, Kraft J, Nieder C, Tay R, Califano R, Soffietti R, et al. Optimal management of brain metastases in oncogenic-driven non-small cell lung cancer (NSCLC). Lung Cancer. 2019;129:63&#x02013;71. 10.1016/j.lungcan.2018.12.009.<pub-id pub-id-type="pmid">30797493</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>N</given-names></name><name><surname>Chu</surname><given-names>Y</given-names></name><name><surname>Song</surname><given-names>Q</given-names></name></person-group><article-title>Brain metastasis in patients with small cell lung cancer</article-title><source>Int J Gen Med</source><year>2021</year><volume>14</volume><fpage>10131</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.2147/IJGM.S342009</pub-id><pub-id pub-id-type="pmid">34992434</pub-id>
</element-citation><mixed-citation id="mc-CR6" publication-type="journal">Li N, Chu Y, Song Q. Brain metastasis in patients with small cell lung cancer. Int J Gen Med. 2021;14:10131&#x02013;9. 10.2147/IJGM.S342009.<pub-id pub-id-type="pmid">34992434</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Cui</surname><given-names>Y</given-names></name><name><surname>Zheng</surname><given-names>X</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Sun</surname><given-names>G</given-names></name></person-group><article-title>Small-cell lung cancer brain metastasis: from molecular mechanisms to diagnosis and treatment</article-title><source>Biochim Biophys Acta Mol Basis Dis</source><year>2022</year><volume>1868</volume><fpage>166557</fpage><pub-id pub-id-type="doi">10.1016/j.bbadis.2022.166557</pub-id><pub-id pub-id-type="pmid">36162624</pub-id>
</element-citation><mixed-citation id="mc-CR7" publication-type="journal">Zhu Y, Cui Y, Zheng X, Zhao Y, Sun G. Small-cell lung cancer brain metastasis: from molecular mechanisms to diagnosis and treatment. Biochim Biophys Acta Mol Basis Dis. 2022;1868:166557. 10.1016/j.bbadis.2022.166557.<pub-id pub-id-type="pmid">36162624</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Yousefi</surname><given-names>M</given-names></name><name><surname>Bahrami</surname><given-names>T</given-names></name><name><surname>Salmaninejad</surname><given-names>A</given-names></name><name><surname>Nosrati</surname><given-names>R</given-names></name><name><surname>Ghaffari</surname><given-names>P</given-names></name><name><surname>Ghaffari</surname><given-names>SH</given-names></name></person-group><article-title>Lung cancer-associated brain metastasis: molecular mechanisms and therapeutic options</article-title><source>Cell Oncol (Dordr)</source><year>2017</year><volume>40</volume><fpage>419</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1007/s13402-017-0345-5</pub-id><pub-id pub-id-type="pmid">28921309</pub-id>
</element-citation><mixed-citation id="mc-CR8" publication-type="journal">Yousefi M, Bahrami T, Salmaninejad A, Nosrati R, Ghaffari P, Ghaffari SH. Lung cancer-associated brain metastasis: molecular mechanisms and therapeutic options. Cell Oncol (Dordr). 2017;40:419&#x02013;41. 10.1007/s13402-017-0345-5.<pub-id pub-id-type="pmid">28921309</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>D</given-names></name><name><surname>Deng</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>T</given-names></name><name><surname>Zhang</surname><given-names>T</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><etal/></person-group><article-title>TGF-beta1-mediated exosomal lnc-MMP2-2 increases blood-brain barrier permeability via the miRNA-1207-5p/EPB41L5 axis to promote non-small cell lung cancer brain metastasis</article-title><source>Cell Death Dis</source><year>2021</year><volume>12</volume><fpage>721</fpage><pub-id pub-id-type="doi">10.1038/s41419-021-04004-z</pub-id><pub-id pub-id-type="pmid">34285192</pub-id>
</element-citation><mixed-citation id="mc-CR9" publication-type="journal">Wu D, Deng S, Li L, Liu T, Zhang T, Li J, et al. TGF-beta1-mediated exosomal lnc-MMP2-2 increases blood-brain barrier permeability via the miRNA-1207-5p/EPB41L5 axis to promote non-small cell lung cancer brain metastasis. Cell Death Dis. 2021;12:721. 10.1038/s41419-021-04004-z.<pub-id pub-id-type="pmid">34285192</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>Ye</surname><given-names>LY</given-names></name><name><surname>Sun</surname><given-names>LX</given-names></name><name><surname>Zhong</surname><given-names>XH</given-names></name><name><surname>Chen</surname><given-names>XS</given-names></name><name><surname>Hu</surname><given-names>S</given-names></name><name><surname>Xu</surname><given-names>RR</given-names></name><etal/></person-group><article-title>The structure of blood-tumor barrier and distribution of chemotherapeutic drugs in non-small cell lung cancer brain metastases</article-title><source>Cancer Cell Int</source><year>2021</year><volume>21</volume><fpage>556</fpage><pub-id pub-id-type="doi">10.1186/s12935-021-02263-6</pub-id><pub-id pub-id-type="pmid">34689774</pub-id>
</element-citation><mixed-citation id="mc-CR10" publication-type="journal">Ye LY, Sun LX, Zhong XH, Chen XS, Hu S, Xu RR, et al. The structure of blood-tumor barrier and distribution of chemotherapeutic drugs in non-small cell lung cancer brain metastases. Cancer Cell Int. 2021;21:556. 10.1186/s12935-021-02263-6.<pub-id pub-id-type="pmid">34689774</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Lowery</surname><given-names>FJ</given-names></name><name><surname>Yu</surname><given-names>D</given-names></name></person-group><article-title>Brain metastasis: unique challenges and open opportunities</article-title><source>Biochim Biophys Acta Rev Cancer</source><year>2017</year><volume>1867</volume><fpage>49</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.1016/j.bbcan.2016.12.001</pub-id><pub-id pub-id-type="pmid">27939792</pub-id>
</element-citation><mixed-citation id="mc-CR11" publication-type="journal">Lowery FJ, Yu D. Brain metastasis: unique challenges and open opportunities. Biochim Biophys Acta Rev Cancer. 2017;1867:49&#x02013;57. 10.1016/j.bbcan.2016.12.001.<pub-id pub-id-type="pmid">27939792</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Louveau</surname><given-names>A</given-names></name><name><surname>Smirnov</surname><given-names>I</given-names></name><name><surname>Keyes</surname><given-names>TJ</given-names></name><name><surname>Eccles</surname><given-names>JD</given-names></name><name><surname>Rouhani</surname><given-names>SJ</given-names></name><name><surname>Peske</surname><given-names>JD</given-names></name><etal/></person-group><article-title>Structural and functional features of central nervous system lymphatic vessels</article-title><source>Nature</source><year>2015</year><volume>523</volume><fpage>337</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1038/nature14432</pub-id><pub-id pub-id-type="pmid">26030524</pub-id>
</element-citation><mixed-citation id="mc-CR12" publication-type="journal">Louveau A, Smirnov I, Keyes TJ, Eccles JD, Rouhani SJ, Peske JD, et al. Structural and functional features of central nervous system lymphatic vessels. Nature. 2015;523:337&#x02013;41. 10.1038/nature14432.<pub-id pub-id-type="pmid">26030524</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>X</given-names></name><name><surname>DeAngelis</surname><given-names>LM</given-names></name></person-group><article-title>Treatment of brain metastases</article-title><source>J Clin Oncol</source><year>2015</year><volume>33</volume><fpage>3475</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1200/JCO.2015.60.9503</pub-id><pub-id pub-id-type="pmid">26282648</pub-id>
</element-citation><mixed-citation id="mc-CR13" publication-type="journal">Lin X, DeAngelis LM. Treatment of brain metastases. J Clin Oncol. 2015;33:3475&#x02013;84. 10.1200/JCO.2015.60.9503.<pub-id pub-id-type="pmid">26282648</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>Franchino</surname><given-names>F</given-names></name><name><surname>Ruda</surname><given-names>R</given-names></name><name><surname>Soffietti</surname><given-names>R</given-names></name></person-group><article-title>Mechanisms and therapy for cancer metastasis to the brain</article-title><source>Front Oncol</source><year>2018</year><volume>8</volume><fpage>161</fpage><pub-id pub-id-type="doi">10.3389/fonc.2018.00161</pub-id><pub-id pub-id-type="pmid">29881714</pub-id>
</element-citation><mixed-citation id="mc-CR14" publication-type="journal">Franchino F, Ruda R, Soffietti R. Mechanisms and therapy for cancer metastasis to the brain. Front Oncol. 2018;8:161. 10.3389/fonc.2018.00161.<pub-id pub-id-type="pmid">29881714</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>Suh</surname><given-names>JH</given-names></name><name><surname>Kotecha</surname><given-names>R</given-names></name><name><surname>Chao</surname><given-names>ST</given-names></name><name><surname>Ahluwalia</surname><given-names>MS</given-names></name><name><surname>Sahgal</surname><given-names>A</given-names></name><name><surname>Chang</surname><given-names>EL</given-names></name></person-group><article-title>Current approaches to the management of brain metastases</article-title><source>Nat Rev Clin Oncol</source><year>2020</year><volume>17</volume><fpage>279</fpage><lpage>99</lpage><pub-id pub-id-type="doi">10.1038/s41571-019-0320-3</pub-id><pub-id pub-id-type="pmid">32080373</pub-id>
</element-citation><mixed-citation id="mc-CR15" publication-type="journal">Suh JH, Kotecha R, Chao ST, Ahluwalia MS, Sahgal A, Chang EL. Current approaches to the management of brain metastases. Nat Rev Clin Oncol. 2020;17:279&#x02013;99. 10.1038/s41571-019-0320-3.<pub-id pub-id-type="pmid">32080373</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name><surname>Ramakrishna</surname><given-names>R</given-names></name><name><surname>Rostomily</surname><given-names>R</given-names></name></person-group><article-title>Seed, soil, and beyond: the basic biology of brain metastasis</article-title><source>Surg Neurol Int</source><year>2013</year><volume>4</volume><fpage>S256</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.4103/2152-7806.111303</pub-id><pub-id pub-id-type="pmid">23717797</pub-id>
</element-citation><mixed-citation id="mc-CR16" publication-type="journal">Ramakrishna R, Rostomily R. Seed, soil, and beyond: the basic biology of brain metastasis. Surg Neurol Int. 2013;4:S256-64. 10.4103/2152-7806.111303.<pub-id pub-id-type="pmid">23717797</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name><surname>Brabletz</surname><given-names>S</given-names></name><name><surname>Schuhwerk</surname><given-names>H</given-names></name><name><surname>Brabletz</surname><given-names>T</given-names></name><name><surname>Stemmler</surname><given-names>MP</given-names></name></person-group><article-title>Dynamic EMT: a multi-tool for tumor progression</article-title><source>EMBO J</source><year>2021</year><volume>40</volume><fpage>e108647</fpage><pub-id pub-id-type="doi">10.15252/embj.2021108647</pub-id><pub-id pub-id-type="pmid">34459003</pub-id>
</element-citation><mixed-citation id="mc-CR17" publication-type="journal">Brabletz S, Schuhwerk H, Brabletz T, Stemmler MP. Dynamic EMT: a multi-tool for tumor progression. EMBO J. 2021;40:e108647. 10.15252/embj.2021108647.<pub-id pub-id-type="pmid">34459003</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name><surname>Fantozzi</surname><given-names>A</given-names></name><name><surname>Gruber</surname><given-names>DC</given-names></name><name><surname>Pisarsky</surname><given-names>L</given-names></name><name><surname>Heck</surname><given-names>C</given-names></name><name><surname>Kunita</surname><given-names>A</given-names></name><name><surname>Yilmaz</surname><given-names>M</given-names></name><etal/></person-group><article-title>VEGF-mediated angiogenesis links EMT-induced cancer stemness to tumor initiation</article-title><source>Cancer Res</source><year>2014</year><volume>74</volume><fpage>1566</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-13-1641</pub-id><pub-id pub-id-type="pmid">24413534</pub-id>
</element-citation><mixed-citation id="mc-CR18" publication-type="journal">Fantozzi A, Gruber DC, Pisarsky L, Heck C, Kunita A, Yilmaz M, et al. VEGF-mediated angiogenesis links EMT-induced cancer stemness to tumor initiation. Cancer Res. 2014;74:1566&#x02013;75. 10.1158/0008-5472.CAN-13-1641.<pub-id pub-id-type="pmid">24413534</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name><surname>Ye</surname><given-names>X</given-names></name><name><surname>Weinberg</surname><given-names>RA</given-names></name></person-group><article-title>Epithelial-mesenchymal plasticity: a central regulator of cancer progression</article-title><source>Trends Cell Biol</source><year>2015</year><volume>25</volume><fpage>675</fpage><lpage>86</lpage><pub-id pub-id-type="doi">10.1016/j.tcb.2015.07.012</pub-id><pub-id pub-id-type="pmid">26437589</pub-id>
</element-citation><mixed-citation id="mc-CR19" publication-type="journal">Ye X, Weinberg RA. Epithelial-mesenchymal plasticity: a central regulator of cancer progression. Trends Cell Biol. 2015;25:675&#x02013;86. 10.1016/j.tcb.2015.07.012.<pub-id pub-id-type="pmid">26437589</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name><surname>Pastushenko</surname><given-names>I</given-names></name><name><surname>Brisebarre</surname><given-names>A</given-names></name><name><surname>Sifrim</surname><given-names>A</given-names></name><name><surname>Fioramonti</surname><given-names>M</given-names></name><name><surname>Revenco</surname><given-names>T</given-names></name><name><surname>Boumahdi</surname><given-names>S</given-names></name><etal/></person-group><article-title>Identification of the tumour transition states occurring during EMT</article-title><source>Nature</source><year>2018</year><volume>556</volume><fpage>463</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1038/s41586-018-0040-3</pub-id><pub-id pub-id-type="pmid">29670281</pub-id>
</element-citation><mixed-citation id="mc-CR20" publication-type="journal">Pastushenko I, Brisebarre A, Sifrim A, Fioramonti M, Revenco T, Boumahdi S, et al. Identification of the tumour transition states occurring during EMT. Nature. 2018;556:463&#x02013;8. 10.1038/s41586-018-0040-3.<pub-id pub-id-type="pmid">29670281</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>Katsuno</surname><given-names>Y</given-names></name><name><surname>Lamouille</surname><given-names>S</given-names></name><name><surname>Derynck</surname><given-names>R</given-names></name></person-group><article-title>TGF-beta signaling and epithelial-mesenchymal transition in cancer progression</article-title><source>Curr Opin Oncol</source><year>2013</year><volume>25</volume><fpage>76</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1097/CCO.0b013e32835b6371</pub-id><pub-id pub-id-type="pmid">23197193</pub-id>
</element-citation><mixed-citation id="mc-CR21" publication-type="journal">Katsuno Y, Lamouille S, Derynck R. TGF-beta signaling and epithelial-mesenchymal transition in cancer progression. Curr Opin Oncol. 2013;25:76&#x02013;84. 10.1097/CCO.0b013e32835b6371.<pub-id pub-id-type="pmid">23197193</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name><surname>De Craene</surname><given-names>B</given-names></name><name><surname>Berx</surname><given-names>G</given-names></name></person-group><article-title>Regulatory networks defining EMT during cancer initiation and progression</article-title><source>Nat Rev Cancer</source><year>2013</year><volume>13</volume><fpage>97</fpage><lpage>110</lpage><pub-id pub-id-type="doi">10.1038/nrc3447</pub-id><pub-id pub-id-type="pmid">23344542</pub-id>
</element-citation><mixed-citation id="mc-CR22" publication-type="journal">De Craene B, Berx G. Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer. 2013;13:97&#x02013;110. 10.1038/nrc3447.<pub-id pub-id-type="pmid">23344542</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name><surname>Valastyan</surname><given-names>S</given-names></name><name><surname>Weinberg</surname><given-names>RA</given-names></name></person-group><article-title>Tumor metastasis: molecular insights and evolving paradigms</article-title><source>Cell</source><year>2011</year><volume>147</volume><fpage>275</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2011.09.024</pub-id><pub-id pub-id-type="pmid">22000009</pub-id>
</element-citation><mixed-citation id="mc-CR23" publication-type="journal">Valastyan S, Weinberg RA. Tumor metastasis: molecular insights and evolving paradigms. Cell. 2011;147:275&#x02013;92. 10.1016/j.cell.2011.09.024.<pub-id pub-id-type="pmid">22000009</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name><surname>Erdogan</surname><given-names>B</given-names></name><name><surname>Ao</surname><given-names>M</given-names></name><name><surname>White</surname><given-names>LM</given-names></name><name><surname>Means</surname><given-names>AL</given-names></name><name><surname>Brewer</surname><given-names>BM</given-names></name><name><surname>Yang</surname><given-names>L</given-names></name><etal/></person-group><article-title>Cancer-associated fibroblasts promote directional cancer cell migration by aligning fibronectin</article-title><source>J Cell Biol</source><year>2017</year><volume>216</volume><fpage>3799</fpage><lpage>816</lpage><pub-id pub-id-type="doi">10.1083/jcb.201704053</pub-id><pub-id pub-id-type="pmid">29021221</pub-id>
</element-citation><mixed-citation id="mc-CR24" publication-type="journal">Erdogan B, Ao M, White LM, Means AL, Brewer BM, Yang L, et al. Cancer-associated fibroblasts promote directional cancer cell migration by aligning fibronectin. J Cell Biol. 2017;216:3799&#x02013;816. 10.1083/jcb.201704053.<pub-id pub-id-type="pmid">29021221</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name><surname>Rankin</surname><given-names>EB</given-names></name><name><surname>Giaccia</surname><given-names>AJ</given-names></name></person-group><article-title>Hypoxic control of metastasis</article-title><source>Science</source><year>2016</year><volume>352</volume><fpage>175</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1126/science.aaf4405</pub-id><pub-id pub-id-type="pmid">27124451</pub-id>
</element-citation><mixed-citation id="mc-CR25" publication-type="journal">Rankin EB, Giaccia AJ. Hypoxic control of metastasis. Science. 2016;352:175&#x02013;80. 10.1126/science.aaf4405.<pub-id pub-id-type="pmid">27124451</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name><surname>Lamouille</surname><given-names>S</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Derynck</surname><given-names>R</given-names></name></person-group><article-title>Molecular mechanisms of epithelial-mesenchymal transition</article-title><source>Nat Rev Mol Cell Biol</source><year>2014</year><volume>15</volume><fpage>178</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.1038/nrm3758</pub-id><pub-id pub-id-type="pmid">24556840</pub-id>
</element-citation><mixed-citation id="mc-CR26" publication-type="journal">Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 2014;15:178&#x02013;96. 10.1038/nrm3758.<pub-id pub-id-type="pmid">24556840</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name><surname>Ronaldson</surname><given-names>PT</given-names></name><name><surname>Davis</surname><given-names>TP</given-names></name></person-group><article-title>Regulation of blood-brain barrier integrity by microglia in health and disease: a therapeutic opportunity</article-title><source>J Cereb Blood Flow Metab</source><year>2020</year><volume>40</volume><fpage>S6</fpage><lpage>S24</lpage><pub-id pub-id-type="doi">10.1177/0271678X20951995</pub-id><pub-id pub-id-type="pmid">32928017</pub-id>
</element-citation><mixed-citation id="mc-CR27" publication-type="journal">Ronaldson PT, Davis TP. Regulation of blood-brain barrier integrity by microglia in health and disease: a therapeutic opportunity. J Cereb Blood Flow Metab. 2020;40:S6&#x02013;24. 10.1177/0271678X20951995.<pub-id pub-id-type="pmid">32928017</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name><surname>Steeg</surname><given-names>PS</given-names></name></person-group><article-title>The blood-tumour barrier in cancer biology and therapy</article-title><source>Nat Rev Clin Oncol</source><year>2021</year><volume>18</volume><fpage>696</fpage><lpage>714</lpage><pub-id pub-id-type="doi">10.1038/s41571-021-00529-6</pub-id><pub-id pub-id-type="pmid">34253912</pub-id>
</element-citation><mixed-citation id="mc-CR28" publication-type="journal">Steeg PS. The blood-tumour barrier in cancer biology and therapy. Nat Rev Clin Oncol. 2021;18:696&#x02013;714. 10.1038/s41571-021-00529-6.<pub-id pub-id-type="pmid">34253912</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>B</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Zhao</surname><given-names>XY</given-names></name><name><surname>Huang</surname><given-names>B</given-names></name><name><surname>Wu</surname><given-names>PF</given-names></name><etal/></person-group><article-title>Elevated PLGF contributes to small-cell lung cancer brain metastasis</article-title><source>Oncogene</source><year>2013</year><volume>32</volume><fpage>2952</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.1038/onc.2012.313</pub-id><pub-id pub-id-type="pmid">22797069</pub-id>
</element-citation><mixed-citation id="mc-CR29" publication-type="journal">Li B, Wang C, Zhang Y, Zhao XY, Huang B, Wu PF, et al. Elevated PLGF contributes to small-cell lung cancer brain metastasis. Oncogene. 2013;32:2952&#x02013;62. 10.1038/onc.2012.313.<pub-id pub-id-type="pmid">22797069</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name><surname>Tiwary</surname><given-names>S</given-names></name><name><surname>Morales</surname><given-names>JE</given-names></name><name><surname>Kwiatkowski</surname><given-names>SC</given-names></name><name><surname>Lang</surname><given-names>FF</given-names></name><name><surname>Rao</surname><given-names>G</given-names></name><name><surname>McCarty</surname><given-names>JH</given-names></name></person-group><article-title>Metastatic Brain tumors disrupt the blood-brain barrier and alter lipid metabolism by inhibiting expression of the endothelial cell fatty acid transporter Mfsd2a</article-title><source>Sci Rep</source><year>2018</year><volume>8</volume><fpage>8267</fpage><pub-id pub-id-type="doi">10.1038/s41598-018-26636-6</pub-id><pub-id pub-id-type="pmid">29844613</pub-id>
</element-citation><mixed-citation id="mc-CR30" publication-type="journal">Tiwary S, Morales JE, Kwiatkowski SC, Lang FF, Rao G, McCarty JH. Metastatic Brain tumors disrupt the blood-brain barrier and alter lipid metabolism by inhibiting expression of the endothelial cell fatty acid transporter Mfsd2a. Sci Rep. 2018;8:8267. 10.1038/s41598-018-26636-6.<pub-id pub-id-type="pmid">29844613</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name><surname>Tominaga</surname><given-names>N</given-names></name><name><surname>Kosaka</surname><given-names>N</given-names></name><name><surname>Ono</surname><given-names>M</given-names></name><name><surname>Katsuda</surname><given-names>T</given-names></name><name><surname>Yoshioka</surname><given-names>Y</given-names></name><name><surname>Tamura</surname><given-names>K</given-names></name><etal/></person-group><article-title>Brain metastatic cancer cells release microRNA-181c-containing extracellular vesicles capable of destructing blood-brain barrier</article-title><source>Nat Commun</source><year>2015</year><volume>6</volume><fpage>6716</fpage><pub-id pub-id-type="doi">10.1038/ncomms7716</pub-id><pub-id pub-id-type="pmid">25828099</pub-id>
</element-citation><mixed-citation id="mc-CR31" publication-type="journal">Tominaga N, Kosaka N, Ono M, Katsuda T, Yoshioka Y, Tamura K, et al. Brain metastatic cancer cells release microRNA-181c-containing extracellular vesicles capable of destructing blood-brain barrier. Nat Commun. 2015;6:6716. 10.1038/ncomms7716.<pub-id pub-id-type="pmid">25828099</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name><surname>Kienast</surname><given-names>Y</given-names></name><name><surname>von Baumgarten</surname><given-names>L</given-names></name><name><surname>Fuhrmann</surname><given-names>M</given-names></name><name><surname>Klinkert</surname><given-names>WE</given-names></name><name><surname>Goldbrunner</surname><given-names>R</given-names></name><name><surname>Herms</surname><given-names>J</given-names></name><etal/></person-group><article-title>Real-time imaging reveals the single steps of brain metastasis formation</article-title><source>Nat Med</source><year>2010</year><volume>16</volume><fpage>116</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1038/nm.2072</pub-id><pub-id pub-id-type="pmid">20023634</pub-id>
</element-citation><mixed-citation id="mc-CR32" publication-type="journal">Kienast Y, von Baumgarten L, Fuhrmann M, Klinkert WE, Goldbrunner R, Herms J, et al. Real-time imaging reveals the single steps of brain metastasis formation. Nat Med. 2010;16:116&#x02013;22. 10.1038/nm.2072.<pub-id pub-id-type="pmid">20023634</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name><surname>Mathot</surname><given-names>L</given-names></name><name><surname>Stenninger</surname><given-names>J</given-names></name></person-group><article-title>Behavior of seeds and soil in the mechanism of metastasis: a deeper understanding</article-title><source>Cancer Sci</source><year>2012</year><volume>103</volume><fpage>626</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1111/j.1349-7006.2011.02195.x</pub-id><pub-id pub-id-type="pmid">22212856</pub-id>
</element-citation><mixed-citation id="mc-CR33" publication-type="journal">Mathot L, Stenninger J. Behavior of seeds and soil in the mechanism of metastasis: a deeper understanding. Cancer Sci. 2012;103:626&#x02013;31. 10.1111/j.1349-7006.2011.02195.x.<pub-id pub-id-type="pmid">22212856</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name><surname>Er</surname><given-names>EE</given-names></name><name><surname>Valiente</surname><given-names>M</given-names></name><name><surname>Ganesh</surname><given-names>K</given-names></name><name><surname>Zou</surname><given-names>Y</given-names></name><name><surname>Agrawal</surname><given-names>S</given-names></name><name><surname>Hu</surname><given-names>J</given-names></name><etal/></person-group><article-title>Pericyte-like spreading by disseminated cancer cells activates YAP and MRTF for metastatic colonization</article-title><source>Nat Cell Biol</source><year>2018</year><volume>20</volume><fpage>966</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.1038/s41556-018-0138-8</pub-id><pub-id pub-id-type="pmid">30038252</pub-id>
</element-citation><mixed-citation id="mc-CR34" publication-type="journal">Er EE, Valiente M, Ganesh K, Zou Y, Agrawal S, Hu J, et al. Pericyte-like spreading by disseminated cancer cells activates YAP and MRTF for metastatic colonization. Nat Cell Biol. 2018;20:966&#x02013;78. 10.1038/s41556-018-0138-8.<pub-id pub-id-type="pmid">30038252</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>Q</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Xiao</surname><given-names>D</given-names></name><name><surname>Huang</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Zhai</surname><given-names>K</given-names></name><etal/></person-group><article-title>CD44(+) lung cancer stem cell-derived pericyte-like cells cause brain metastases through GPR124-enhanced trans-endothelial migration</article-title><source>Cancer Cell</source><year>2023</year><volume>41</volume><fpage>1621</fpage><lpage>36 e8</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2023.07.012</pub-id><pub-id pub-id-type="pmid">37595587</pub-id>
</element-citation><mixed-citation id="mc-CR35" publication-type="journal">Huang Q, Liu L, Xiao D, Huang Z, Wang W, Zhai K, et al. CD44(+) lung cancer stem cell-derived pericyte-like cells cause brain metastases through GPR124-enhanced trans-endothelial migration. Cancer Cell. 2023;41:1621-36 e8. 10.1016/j.ccell.2023.07.012.<pub-id pub-id-type="pmid">37595587</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name><surname>Xia</surname><given-names>S</given-names></name><name><surname>Duan</surname><given-names>W</given-names></name><name><surname>Xu</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Tang</surname><given-names>M</given-names></name><name><surname>Wei</surname><given-names>S</given-names></name><etal/></person-group><article-title>Mesothelin promotes brain metastasis of non-small cell lung cancer by activating MET</article-title><source>J Exp Clin Cancer Res</source><year>2024</year><volume>43</volume><fpage>103</fpage><pub-id pub-id-type="doi">10.1186/s13046-024-03015-w</pub-id><pub-id pub-id-type="pmid">38570866</pub-id>
</element-citation><mixed-citation id="mc-CR36" publication-type="journal">Xia S, Duan W, Xu M, Li M, Tang M, Wei S, et al. Mesothelin promotes brain metastasis of non-small cell lung cancer by activating MET. J Exp Clin Cancer Res. 2024;43:103. 10.1186/s13046-024-03015-w.<pub-id pub-id-type="pmid">38570866</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name><surname>Lugano</surname><given-names>R</given-names></name><name><surname>Ramachandran</surname><given-names>M</given-names></name><name><surname>Dimberg</surname><given-names>A</given-names></name></person-group><article-title>Tumor angiogenesis: causes, consequences, challenges and opportunities</article-title><source>Cell Mol Life Sci</source><year>2020</year><volume>77</volume><fpage>1745</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1007/s00018-019-03351-7</pub-id><pub-id pub-id-type="pmid">31690961</pub-id>
</element-citation><mixed-citation id="mc-CR37" publication-type="journal">Lugano R, Ramachandran M, Dimberg A. Tumor angiogenesis: causes, consequences, challenges and opportunities. Cell Mol Life Sci. 2020;77:1745&#x02013;70. 10.1007/s00018-019-03351-7.<pub-id pub-id-type="pmid">31690961</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Lu</surname><given-names>W</given-names></name><name><surname>Chen</surname><given-names>M</given-names></name><name><surname>Ye</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>D</given-names></name></person-group><article-title>The tumor vessel targeting strategy: a double-edged sword in tumor metastasis</article-title><source>Cells</source><year>2019</year><volume>8</volume><fpage>1602</fpage><pub-id pub-id-type="doi">10.3390/cells8121602</pub-id><pub-id pub-id-type="pmid">31835465</pub-id>
</element-citation><mixed-citation id="mc-CR38" publication-type="journal">Li X, Li Y, Lu W, Chen M, Ye W, Zhang D. The tumor vessel targeting strategy: a double-edged sword in tumor metastasis. Cells. 2019;8:1602. 10.3390/cells8121602.<pub-id pub-id-type="pmid">31835465</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name><surname>Donnem</surname><given-names>T</given-names></name><name><surname>Hu</surname><given-names>J</given-names></name><name><surname>Ferguson</surname><given-names>M</given-names></name><name><surname>Adighibe</surname><given-names>O</given-names></name><name><surname>Snell</surname><given-names>C</given-names></name><name><surname>Harris</surname><given-names>AL</given-names></name><etal/></person-group><article-title>Vessel co-option in primary human tumors and metastases: an obstacle to effective anti-angiogenic treatment?</article-title><source>Cancer Med</source><year>2013</year><volume>2</volume><fpage>427</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1002/cam4.105</pub-id><pub-id pub-id-type="pmid">24156015</pub-id>
</element-citation><mixed-citation id="mc-CR39" publication-type="journal">Donnem T, Hu J, Ferguson M, Adighibe O, Snell C, Harris AL, et al. Vessel co-option in primary human tumors and metastases: an obstacle to effective anti-angiogenic treatment? Cancer Med. 2013;2:427&#x02013;36. 10.1002/cam4.105.<pub-id pub-id-type="pmid">24156015</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name><surname>Ruan</surname><given-names>H</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Shen</surname><given-names>J</given-names></name><name><surname>Zhai</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Pi</surname><given-names>L</given-names></name><etal/></person-group><article-title>Circulating tumor cell characterization of lung cancer brain metastases in the cerebrospinal fluid through single-cell transcriptome analysis</article-title><source>Clin Transl Med</source><year>2020</year><volume>10</volume><fpage>e246</fpage><pub-id pub-id-type="doi">10.1002/ctm2.246</pub-id><pub-id pub-id-type="pmid">33377642</pub-id>
</element-citation><mixed-citation id="mc-CR40" publication-type="journal">Ruan H, Zhou Y, Shen J, Zhai Y, Xu Y, Pi L, et al. Circulating tumor cell characterization of lung cancer brain metastases in the cerebrospinal fluid through single-cell transcriptome analysis. Clin Transl Med. 2020;10:e246. 10.1002/ctm2.246.<pub-id pub-id-type="pmid">33377642</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>Y</given-names></name><name><surname>Miyamoto</surname><given-names>DT</given-names></name><name><surname>Wittner</surname><given-names>BS</given-names></name><name><surname>Sullivan</surname><given-names>JP</given-names></name><name><surname>Aceto</surname><given-names>N</given-names></name><name><surname>Jordan</surname><given-names>NV</given-names></name><etal/></person-group><article-title>Expression of beta-globin by cancer cells promotes cell survival during blood-borne dissemination</article-title><source>Nat Commun</source><year>2017</year><volume>8</volume><fpage>14344</fpage><pub-id pub-id-type="doi">10.1038/ncomms14344</pub-id><pub-id pub-id-type="pmid">28181495</pub-id>
</element-citation><mixed-citation id="mc-CR41" publication-type="journal">Zheng Y, Miyamoto DT, Wittner BS, Sullivan JP, Aceto N, Jordan NV, et al. Expression of beta-globin by cancer cells promotes cell survival during blood-borne dissemination. Nat Commun. 2017;8:14344. 10.1038/ncomms14344.<pub-id pub-id-type="pmid">28181495</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name><surname>Duda</surname><given-names>DG</given-names></name><name><surname>Duyverman</surname><given-names>AM</given-names></name><name><surname>Kohno</surname><given-names>M</given-names></name><name><surname>Snuderl</surname><given-names>M</given-names></name><name><surname>Steller</surname><given-names>EJ</given-names></name><name><surname>Fukumura</surname><given-names>D</given-names></name><etal/></person-group><article-title>Malignant cells facilitate lung metastasis by bringing their own soil</article-title><source>Proc Natl Acad Sci U S A</source><year>2010</year><volume>107</volume><fpage>21677</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1073/pnas.1016234107</pub-id><pub-id pub-id-type="pmid">21098274</pub-id>
</element-citation><mixed-citation id="mc-CR42" publication-type="journal">Duda DG, Duyverman AM, Kohno M, Snuderl M, Steller EJ, Fukumura D, et al. Malignant cells facilitate lung metastasis by bringing their own soil. Proc Natl Acad Sci U S A. 2010;107:21677&#x02013;82. 10.1073/pnas.1016234107.<pub-id pub-id-type="pmid">21098274</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name><surname>Ao</surname><given-names>Z</given-names></name><name><surname>Shah</surname><given-names>SH</given-names></name><name><surname>Machlin</surname><given-names>LM</given-names></name><name><surname>Parajuli</surname><given-names>R</given-names></name><name><surname>Miller</surname><given-names>PC</given-names></name><name><surname>Rawal</surname><given-names>S</given-names></name><etal/></person-group><article-title>Identification of cancer-associated fibroblasts in circulating blood from patients with metastatic breast cancer</article-title><source>Cancer Res</source><year>2015</year><volume>75</volume><fpage>4681</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-15-1633</pub-id><pub-id pub-id-type="pmid">26471358</pub-id>
</element-citation><mixed-citation id="mc-CR43" publication-type="journal">Ao Z, Shah SH, Machlin LM, Parajuli R, Miller PC, Rawal S, et al. Identification of cancer-associated fibroblasts in circulating blood from patients with metastatic breast cancer. Cancer Res. 2015;75:4681&#x02013;7. 10.1158/0008-5472.CAN-15-1633.<pub-id pub-id-type="pmid">26471358</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name><surname>Glentis</surname><given-names>A</given-names></name><name><surname>Oertle</surname><given-names>P</given-names></name><name><surname>Mariani</surname><given-names>P</given-names></name><name><surname>Chikina</surname><given-names>A</given-names></name><name><surname>El Marjou</surname><given-names>F</given-names></name><name><surname>Attieh</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Cancer-associated fibroblasts induce metalloprotease-independent cancer cell invasion of the basement membrane</article-title><source>Nat Commun</source><year>2017</year><volume>8</volume><fpage>924</fpage><pub-id pub-id-type="doi">10.1038/s41467-017-00985-8</pub-id><pub-id pub-id-type="pmid">29030636</pub-id>
</element-citation><mixed-citation id="mc-CR44" publication-type="journal">Glentis A, Oertle P, Mariani P, Chikina A, El Marjou F, Attieh Y, et al. Cancer-associated fibroblasts induce metalloprotease-independent cancer cell invasion of the basement membrane. Nat Commun. 2017;8:924. 10.1038/s41467-017-00985-8.<pub-id pub-id-type="pmid">29030636</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name><surname>Asif</surname><given-names>PJ</given-names></name><name><surname>Longobardi</surname><given-names>C</given-names></name><name><surname>Hahne</surname><given-names>M</given-names></name><name><surname>Medema</surname><given-names>JP</given-names></name></person-group><article-title>The role of cancer-associated fibroblasts in cancer invasion and metastasis</article-title><source>Cancers (Basel)</source><year>2021</year><volume>13</volume><fpage>4720</fpage><pub-id pub-id-type="doi">10.3390/cancers13184720</pub-id><pub-id pub-id-type="pmid">34572947</pub-id>
</element-citation><mixed-citation id="mc-CR45" publication-type="journal">Asif PJ, Longobardi C, Hahne M, Medema JP. The role of cancer-associated fibroblasts in cancer invasion and metastasis. Cancers (Basel). 2021;13:4720. 10.3390/cancers13184720.<pub-id pub-id-type="pmid">34572947</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name><surname>Ziani</surname><given-names>L</given-names></name><name><surname>Chouaib</surname><given-names>S</given-names></name><name><surname>Thiery</surname><given-names>J</given-names></name></person-group><article-title>Alteration of the antitumor immune response by cancer-associated fibroblasts</article-title><source>Front Immunol</source><year>2018</year><volume>9</volume><fpage>414</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2018.00414</pub-id><pub-id pub-id-type="pmid">29545811</pub-id>
</element-citation><mixed-citation id="mc-CR46" publication-type="journal">Ziani L, Chouaib S, Thiery J. Alteration of the antitumor immune response by cancer-associated fibroblasts. Front Immunol. 2018;9:414. 10.3389/fimmu.2018.00414.<pub-id pub-id-type="pmid">29545811</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name><surname>Monteran</surname><given-names>L</given-names></name><name><surname>Erez</surname><given-names>N</given-names></name></person-group><article-title>The dark side of fibroblasts: cancer-associated fibroblasts as mediators of immunosuppression in the tumor microenvironment</article-title><source>Front Immunol</source><year>2019</year><volume>10</volume><fpage>1835</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2019.01835</pub-id><pub-id pub-id-type="pmid">31428105</pub-id>
</element-citation><mixed-citation id="mc-CR47" publication-type="journal">Monteran L, Erez N. The dark side of fibroblasts: cancer-associated fibroblasts as mediators of immunosuppression in the tumor microenvironment. Front Immunol. 2019;10:1835. 10.3389/fimmu.2019.01835.<pub-id pub-id-type="pmid">31428105</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name><surname>Karre</surname><given-names>K</given-names></name></person-group><article-title>Express yourself or die: peptides, MHC molecules, and NK cells</article-title><source>Science</source><year>1995</year><volume>267</volume><fpage>978</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1126/science.7863341</pub-id><pub-id pub-id-type="pmid">7863341</pub-id>
</element-citation><mixed-citation id="mc-CR48" publication-type="journal">Karre K. Express yourself or die: peptides, MHC molecules, and NK cells. Science. 1995;267:978&#x02013;9. 10.1126/science.7863341.<pub-id pub-id-type="pmid">7863341</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49.</label><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name><surname>Labelle</surname><given-names>M</given-names></name><name><surname>Begum</surname><given-names>S</given-names></name><name><surname>Hynes</surname><given-names>RO</given-names></name></person-group><article-title>Platelets guide the formation of early metastatic niches</article-title><source>Proc Natl Acad Sci U S A</source><year>2014</year><volume>111</volume><fpage>E3053</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1073/pnas.1411082111</pub-id><pub-id pub-id-type="pmid">25024172</pub-id>
</element-citation><mixed-citation id="mc-CR49" publication-type="journal">Labelle M, Begum S, Hynes RO. Platelets guide the formation of early metastatic niches. Proc Natl Acad Sci U S A. 2014;111:E3053-61. 10.1073/pnas.1411082111.<pub-id pub-id-type="pmid">25024172</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR50"><label>50.</label><citation-alternatives><element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name><surname>Labelle</surname><given-names>M</given-names></name><name><surname>Begum</surname><given-names>S</given-names></name><name><surname>Hynes</surname><given-names>RO</given-names></name></person-group><article-title>Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis</article-title><source>Cancer Cell</source><year>2011</year><volume>20</volume><fpage>576</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2011.09.009</pub-id><pub-id pub-id-type="pmid">22094253</pub-id>
</element-citation><mixed-citation id="mc-CR50" publication-type="journal">Labelle M, Begum S, Hynes RO. Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell. 2011;20:576&#x02013;90. 10.1016/j.ccr.2011.09.009.<pub-id pub-id-type="pmid">22094253</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR51"><label>51.</label><citation-alternatives><element-citation id="ec-CR51" publication-type="journal"><person-group person-group-type="author"><name><surname>Franco</surname><given-names>AT</given-names></name><name><surname>Corken</surname><given-names>A</given-names></name><name><surname>Ware</surname><given-names>J</given-names></name></person-group><article-title>Platelets at the interface of thrombosis, inflammation, and cancer</article-title><source>Blood</source><year>2015</year><volume>126</volume><fpage>582</fpage><lpage>588</lpage><pub-id pub-id-type="doi">10.1182/blood-2014-08-531582</pub-id><pub-id pub-id-type="pmid">26109205</pub-id>
</element-citation><mixed-citation id="mc-CR51" publication-type="journal">Franco AT, Corken A, Ware J. Platelets at the interface of thrombosis, inflammation, and cancer. Blood. 2015;126:582&#x02013;8. 10.1182/blood-2014-08-531582.<pub-id pub-id-type="pmid">26109205</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR52"><label>52.</label><citation-alternatives><element-citation id="ec-CR52" publication-type="journal"><person-group person-group-type="author"><name><surname>Pereira-Veiga</surname><given-names>T</given-names></name><name><surname>Schneegans</surname><given-names>S</given-names></name><name><surname>Pantel</surname><given-names>K</given-names></name><name><surname>Wikman</surname><given-names>H</given-names></name></person-group><article-title>Circulating tumor cell-blood cell crosstalk: biology and clinical relevance</article-title><source>Cell Rep</source><year>2022</year><volume>40</volume><fpage>111298</fpage><pub-id pub-id-type="doi">10.1016/j.celrep.2022.111298</pub-id><pub-id pub-id-type="pmid">36044866</pub-id>
</element-citation><mixed-citation id="mc-CR52" publication-type="journal">Pereira-Veiga T, Schneegans S, Pantel K, Wikman H. Circulating tumor cell-blood cell crosstalk: biology and clinical relevance. Cell Rep. 2022;40:111298. 10.1016/j.celrep.2022.111298.<pub-id pub-id-type="pmid">36044866</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR53"><label>53.</label><citation-alternatives><element-citation id="ec-CR53" publication-type="journal"><person-group person-group-type="author"><name><surname>Velez</surname><given-names>J</given-names></name><name><surname>Enciso</surname><given-names>LJ</given-names></name><name><surname>Suarez</surname><given-names>M</given-names></name><name><surname>Fiegl</surname><given-names>M</given-names></name><name><surname>Grismaldo</surname><given-names>A</given-names></name><name><surname>Lopez</surname><given-names>C</given-names></name><etal/></person-group><article-title>Platelets promote mitochondrial uncoupling and resistance to apoptosis in leukemia cells: a novel paradigm for the bone marrow microenvironment</article-title><source>Cancer Microenviron</source><year>2014</year><volume>7</volume><fpage>79</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1007/s12307-014-0149-3</pub-id><pub-id pub-id-type="pmid">25112275</pub-id>
</element-citation><mixed-citation id="mc-CR53" publication-type="journal">Velez J, Enciso LJ, Suarez M, Fiegl M, Grismaldo A, Lopez C, et al. Platelets promote mitochondrial uncoupling and resistance to apoptosis in leukemia cells: a novel paradigm for the bone marrow microenvironment. Cancer Microenviron. 2014;7:79&#x02013;90. 10.1007/s12307-014-0149-3.<pub-id pub-id-type="pmid">25112275</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR54"><label>54.</label><citation-alternatives><element-citation id="ec-CR54" publication-type="journal"><person-group person-group-type="author"><name><surname>Beck</surname><given-names>TN</given-names></name><name><surname>Boumber</surname><given-names>YA</given-names></name><name><surname>Aggarwal</surname><given-names>C</given-names></name><name><surname>Pei</surname><given-names>J</given-names></name><name><surname>Thrash-Bingham</surname><given-names>C</given-names></name><name><surname>Fittipaldi</surname><given-names>P</given-names></name><etal/></person-group><article-title>Circulating tumor cell and cell-free RNA capture and expression analysis identify platelet-associated genes in metastatic lung cancer</article-title><source>BMC Cancer</source><year>2019</year><volume>19</volume><fpage>603</fpage><pub-id pub-id-type="doi">10.1186/s12885-019-5795-x</pub-id><pub-id pub-id-type="pmid">31215484</pub-id>
</element-citation><mixed-citation id="mc-CR54" publication-type="journal">Beck TN, Boumber YA, Aggarwal C, Pei J, Thrash-Bingham C, Fittipaldi P, et al. Circulating tumor cell and cell-free RNA capture and expression analysis identify platelet-associated genes in metastatic lung cancer. BMC Cancer. 2019;19:603. 10.1186/s12885-019-5795-x.<pub-id pub-id-type="pmid">31215484</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR55"><label>55.</label><citation-alternatives><element-citation id="ec-CR55" publication-type="journal"><person-group person-group-type="author"><name><surname>Szczerba</surname><given-names>BM</given-names></name><name><surname>Castro-Giner</surname><given-names>F</given-names></name><name><surname>Vetter</surname><given-names>M</given-names></name><name><surname>Krol</surname><given-names>I</given-names></name><name><surname>Gkountela</surname><given-names>S</given-names></name><name><surname>Landin</surname><given-names>J</given-names></name><etal/></person-group><article-title>Neutrophils escort circulating tumour cells to enable cell cycle progression</article-title><source>Nature</source><year>2019</year><volume>566</volume><fpage>553</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1038/s41586-019-0915-y</pub-id><pub-id pub-id-type="pmid">30728496</pub-id>
</element-citation><mixed-citation id="mc-CR55" publication-type="journal">Szczerba BM, Castro-Giner F, Vetter M, Krol I, Gkountela S, Landin J, et al. Neutrophils escort circulating tumour cells to enable cell cycle progression. Nature. 2019;566:553&#x02013;7. 10.1038/s41586-019-0915-y.<pub-id pub-id-type="pmid">30728496</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR56"><label>56.</label><citation-alternatives><element-citation id="ec-CR56" publication-type="journal"><person-group person-group-type="author"><name><surname>Ciminera</surname><given-names>AK</given-names></name><name><surname>Jandial</surname><given-names>R</given-names></name><name><surname>Termini</surname><given-names>J</given-names></name></person-group><article-title>Metabolic advantages and vulnerabilities in brain metastases</article-title><source>Clin Exp Metastasis</source><year>2017</year><volume>34</volume><fpage>401</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1007/s10585-017-9864-8</pub-id><pub-id pub-id-type="pmid">29063238</pub-id>
</element-citation><mixed-citation id="mc-CR56" publication-type="journal">Ciminera AK, Jandial R, Termini J. Metabolic advantages and vulnerabilities in brain metastases. Clin Exp Metastasis. 2017;34:401&#x02013;10. 10.1007/s10585-017-9864-8.<pub-id pub-id-type="pmid">29063238</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR57"><label>57.</label><citation-alternatives><element-citation id="ec-CR57" publication-type="journal"><person-group person-group-type="author"><name><surname>Srinivasan</surname><given-names>ES</given-names></name><name><surname>Deshpande</surname><given-names>K</given-names></name><name><surname>Neman</surname><given-names>J</given-names></name><name><surname>Winkler</surname><given-names>F</given-names></name><name><surname>Khasraw</surname><given-names>M</given-names></name></person-group><article-title>The microenvironment of brain metastases from solid tumors</article-title><source>Neurooncol Adv</source><year>2021</year><volume>3</volume><fpage>v121</fpage><lpage>v32</lpage><pub-id pub-id-type="doi">10.1093/noajnl/vdab121</pub-id><pub-id pub-id-type="pmid">34859239</pub-id>
</element-citation><mixed-citation id="mc-CR57" publication-type="journal">Srinivasan ES, Deshpande K, Neman J, Winkler F, Khasraw M. The microenvironment of brain metastases from solid tumors. Neurooncol Adv. 2021;3:v121&#x02013;32. 10.1093/noajnl/vdab121.<pub-id pub-id-type="pmid">34859239</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR58"><label>58.</label><citation-alternatives><element-citation id="ec-CR58" publication-type="journal"><person-group person-group-type="author"><name><surname>Onwudiwe</surname><given-names>K</given-names></name><name><surname>Burchett</surname><given-names>AA</given-names></name><name><surname>Datta</surname><given-names>M</given-names></name></person-group><article-title>Mechanical and metabolic interplay in the brain metastatic microenvironment</article-title><source>Front Oncol</source><year>2022</year><volume>12</volume><fpage>932285</fpage><pub-id pub-id-type="doi">10.3389/fonc.2022.932285</pub-id><pub-id pub-id-type="pmid">36059679</pub-id>
</element-citation><mixed-citation id="mc-CR58" publication-type="journal">Onwudiwe K, Burchett AA, Datta M. Mechanical and metabolic interplay in the brain metastatic microenvironment. Front Oncol. 2022;12:932285. 10.3389/fonc.2022.932285.<pub-id pub-id-type="pmid">36059679</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR59"><label>59.</label><citation-alternatives><element-citation id="ec-CR59" publication-type="journal"><person-group person-group-type="author"><name><surname>Fukumura</surname><given-names>K</given-names></name><name><surname>Malgulwar</surname><given-names>PB</given-names></name><name><surname>Fischer</surname><given-names>GM</given-names></name><name><surname>Hu</surname><given-names>X</given-names></name><name><surname>Mao</surname><given-names>X</given-names></name><name><surname>Song</surname><given-names>X</given-names></name><etal/></person-group><article-title>Multi-omic molecular profiling reveals potentially targetable abnormalities shared across multiple histologies of brain metastasis</article-title><source>Acta Neuropathol</source><year>2021</year><volume>141</volume><fpage>303</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1007/s00401-020-02256-1</pub-id><pub-id pub-id-type="pmid">33394124</pub-id>
</element-citation><mixed-citation id="mc-CR59" publication-type="journal">Fukumura K, Malgulwar PB, Fischer GM, Hu X, Mao X, Song X, et al. Multi-omic molecular profiling reveals potentially targetable abnormalities shared across multiple histologies of brain metastasis. Acta Neuropathol. 2021;141:303&#x02013;21. 10.1007/s00401-020-02256-1.<pub-id pub-id-type="pmid">33394124</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR60"><label>60.</label><citation-alternatives><element-citation id="ec-CR60" publication-type="journal"><person-group person-group-type="author"><name><surname>Ngo</surname><given-names>B</given-names></name><name><surname>Kim</surname><given-names>E</given-names></name><name><surname>Osorio-Vasquez</surname><given-names>V</given-names></name><name><surname>Doll</surname><given-names>S</given-names></name><name><surname>Bustraan</surname><given-names>S</given-names></name><name><surname>Liang</surname><given-names>RJ</given-names></name><etal/></person-group><article-title>Limited environmental serine and glycine confer brain metastasis sensitivity to PHGDH inhibition</article-title><source>Cancer Discov</source><year>2020</year><volume>10</volume><fpage>1352</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-19-1228</pub-id><pub-id pub-id-type="pmid">32571778</pub-id>
</element-citation><mixed-citation id="mc-CR60" publication-type="journal">Ngo B, Kim E, Osorio-Vasquez V, Doll S, Bustraan S, Liang RJ, et al. Limited environmental serine and glycine confer brain metastasis sensitivity to PHGDH inhibition. Cancer Discov. 2020;10:1352&#x02013;73. 10.1158/2159-8290.CD-19-1228.<pub-id pub-id-type="pmid">32571778</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR61"><label>61.</label><citation-alternatives><element-citation id="ec-CR61" publication-type="journal"><person-group person-group-type="author"><name><surname>Zeng</surname><given-names>Q</given-names></name><name><surname>Michael</surname><given-names>IP</given-names></name><name><surname>Zhang</surname><given-names>P</given-names></name><name><surname>Saghafinia</surname><given-names>S</given-names></name><name><surname>Knott</surname><given-names>G</given-names></name><name><surname>Jiao</surname><given-names>W</given-names></name><etal/></person-group><article-title>Synaptic proximity enables NMDAR signalling to promote brain metastasis</article-title><source>Nature</source><year>2019</year><volume>573</volume><fpage>526</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1038/s41586-019-1576-6</pub-id><pub-id pub-id-type="pmid">31534217</pub-id>
</element-citation><mixed-citation id="mc-CR61" publication-type="journal">Zeng Q, Michael IP, Zhang P, Saghafinia S, Knott G, Jiao W, et al. Synaptic proximity enables NMDAR signalling to promote brain metastasis. Nature. 2019;573:526&#x02013;31. 10.1038/s41586-019-1576-6.<pub-id pub-id-type="pmid">31534217</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR62"><label>62.</label><citation-alternatives><element-citation id="ec-CR62" publication-type="journal"><person-group person-group-type="author"><name><surname>Luttman</surname><given-names>JH</given-names></name><name><surname>Hoj</surname><given-names>JP</given-names></name><name><surname>Lin</surname><given-names>KH</given-names></name><name><surname>Lin</surname><given-names>J</given-names></name><name><surname>Gu</surname><given-names>JJ</given-names></name><name><surname>Rouse</surname><given-names>C</given-names></name><etal/></person-group><article-title>ABL allosteric inhibitors synergize with statins to enhance apoptosis of metastatic lung cancer cells</article-title><source>Cell Rep</source><year>2021</year><volume>37</volume><fpage>109880</fpage><pub-id pub-id-type="doi">10.1016/j.celrep.2021.109880</pub-id><pub-id pub-id-type="pmid">34706244</pub-id>
</element-citation><mixed-citation id="mc-CR62" publication-type="journal">Luttman JH, Hoj JP, Lin KH, Lin J, Gu JJ, Rouse C, et al. ABL allosteric inhibitors synergize with statins to enhance apoptosis of metastatic lung cancer cells. Cell Rep. 2021;37:109880. 10.1016/j.celrep.2021.109880.<pub-id pub-id-type="pmid">34706244</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR63"><label>63.</label><citation-alternatives><element-citation id="ec-CR63" publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>G</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Pan</surname><given-names>J</given-names></name><name><surname>Lee</surname><given-names>Y</given-names></name><name><surname>Ouari</surname><given-names>O</given-names></name><name><surname>Hardy</surname><given-names>M</given-names></name><etal/></person-group><article-title>Targeting lonidamine to mitochondria mitigates lung tumorigenesis and brain metastasis</article-title><source>Nat Commun</source><year>2019</year><volume>10</volume><fpage>2205</fpage><pub-id pub-id-type="doi">10.1038/s41467-019-10042-1</pub-id><pub-id pub-id-type="pmid">31101821</pub-id>
</element-citation><mixed-citation id="mc-CR63" publication-type="journal">Cheng G, Zhang Q, Pan J, Lee Y, Ouari O, Hardy M, et al. Targeting lonidamine to mitochondria mitigates lung tumorigenesis and brain metastasis. Nat Commun. 2019;10:2205. 10.1038/s41467-019-10042-1.<pub-id pub-id-type="pmid">31101821</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR64"><label>64.</label><citation-alternatives><element-citation id="ec-CR64" publication-type="journal"><person-group person-group-type="author"><name><surname>Naumov</surname><given-names>GN</given-names></name><name><surname>Akslen</surname><given-names>LA</given-names></name><name><surname>Folkman</surname><given-names>J</given-names></name></person-group><article-title>Role of angiogenesis in human tumor dormancy: animal models of the angiogenic switch</article-title><source>Cell Cycle</source><year>2006</year><volume>5</volume><fpage>1779</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.4161/cc.5.16.3018</pub-id><pub-id pub-id-type="pmid">16931911</pub-id>
</element-citation><mixed-citation id="mc-CR64" publication-type="journal">Naumov GN, Akslen LA, Folkman J. Role of angiogenesis in human tumor dormancy: animal models of the angiogenic switch. Cell Cycle. 2006;5:1779&#x02013;87. 10.4161/cc.5.16.3018.<pub-id pub-id-type="pmid">16931911</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR65"><label>65.</label><citation-alternatives><element-citation id="ec-CR65" publication-type="journal"><person-group person-group-type="author"><name><surname>Malladi</surname><given-names>S</given-names></name><name><surname>Macalinao</surname><given-names>DG</given-names></name><name><surname>Jin</surname><given-names>X</given-names></name><name><surname>He</surname><given-names>L</given-names></name><name><surname>Basnet</surname><given-names>H</given-names></name><name><surname>Zou</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Metastatic latency and immune evasion through autocrine inhibition of WNT</article-title><source>Cell</source><year>2016</year><volume>165</volume><fpage>45</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2016.02.025</pub-id><pub-id pub-id-type="pmid">27015306</pub-id>
</element-citation><mixed-citation id="mc-CR65" publication-type="journal">Malladi S, Macalinao DG, Jin X, He L, Basnet H, Zou Y, et al. Metastatic latency and immune evasion through autocrine inhibition of WNT. Cell. 2016;165:45&#x02013;60. 10.1016/j.cell.2016.02.025.<pub-id pub-id-type="pmid">27015306</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR66"><label>66.</label><citation-alternatives><element-citation id="ec-CR66" publication-type="journal"><person-group person-group-type="author"><name><surname>Horak</surname><given-names>CE</given-names></name><name><surname>Lee</surname><given-names>JH</given-names></name><name><surname>Marshall</surname><given-names>JC</given-names></name><name><surname>Shreeve</surname><given-names>SM</given-names></name><name><surname>Steeg</surname><given-names>PS</given-names></name></person-group><article-title>The role of metastasis suppressor genes in metastatic dormancy</article-title><source>APMIS</source><year>2008</year><volume>116</volume><fpage>586</fpage><lpage>601</lpage><pub-id pub-id-type="doi">10.1111/j.1600-0463.2008.01213.x</pub-id><pub-id pub-id-type="pmid">18834404</pub-id>
</element-citation><mixed-citation id="mc-CR66" publication-type="journal">Horak CE, Lee JH, Marshall JC, Shreeve SM, Steeg PS. The role of metastasis suppressor genes in metastatic dormancy. APMIS. 2008;116:586&#x02013;601. 10.1111/j.1600-0463.2008.01213.x.<pub-id pub-id-type="pmid">18834404</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR67"><label>67.</label><citation-alternatives><element-citation id="ec-CR67" publication-type="journal"><person-group person-group-type="author"><name><surname>Valiente</surname><given-names>M</given-names></name><name><surname>Obenauf</surname><given-names>AC</given-names></name><name><surname>Jin</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>Q</given-names></name><name><surname>Zhang</surname><given-names>XH</given-names></name><name><surname>Lee</surname><given-names>DJ</given-names></name><etal/></person-group><article-title>Serpins promote cancer cell survival and vascular co-option in brain metastasis</article-title><source>Cell</source><year>2014</year><volume>156</volume><fpage>1002</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2014.01.040</pub-id><pub-id pub-id-type="pmid">24581498</pub-id>
</element-citation><mixed-citation id="mc-CR67" publication-type="journal">Valiente M, Obenauf AC, Jin X, Chen Q, Zhang XH, Lee DJ, et al. Serpins promote cancer cell survival and vascular co-option in brain metastasis. Cell. 2014;156:1002&#x02013;16. 10.1016/j.cell.2014.01.040.<pub-id pub-id-type="pmid">24581498</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR68"><label>68.</label><citation-alternatives><element-citation id="ec-CR68" publication-type="journal"><person-group person-group-type="author"><name><surname>Berrout</surname><given-names>J</given-names></name><name><surname>Kyriakopoulou</surname><given-names>E</given-names></name><name><surname>Moparthi</surname><given-names>L</given-names></name><name><surname>Hogea</surname><given-names>AS</given-names></name><name><surname>Berrout</surname><given-names>L</given-names></name><name><surname>Ivan</surname><given-names>C</given-names></name><etal/></person-group><article-title>TRPA1-FGFR2 binding event is a regulatory oncogenic driver modulated by miRNA-142-3p</article-title><source>Nat Commun</source><year>2017</year><volume>8</volume><fpage>947</fpage><pub-id pub-id-type="doi">10.1038/s41467-017-00983-w</pub-id><pub-id pub-id-type="pmid">29038531</pub-id>
</element-citation><mixed-citation id="mc-CR68" publication-type="journal">Berrout J, Kyriakopoulou E, Moparthi L, Hogea AS, Berrout L, Ivan C, et al. TRPA1-FGFR2 binding event is a regulatory oncogenic driver modulated by miRNA-142-3p. Nat Commun. 2017;8:947. 10.1038/s41467-017-00983-w.<pub-id pub-id-type="pmid">29038531</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR69"><label>69.</label><citation-alternatives><element-citation id="ec-CR69" publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Q</given-names></name><name><surname>Boire</surname><given-names>A</given-names></name><name><surname>Jin</surname><given-names>X</given-names></name><name><surname>Valiente</surname><given-names>M</given-names></name><name><surname>Er</surname><given-names>EE</given-names></name><name><surname>Lopez-Soto</surname><given-names>A</given-names></name><etal/></person-group><article-title>Carcinoma-astrocyte gap junctions promote brain metastasis by cGAMP transfer</article-title><source>Nature</source><year>2016</year><volume>533</volume><fpage>493</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1038/nature18268</pub-id><pub-id pub-id-type="pmid">27225120</pub-id>
</element-citation><mixed-citation id="mc-CR69" publication-type="journal">Chen Q, Boire A, Jin X, Valiente M, Er EE, Lopez-Soto A, et al. Carcinoma-astrocyte gap junctions promote brain metastasis by cGAMP transfer. Nature. 2016;533:493&#x02013;8. 10.1038/nature18268.<pub-id pub-id-type="pmid">27225120</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR70"><label>70.</label><citation-alternatives><element-citation id="ec-CR70" publication-type="journal"><person-group person-group-type="author"><name><surname>Priego</surname><given-names>N</given-names></name><name><surname>Zhu</surname><given-names>L</given-names></name><name><surname>Monteiro</surname><given-names>C</given-names></name><name><surname>Mulders</surname><given-names>M</given-names></name><name><surname>Wasilewski</surname><given-names>D</given-names></name><name><surname>Bindeman</surname><given-names>W</given-names></name><etal/></person-group><article-title>STAT3 labels a subpopulation of reactive astrocytes required for brain metastasis</article-title><source>Nat Med</source><year>2018</year><volume>24</volume><fpage>1024</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1038/s41591-018-0044-4</pub-id><pub-id pub-id-type="pmid">29892069</pub-id>
</element-citation><mixed-citation id="mc-CR70" publication-type="journal">Priego N, Zhu L, Monteiro C, Mulders M, Wasilewski D, Bindeman W, et al. STAT3 labels a subpopulation of reactive astrocytes required for brain metastasis. Nat Med. 2018;24:1024&#x02013;35. 10.1038/s41591-018-0044-4.<pub-id pub-id-type="pmid">29892069</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR71"><label>71.</label><citation-alternatives><element-citation id="ec-CR71" publication-type="journal"><person-group person-group-type="author"><name><surname>Monteiro</surname><given-names>C</given-names></name><name><surname>Miarka</surname><given-names>L</given-names></name><name><surname>Perea-Garcia</surname><given-names>M</given-names></name><name><surname>Priego</surname><given-names>N</given-names></name><name><surname>Garcia-Gomez</surname><given-names>P</given-names></name><name><surname>Alvaro-Espinosa</surname><given-names>L</given-names></name><etal/></person-group><article-title>Stratification of radiosensitive brain metastases based on an actionable S100A9/RAGE resistance mechanism</article-title><source>Nat Med</source><year>2022</year><volume>28</volume><fpage>752</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1038/s41591-022-01749-8</pub-id><pub-id pub-id-type="pmid">35411077</pub-id>
</element-citation><mixed-citation id="mc-CR71" publication-type="journal">Monteiro C, Miarka L, Perea-Garcia M, Priego N, Garcia-Gomez P, Alvaro-Espinosa L, et al. Stratification of radiosensitive brain metastases based on an actionable S100A9/RAGE resistance mechanism. Nat Med. 2022;28:752&#x02013;65. 10.1038/s41591-022-01749-8.<pub-id pub-id-type="pmid">35411077</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR72"><label>72.</label><citation-alternatives><element-citation id="ec-CR72" publication-type="journal"><person-group person-group-type="author"><name><surname>Qu</surname><given-names>F</given-names></name><name><surname>Brough</surname><given-names>SC</given-names></name><name><surname>Michno</surname><given-names>W</given-names></name><name><surname>Madubata</surname><given-names>CJ</given-names></name><name><surname>Hartmann</surname><given-names>GG</given-names></name><name><surname>Puno</surname><given-names>A</given-names></name><etal/></person-group><article-title>Crosstalk between small-cell lung cancer cells and astrocytes mimics brain development to promote brain metastasis</article-title><source>Nat Cell Biol</source><year>2023</year><volume>25</volume><fpage>1506</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.1038/s41556-023-01241-6</pub-id><pub-id pub-id-type="pmid">37783795</pub-id>
</element-citation><mixed-citation id="mc-CR72" publication-type="journal">Qu F, Brough SC, Michno W, Madubata CJ, Hartmann GG, Puno A, et al. Crosstalk between small-cell lung cancer cells and astrocytes mimics brain development to promote brain metastasis. Nat Cell Biol. 2023;25:1506&#x02013;19. 10.1038/s41556-023-01241-6.<pub-id pub-id-type="pmid">37783795</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR73"><label>73.</label><citation-alternatives><element-citation id="ec-CR73" publication-type="journal"><person-group person-group-type="author"><name><surname>Ishibashi</surname><given-names>K</given-names></name><name><surname>Ichinose</surname><given-names>T</given-names></name><name><surname>Kadokawa</surname><given-names>R</given-names></name><name><surname>Mizutani</surname><given-names>R</given-names></name><name><surname>Iwabuchi</surname><given-names>S</given-names></name><name><surname>Togi</surname><given-names>S</given-names></name><etal/></person-group><article-title>Astrocyte-induced mGluR1 activates human lung cancer brain metastasis via glutamate-dependent stabilization of EGFR</article-title><source>Dev Cell</source><year>2024</year><volume>59</volume><fpage>579</fpage><lpage>94 e6</lpage><pub-id pub-id-type="doi">10.1016/j.devcel.2024.01.010</pub-id><pub-id pub-id-type="pmid">38309264</pub-id>
</element-citation><mixed-citation id="mc-CR73" publication-type="journal">Ishibashi K, Ichinose T, Kadokawa R, Mizutani R, Iwabuchi S, Togi S, et al. Astrocyte-induced mGluR1 activates human lung cancer brain metastasis via glutamate-dependent stabilization of EGFR. Dev Cell. 2024;59:579-94 e6. 10.1016/j.devcel.2024.01.010.<pub-id pub-id-type="pmid">38309264</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR74"><label>74.</label><citation-alternatives><element-citation id="ec-CR74" publication-type="journal"><person-group person-group-type="author"><name><surname>Guldner</surname><given-names>IH</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Golomb</surname><given-names>SM</given-names></name><name><surname>Zhao</surname><given-names>Z</given-names></name><name><surname>Lopez</surname><given-names>JA</given-names></name><etal/></person-group><article-title>CNS-native myeloid cells drive immune suppression in the brain metastatic niche through Cxcl10</article-title><source>Cell</source><year>2020</year><volume>183</volume><fpage>1234</fpage><lpage>48 e25</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.09.064</pub-id><pub-id pub-id-type="pmid">33113353</pub-id>
</element-citation><mixed-citation id="mc-CR74" publication-type="journal">Guldner IH, Wang Q, Yang L, Golomb SM, Zhao Z, Lopez JA, et al. CNS-native myeloid cells drive immune suppression in the brain metastatic niche through Cxcl10. Cell. 2020;183:1234-48 e25. 10.1016/j.cell.2020.09.064.<pub-id pub-id-type="pmid">33113353</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR75"><label>75.</label><citation-alternatives><element-citation id="ec-CR75" publication-type="journal"><person-group person-group-type="author"><name><surname>Bejarano</surname><given-names>L</given-names></name><name><surname>Kauzlaric</surname><given-names>A</given-names></name><name><surname>Lamprou</surname><given-names>E</given-names></name><name><surname>Lourenco</surname><given-names>J</given-names></name><name><surname>Fournier</surname><given-names>N</given-names></name><name><surname>Ballabio</surname><given-names>M</given-names></name><etal/></person-group><article-title>Interrogation of endothelial and mural cells in brain metastasis reveals key immune-regulatory mechanisms</article-title><source>Cancer Cell</source><year>2024</year><volume>42</volume><fpage>378</fpage><lpage>95 e10</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2023.12.018</pub-id><pub-id pub-id-type="pmid">38242126</pub-id>
</element-citation><mixed-citation id="mc-CR75" publication-type="journal">Bejarano L, Kauzlaric A, Lamprou E, Lourenco J, Fournier N, Ballabio M, et al. Interrogation of endothelial and mural cells in brain metastasis reveals key immune-regulatory mechanisms. Cancer Cell. 2024;42:378-95 e10. 10.1016/j.ccell.2023.12.018.<pub-id pub-id-type="pmid">38242126</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR76"><label>76.</label><citation-alternatives><element-citation id="ec-CR76" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Zhan</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Zeng</surname><given-names>K</given-names></name><name><surname>Xu</surname><given-names>C</given-names></name><etal/></person-group><article-title>Targeting the HSP47-collagen axis inhibits brain metastasis by reversing M2 microglial polarization and restoring anti-tumor immunity</article-title><source>Cell Rep Med</source><year>2024</year><volume>5</volume><fpage>101533</fpage><pub-id pub-id-type="doi">10.1016/j.xcrm.2024.101533</pub-id><pub-id pub-id-type="pmid">38744278</pub-id>
</element-citation><mixed-citation id="mc-CR76" publication-type="journal">Wang L, Li C, Zhan H, Li S, Zeng K, Xu C, et al. Targeting the HSP47-collagen axis inhibits brain metastasis by reversing M2 microglial polarization and restoring anti-tumor immunity. Cell Rep Med. 2024;5:101533. 10.1016/j.xcrm.2024.101533.<pub-id pub-id-type="pmid">38744278</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR77"><label>77.</label><citation-alternatives><element-citation id="ec-CR77" publication-type="journal"><person-group person-group-type="author"><name><surname>Kelly</surname><given-names>WJ</given-names></name><name><surname>Shah</surname><given-names>NJ</given-names></name><name><surname>Subramaniam</surname><given-names>DS</given-names></name></person-group><article-title>Management of brain metastases in epidermal growth factor receptor mutant non-small-cell lung cancer</article-title><source>Front Oncol</source><year>2018</year><volume>8</volume><fpage>208</fpage><pub-id pub-id-type="doi">10.3389/fonc.2018.00208</pub-id><pub-id pub-id-type="pmid">30018881</pub-id>
</element-citation><mixed-citation id="mc-CR77" publication-type="journal">Kelly WJ, Shah NJ, Subramaniam DS. Management of brain metastases in epidermal growth factor receptor mutant non-small-cell lung cancer. Front Oncol. 2018;8:208. 10.3389/fonc.2018.00208.<pub-id pub-id-type="pmid">30018881</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR78"><label>78.</label><citation-alternatives><element-citation id="ec-CR78" publication-type="journal"><person-group person-group-type="author"><name><surname>Baek</surname><given-names>MY</given-names></name><name><surname>Ahn</surname><given-names>HK</given-names></name><name><surname>Park</surname><given-names>KR</given-names></name><name><surname>Park</surname><given-names>HS</given-names></name><name><surname>Kang</surname><given-names>SM</given-names></name><name><surname>Park</surname><given-names>I</given-names></name><etal/></person-group><article-title>Epidermal growth factor receptor mutation and pattern of brain metastasis in patients with non-small cell lung cancer</article-title><source>Korean J Intern Med</source><year>2018</year><volume>33</volume><fpage>168</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.3904/kjim.2015.158</pub-id><pub-id pub-id-type="pmid">27093978</pub-id>
</element-citation><mixed-citation id="mc-CR78" publication-type="journal">Baek MY, Ahn HK, Park KR, Park HS, Kang SM, Park I, et al. Epidermal growth factor receptor mutation and pattern of brain metastasis in patients with non-small cell lung cancer. Korean J Intern Med. 2018;33:168&#x02013;75. 10.3904/kjim.2015.158.<pub-id pub-id-type="pmid">27093978</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR79"><label>79.</label><citation-alternatives><element-citation id="ec-CR79" publication-type="journal"><person-group person-group-type="author"><name><surname>Shih</surname><given-names>DJH</given-names></name><name><surname>Nayyar</surname><given-names>N</given-names></name><name><surname>Bihun</surname><given-names>I</given-names></name><name><surname>Dagogo-Jack</surname><given-names>I</given-names></name><name><surname>Gill</surname><given-names>CM</given-names></name><name><surname>Aquilanti</surname><given-names>E</given-names></name><etal/></person-group><article-title>Genomic characterization of human brain metastases identifies drivers of metastatic lung adenocarcinoma</article-title><source>Nat Genet</source><year>2020</year><volume>52</volume><fpage>371</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1038/s41588-020-0592-7</pub-id><pub-id pub-id-type="pmid">32203465</pub-id>
</element-citation><mixed-citation id="mc-CR79" publication-type="journal">Shih DJH, Nayyar N, Bihun I, Dagogo-Jack I, Gill CM, Aquilanti E, et al. Genomic characterization of human brain metastases identifies drivers of metastatic lung adenocarcinoma. Nat Genet. 2020;52:371&#x02013;7. 10.1038/s41588-020-0592-7.<pub-id pub-id-type="pmid">32203465</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR80"><label>80.</label><citation-alternatives><element-citation id="ec-CR80" publication-type="journal"><person-group person-group-type="author"><name><surname>Skakodub</surname><given-names>A</given-names></name><name><surname>Walch</surname><given-names>H</given-names></name><name><surname>Tringale</surname><given-names>KR</given-names></name><name><surname>Eichholz</surname><given-names>J</given-names></name><name><surname>Imber</surname><given-names>BS</given-names></name><name><surname>Vasudevan</surname><given-names>HN</given-names></name><etal/></person-group><article-title>Genomic analysis and clinical correlations of non-small cell lung cancer brain metastasis</article-title><source>Nat Commun</source><year>2023</year><volume>14</volume><fpage>4980</fpage><pub-id pub-id-type="doi">10.1038/s41467-023-40793-x</pub-id><pub-id pub-id-type="pmid">37591896</pub-id>
</element-citation><mixed-citation id="mc-CR80" publication-type="journal">Skakodub A, Walch H, Tringale KR, Eichholz J, Imber BS, Vasudevan HN, et al. Genomic analysis and clinical correlations of non-small cell lung cancer brain metastasis. Nat Commun. 2023;14:4980. 10.1038/s41467-023-40793-x.<pub-id pub-id-type="pmid">37591896</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR81"><label>81.</label><citation-alternatives><element-citation id="ec-CR81" publication-type="journal"><person-group person-group-type="author"><name><surname>Fischer</surname><given-names>B</given-names></name><name><surname>Marinov</surname><given-names>M</given-names></name><name><surname>Arcaro</surname><given-names>A</given-names></name></person-group><article-title>Targeting receptor tyrosine kinase signalling in small cell lung cancer (SCLC): what have we learned so far?</article-title><source>Cancer Treat Rev</source><year>2007</year><volume>33</volume><fpage>391</fpage><lpage>406</lpage><pub-id pub-id-type="doi">10.1016/j.ctrv.2007.01.006</pub-id><pub-id pub-id-type="pmid">17368733</pub-id>
</element-citation><mixed-citation id="mc-CR81" publication-type="journal">Fischer B, Marinov M, Arcaro A. Targeting receptor tyrosine kinase signalling in small cell lung cancer (SCLC): what have we learned so far? Cancer Treat Rev. 2007;33:391&#x02013;406. 10.1016/j.ctrv.2007.01.006.<pub-id pub-id-type="pmid">17368733</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR82"><label>82.</label><citation-alternatives><element-citation id="ec-CR82" publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>K</given-names></name><name><surname>Yang</surname><given-names>Z</given-names></name><name><surname>Guan</surname><given-names>M</given-names></name></person-group><article-title>Targeted sequencing reveals distinct pathogenic variants in Chinese patients with lung adenocarcinoma brain metastases</article-title><source>Oncol Lett</source><year>2018</year><volume>15</volume><fpage>4503</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.3892/ol.2018.7859</pub-id><pub-id pub-id-type="pmid">29541220</pub-id>
</element-citation><mixed-citation id="mc-CR82" publication-type="journal">Ma Y, Chen K, Yang Z, Guan M. Targeted sequencing reveals distinct pathogenic variants in Chinese patients with lung adenocarcinoma brain metastases. Oncol Lett. 2018;15:4503&#x02013;10. 10.3892/ol.2018.7859.<pub-id pub-id-type="pmid">29541220</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR83"><label>83.</label><citation-alternatives><element-citation id="ec-CR83" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Ou</surname><given-names>Q</given-names></name><name><surname>Li</surname><given-names>D</given-names></name><name><surname>Qin</surname><given-names>T</given-names></name><name><surname>Bao</surname><given-names>H</given-names></name><name><surname>Hou</surname><given-names>X</given-names></name><etal/></person-group><article-title>Genes associated with increased brain metastasis risk in non-small cell lung cancer: Comprehensive genomic profiling of 61 resected brain metastases versus primary non-small cell lung cancer (Guangdong Association Study of Thoracic Oncology 1036)</article-title><source>Cancer</source><year>2019</year><volume>125</volume><fpage>3535</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1002/cncr.32372</pub-id><pub-id pub-id-type="pmid">31287555</pub-id>
</element-citation><mixed-citation id="mc-CR83" publication-type="journal">Wang H, Ou Q, Li D, Qin T, Bao H, Hou X, et al. Genes associated with increased brain metastasis risk in non-small cell lung cancer: Comprehensive genomic profiling of 61 resected brain metastases versus primary non-small cell lung cancer (Guangdong Association Study of Thoracic Oncology 1036). Cancer. 2019;125:3535&#x02013;44. 10.1002/cncr.32372.<pub-id pub-id-type="pmid">31287555</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR84"><label>84.</label><citation-alternatives><element-citation id="ec-CR84" publication-type="journal"><person-group person-group-type="author"><name><surname>Pellerino</surname><given-names>A</given-names></name><name><surname>Bruno</surname><given-names>F</given-names></name><name><surname>Ruda</surname><given-names>R</given-names></name><name><surname>Soffietti</surname><given-names>R</given-names></name></person-group><article-title>Systemic therapy for lung cancer brain metastases</article-title><source>Curr Treat Options Oncol</source><year>2021</year><volume>22</volume><fpage>110</fpage><pub-id pub-id-type="doi">10.1007/s11864-021-00911-7</pub-id><pub-id pub-id-type="pmid">34693454</pub-id>
</element-citation><mixed-citation id="mc-CR84" publication-type="journal">Pellerino A, Bruno F, Ruda R, Soffietti R. Systemic therapy for lung cancer brain metastases. Curr Treat Options Oncol. 2021;22:110. 10.1007/s11864-021-00911-7.<pub-id pub-id-type="pmid">34693454</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR85"><label>85.</label><citation-alternatives><element-citation id="ec-CR85" publication-type="journal"><person-group person-group-type="author"><name><surname>Schuler</surname><given-names>M</given-names></name><name><surname>Wu</surname><given-names>YL</given-names></name><name><surname>Hirsh</surname><given-names>V</given-names></name><name><surname>O'Byrne</surname><given-names>K</given-names></name><name><surname>Yamamoto</surname><given-names>N</given-names></name><name><surname>Mok</surname><given-names>T</given-names></name><etal/></person-group><article-title>First-line Afatinib versus chemotherapy in patients with non-small cell lung cancer and common epidermal growth factor receptor gene mutations and brain metastases</article-title><source>J Thorac Oncol</source><year>2016</year><volume>11</volume><fpage>380</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1016/j.jtho.2015.11.014</pub-id><pub-id pub-id-type="pmid">26823294</pub-id>
</element-citation><mixed-citation id="mc-CR85" publication-type="journal">Schuler M, Wu YL, Hirsh V, O&#x02019;Byrne K, Yamamoto N, Mok T, et al. First-line Afatinib versus chemotherapy in patients with non-small cell lung cancer and common epidermal growth factor receptor gene mutations and brain metastases. J Thorac Oncol. 2016;11:380&#x02013;90. 10.1016/j.jtho.2015.11.014.<pub-id pub-id-type="pmid">26823294</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR86"><label>86.</label><mixed-citation publication-type="other">Gainor JF, Tseng D, Yoda S, Dagogo-Jack I, Friboulet L, Lin JJ, et al. Patterns of metastatic spread and mechanisms of resistance to crizotinib in ROS1-positive non-small-cell lung cancer. JCO Precis Oncol. 2017;2017. 10.1200/PO.17.00063.</mixed-citation></ref><ref id="CR87"><label>87.</label><citation-alternatives><element-citation id="ec-CR87" publication-type="journal"><person-group person-group-type="author"><name><surname>Chamberlain</surname><given-names>MC</given-names></name><name><surname>Baik</surname><given-names>CS</given-names></name><name><surname>Gadi</surname><given-names>VK</given-names></name><name><surname>Bhatia</surname><given-names>S</given-names></name><name><surname>Chow</surname><given-names>LQ</given-names></name></person-group><article-title>Systemic therapy of brain metastases: non-small cell lung cancer, breast cancer, and melanoma</article-title><source>Neuro Oncol</source><year>2017</year><volume>19</volume><fpage>i1</fpage><lpage>i24</lpage><pub-id pub-id-type="doi">10.1093/neuonc/now197</pub-id><pub-id pub-id-type="pmid">28031389</pub-id>
</element-citation><mixed-citation id="mc-CR87" publication-type="journal">Chamberlain MC, Baik CS, Gadi VK, Bhatia S, Chow LQ. Systemic therapy of brain metastases: non-small cell lung cancer, breast cancer, and melanoma. Neuro Oncol. 2017;19:i1&#x02013;24. 10.1093/neuonc/now197.<pub-id pub-id-type="pmid">28031389</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR88"><label>88.</label><citation-alternatives><element-citation id="ec-CR88" publication-type="journal"><person-group person-group-type="author"><name><surname>Drilon</surname><given-names>A</given-names></name><name><surname>Lin</surname><given-names>JJ</given-names></name><name><surname>Filleron</surname><given-names>T</given-names></name><name><surname>Ni</surname><given-names>A</given-names></name><name><surname>Milia</surname><given-names>J</given-names></name><name><surname>Bergagnini</surname><given-names>I</given-names></name><etal/></person-group><article-title>Frequency of brain metastases and multikinase inhibitor outcomes in patients with RET-rearranged lung cancers</article-title><source>J Thorac Oncol</source><year>2018</year><volume>13</volume><fpage>1595</fpage><lpage>601</lpage><pub-id pub-id-type="doi">10.1016/j.jtho.2018.07.004</pub-id><pub-id pub-id-type="pmid">30017832</pub-id>
</element-citation><mixed-citation id="mc-CR88" publication-type="journal">Drilon A, Lin JJ, Filleron T, Ni A, Milia J, Bergagnini I, et al. Frequency of brain metastases and multikinase inhibitor outcomes in patients with RET-rearranged lung cancers. J Thorac Oncol. 2018;13:1595&#x02013;601. 10.1016/j.jtho.2018.07.004.<pub-id pub-id-type="pmid">30017832</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR89"><label>89.</label><citation-alternatives><element-citation id="ec-CR89" publication-type="journal"><person-group person-group-type="author"><name><surname>Mercer</surname><given-names>TR</given-names></name><name><surname>Dinger</surname><given-names>ME</given-names></name><name><surname>Mattick</surname><given-names>JS</given-names></name></person-group><article-title>Long non-coding RNAs: insights into functions</article-title><source>Nat Rev Genet</source><year>2009</year><volume>10</volume><fpage>155</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1038/nrg2521</pub-id><pub-id pub-id-type="pmid">19188922</pub-id>
</element-citation><mixed-citation id="mc-CR89" publication-type="journal">Mercer TR, Dinger ME, Mattick JS. Long non-coding RNAs: insights into functions. Nat Rev Genet. 2009;10:155&#x02013;9. 10.1038/nrg2521.<pub-id pub-id-type="pmid">19188922</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR90"><label>90.</label><citation-alternatives><element-citation id="ec-CR90" publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>W</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>C</given-names></name><name><surname>Guo</surname><given-names>J</given-names></name></person-group><article-title>Regulatory mechanisms of long noncoding RNAs on gene expression in cancers</article-title><source>Cancer Genet</source><year>2017</year><volume>216&#x02013;217</volume><fpage>105</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1016/j.cancergen.2017.06.003</pub-id><pub-id pub-id-type="pmid">29025584</pub-id>
</element-citation><mixed-citation id="mc-CR90" publication-type="journal">Sun W, Yang Y, Xu C, Guo J. Regulatory mechanisms of long noncoding RNAs on gene expression in cancers. Cancer Genet. 2017;216&#x02013;217:105&#x02013;10. 10.1016/j.cancergen.2017.06.003.<pub-id pub-id-type="pmid">29025584</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR91"><label>91.</label><citation-alternatives><element-citation id="ec-CR91" publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>L</given-names></name><name><surname>Bajic</surname><given-names>VB</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name></person-group><article-title>On the classification of long non-coding RNAs</article-title><source>RNA Biol</source><year>2013</year><volume>10</volume><fpage>925</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.4161/rna.24604</pub-id><pub-id pub-id-type="pmid">23696037</pub-id>
</element-citation><mixed-citation id="mc-CR91" publication-type="journal">Ma L, Bajic VB, Zhang Z. On the classification of long non-coding RNAs. RNA Biol. 2013;10:925&#x02013;33. 10.4161/rna.24604.<pub-id pub-id-type="pmid">23696037</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR92"><label>92.</label><citation-alternatives><element-citation id="ec-CR92" publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Wu</surname><given-names>H</given-names></name><name><surname>Zhou</surname><given-names>C</given-names></name><name><surname>Zhu</surname><given-names>H</given-names></name><etal/></person-group><article-title>Association of serum microRNA expression in hepatocellular carcinomas treated with transarterial chemoembolization and patient survival</article-title><source>PLoS ONE</source><year>2014</year><volume>9</volume><fpage>e109347</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0109347</pub-id><pub-id pub-id-type="pmid">25275448</pub-id>
</element-citation><mixed-citation id="mc-CR92" publication-type="journal">Liu M, Liu J, Wang L, Wu H, Zhou C, Zhu H, et al. Association of serum microRNA expression in hepatocellular carcinomas treated with transarterial chemoembolization and patient survival. PLoS ONE. 2014;9:e109347. 10.1371/journal.pone.0109347.<pub-id pub-id-type="pmid">25275448</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR93"><label>93.</label><citation-alternatives><element-citation id="ec-CR93" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>FF</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Xue</surname><given-names>WH</given-names></name><name><surname>Cheng</surname><given-names>JL</given-names></name></person-group><article-title>microRNA-590 suppresses the tumorigenesis and invasiveness of non-small cell lung cancer cells by targeting ADAM9</article-title><source>Mol Cell Biochem</source><year>2016</year><volume>423</volume><fpage>29</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1007/s11010-016-2822-y</pub-id><pub-id pub-id-type="pmid">27770372</pub-id>
</element-citation><mixed-citation id="mc-CR93" publication-type="journal">Wang FF, Wang S, Xue WH, Cheng JL. microRNA-590 suppresses the tumorigenesis and invasiveness of non-small cell lung cancer cells by targeting ADAM9. Mol Cell Biochem. 2016;423:29&#x02013;37. 10.1007/s11010-016-2822-y.<pub-id pub-id-type="pmid">27770372</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR94"><label>94.</label><citation-alternatives><element-citation id="ec-CR94" publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>LJ</given-names></name><name><surname>Li</surname><given-names>XY</given-names></name><name><surname>Zhao</surname><given-names>YQ</given-names></name><name><surname>Liu</surname><given-names>WJ</given-names></name><name><surname>Wu</surname><given-names>HJ</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><etal/></person-group><article-title>Down-regulated microRNA-375 expression as a predictive biomarker in non-small cell lung cancer brain metastasis and its prognostic significance</article-title><source>Pathol Res Pract</source><year>2017</year><volume>213</volume><fpage>882</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/j.prp.2017.06.012</pub-id><pub-id pub-id-type="pmid">28688608</pub-id>
</element-citation><mixed-citation id="mc-CR94" publication-type="journal">Chen LJ, Li XY, Zhao YQ, Liu WJ, Wu HJ, Liu J, et al. Down-regulated microRNA-375 expression as a predictive biomarker in non-small cell lung cancer brain metastasis and its prognostic significance. Pathol Res Pract. 2017;213:882&#x02013;8. 10.1016/j.prp.2017.06.012.<pub-id pub-id-type="pmid">28688608</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR95"><label>95.</label><citation-alternatives><element-citation id="ec-CR95" publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>M</given-names></name><name><surname>Garg</surname><given-names>N</given-names></name><name><surname>Venugopal</surname><given-names>C</given-names></name><name><surname>Hallett</surname><given-names>R</given-names></name><name><surname>Tokar</surname><given-names>T</given-names></name><name><surname>McFarlane</surname><given-names>N</given-names></name><etal/></person-group><article-title>STAT3 pathway regulates lung-derived brain metastasis initiating cell capacity through miR-21 activation</article-title><source>Oncotarget</source><year>2015</year><volume>6</volume><fpage>27461</fpage><lpage>77</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.4742</pub-id><pub-id pub-id-type="pmid">26314961</pub-id>
</element-citation><mixed-citation id="mc-CR95" publication-type="journal">Singh M, Garg N, Venugopal C, Hallett R, Tokar T, McFarlane N, et al. STAT3 pathway regulates lung-derived brain metastasis initiating cell capacity through miR-21 activation. Oncotarget. 2015;6:27461&#x02013;77. 10.18632/oncotarget.4742.<pub-id pub-id-type="pmid">26314961</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR96"><label>96.</label><citation-alternatives><element-citation id="ec-CR96" publication-type="journal"><person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>K</given-names></name><name><surname>Joyce</surname><given-names>CE</given-names></name><name><surname>Buquicchio</surname><given-names>F</given-names></name><name><surname>Brown</surname><given-names>A</given-names></name><name><surname>Ritz</surname><given-names>J</given-names></name><name><surname>Distel</surname><given-names>RJ</given-names></name><etal/></person-group><article-title>The lncRNA SLNCR1 mediates melanoma invasion through a conserved SRA1-like region</article-title><source>Cell Rep</source><year>2016</year><volume>15</volume><fpage>2025</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2016.04.018</pub-id><pub-id pub-id-type="pmid">27210747</pub-id>
</element-citation><mixed-citation id="mc-CR96" publication-type="journal">Schmidt K, Joyce CE, Buquicchio F, Brown A, Ritz J, Distel RJ, et al. The lncRNA SLNCR1 mediates melanoma invasion through a conserved SRA1-like region. Cell Rep. 2016;15:2025&#x02013;37. 10.1016/j.celrep.2016.04.018.<pub-id pub-id-type="pmid">27210747</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR97"><label>97.</label><citation-alternatives><element-citation id="ec-CR97" publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Jiang</surname><given-names>X</given-names></name><name><surname>Xia</surname><given-names>H</given-names></name><name><surname>Zhuang</surname><given-names>Z</given-names></name></person-group><article-title>Long noncoding RNA MALAT1 promotes brain metastasis by inducing epithelial-mesenchymal transition in lung cancer</article-title><source>J Neurooncol</source><year>2015</year><volume>121</volume><fpage>101</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1007/s11060-014-1613-0</pub-id><pub-id pub-id-type="pmid">25217850</pub-id>
</element-citation><mixed-citation id="mc-CR97" publication-type="journal">Shen L, Chen L, Wang Y, Jiang X, Xia H, Zhuang Z. Long noncoding RNA MALAT1 promotes brain metastasis by inducing epithelial-mesenchymal transition in lung cancer. J Neurooncol. 2015;121:101&#x02013;8. 10.1007/s11060-014-1613-0.<pub-id pub-id-type="pmid">25217850</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR98"><label>98.</label><citation-alternatives><element-citation id="ec-CR98" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Liang</surname><given-names>K</given-names></name><name><surname>Hu</surname><given-names>Q</given-names></name><name><surname>Li</surname><given-names>P</given-names></name><name><surname>Song</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>JAK2-binding long noncoding RNA promotes breast cancer brain metastasis</article-title><source>J Clin Invest</source><year>2017</year><volume>127</volume><fpage>4498</fpage><lpage>515</lpage><pub-id pub-id-type="doi">10.1172/JCI91553</pub-id><pub-id pub-id-type="pmid">29130936</pub-id>
</element-citation><mixed-citation id="mc-CR98" publication-type="journal">Wang S, Liang K, Hu Q, Li P, Song J, Yang Y, et al. JAK2-binding long noncoding RNA promotes breast cancer brain metastasis. J Clin Invest. 2017;127:4498&#x02013;515. 10.1172/JCI91553.<pub-id pub-id-type="pmid">29130936</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR99"><label>99.</label><citation-alternatives><element-citation id="ec-CR99" publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Sun</surname><given-names>P</given-names></name><name><surname>Xia</surname><given-names>L</given-names></name><name><surname>He</surname><given-names>X</given-names></name><name><surname>Xia</surname><given-names>Z</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>A brain-enriched lncRNA shields cancer cells from immune-mediated killing for metastatic colonization in the brain</article-title><source>Proc Natl Acad Sci U S A</source><year>2022</year><volume>119</volume><fpage>e2200230119</fpage><pub-id pub-id-type="doi">10.1073/pnas.2200230119</pub-id><pub-id pub-id-type="pmid">35617432</pub-id>
</element-citation><mixed-citation id="mc-CR99" publication-type="journal">Liu W, Sun P, Xia L, He X, Xia Z, Huang Y, et al. A brain-enriched lncRNA shields cancer cells from immune-mediated killing for metastatic colonization in the brain. Proc Natl Acad Sci U S A. 2022;119:e2200230119. 10.1073/pnas.2200230119.<pub-id pub-id-type="pmid">35617432</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR100"><label>100.</label><citation-alternatives><element-citation id="ec-CR100" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhong</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>B</given-names></name></person-group><article-title>Long noncoding RNA LGALS8-AS1 promotes angiogenesis and brain metastases in non-small cell lung cancer</article-title><source>Acta Biochim Pol</source><year>2023</year><volume>70</volume><fpage>551</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.18388/abp.2020_6501</pub-id><pub-id pub-id-type="pmid">37716002</pub-id>
</element-citation><mixed-citation id="mc-CR100" publication-type="journal">Zhong J, Wang B. Long noncoding RNA LGALS8-AS1 promotes angiogenesis and brain metastases in non-small cell lung cancer. Acta Biochim Pol. 2023;70:551&#x02013;9. 10.18388/abp.2020_6501.<pub-id pub-id-type="pmid">37716002</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR101"><label>101.</label><citation-alternatives><element-citation id="ec-CR101" publication-type="journal"><person-group person-group-type="author"><name><surname>Martinez-Ruiz</surname><given-names>C</given-names></name><name><surname>Black</surname><given-names>JRM</given-names></name><name><surname>Puttick</surname><given-names>C</given-names></name><name><surname>Hill</surname><given-names>MS</given-names></name><name><surname>Demeulemeester</surname><given-names>J</given-names></name><name><surname>Larose Cadieux</surname><given-names>E</given-names></name><etal/></person-group><article-title>Genomic-transcriptomic evolution in lung cancer and metastasis</article-title><source>Nature</source><year>2023</year><volume>616</volume><fpage>543</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1038/s41586-023-05706-4</pub-id><pub-id pub-id-type="pmid">37046093</pub-id>
</element-citation><mixed-citation id="mc-CR101" publication-type="journal">Martinez-Ruiz C, Black JRM, Puttick C, Hill MS, Demeulemeester J, Larose Cadieux E, et al. Genomic-transcriptomic evolution in lung cancer and metastasis. Nature. 2023;616:543&#x02013;52. 10.1038/s41586-023-05706-4.<pub-id pub-id-type="pmid">37046093</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR102"><label>102.</label><citation-alternatives><element-citation id="ec-CR102" publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>T</given-names></name><name><surname>Yan</surname><given-names>Y</given-names></name><name><surname>Zhou</surname><given-names>K</given-names></name><name><surname>Su</surname><given-names>C</given-names></name><name><surname>Ren</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>N</given-names></name><etal/></person-group><article-title>Characterization of evolution trajectory and immune profiling of brain metastasis in lung adenocarcinoma</article-title><source>NPJ Precis Oncol</source><year>2021</year><volume>5</volume><fpage>6</fpage><pub-id pub-id-type="doi">10.1038/s41698-021-00151-w</pub-id><pub-id pub-id-type="pmid">33580130</pub-id>
</element-citation><mixed-citation id="mc-CR102" publication-type="journal">Jiang T, Yan Y, Zhou K, Su C, Ren S, Li N, et al. Characterization of evolution trajectory and immune profiling of brain metastasis in lung adenocarcinoma. NPJ Precis Oncol. 2021;5:6. 10.1038/s41698-021-00151-w.<pub-id pub-id-type="pmid">33580130</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR103"><label>103.</label><citation-alternatives><element-citation id="ec-CR103" publication-type="journal"><person-group person-group-type="author"><name><surname>Saunus</surname><given-names>JM</given-names></name><name><surname>Quinn</surname><given-names>MC</given-names></name><name><surname>Patch</surname><given-names>AM</given-names></name><name><surname>Pearson</surname><given-names>JV</given-names></name><name><surname>Bailey</surname><given-names>PJ</given-names></name><name><surname>Nones</surname><given-names>K</given-names></name><etal/></person-group><article-title>Integrated genomic and transcriptomic analysis of human brain metastases identifies alterations of potential clinical significance</article-title><source>J Pathol</source><year>2015</year><volume>237</volume><fpage>363</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.1002/path.4583</pub-id><pub-id pub-id-type="pmid">26172396</pub-id>
</element-citation><mixed-citation id="mc-CR103" publication-type="journal">Saunus JM, Quinn MC, Patch AM, Pearson JV, Bailey PJ, Nones K, et al. Integrated genomic and transcriptomic analysis of human brain metastases identifies alterations of potential clinical significance. J Pathol. 2015;237:363&#x02013;78. 10.1002/path.4583.<pub-id pub-id-type="pmid">26172396</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR104"><label>104.</label><citation-alternatives><element-citation id="ec-CR104" publication-type="journal"><person-group person-group-type="author"><name><surname>Biswas</surname><given-names>AK</given-names></name><name><surname>Han</surname><given-names>S</given-names></name><name><surname>Tai</surname><given-names>Y</given-names></name><name><surname>Ma</surname><given-names>W</given-names></name><name><surname>Coker</surname><given-names>C</given-names></name><name><surname>Quinn</surname><given-names>SA</given-names></name><etal/></person-group><article-title>Targeting S100A9-ALDH1A1-retinoic acid signaling to suppress brain relapse in EGFR-mutant lung cancer</article-title><source>Cancer Discov</source><year>2022</year><volume>12</volume><fpage>1002</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-21-0910</pub-id><pub-id pub-id-type="pmid">35078784</pub-id>
</element-citation><mixed-citation id="mc-CR104" publication-type="journal">Biswas AK, Han S, Tai Y, Ma W, Coker C, Quinn SA, et al. Targeting S100A9-ALDH1A1-retinoic acid signaling to suppress brain relapse in EGFR-mutant lung cancer. Cancer Discov. 2022;12:1002&#x02013;21. 10.1158/2159-8290.CD-21-0910.<pub-id pub-id-type="pmid">35078784</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR105"><label>105.</label><citation-alternatives><element-citation id="ec-CR105" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Bai</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Duan</surname><given-names>J</given-names></name><name><surname>Cai</surname><given-names>H</given-names></name><etal/></person-group><article-title>Genetic intratumor heterogeneity remodels the immune microenvironment and induces immune evasion in brain metastasis of lung cancer</article-title><source>J Thorac Oncol</source><year>2024</year><volume>19</volume><fpage>252</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1016/j.jtho.2023.09.276</pub-id><pub-id pub-id-type="pmid">37717855</pub-id>
</element-citation><mixed-citation id="mc-CR105" publication-type="journal">Wang X, Bai H, Zhang J, Wang Z, Duan J, Cai H, et al. Genetic intratumor heterogeneity remodels the immune microenvironment and induces immune evasion in brain metastasis of lung cancer. J Thorac Oncol. 2024;19:252&#x02013;72. 10.1016/j.jtho.2023.09.276.<pub-id pub-id-type="pmid">37717855</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR106"><label>106.</label><citation-alternatives><element-citation id="ec-CR106" publication-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>C</given-names></name><name><surname>Dong</surname><given-names>X</given-names></name><name><surname>Lu</surname><given-names>H</given-names></name><name><surname>Tong</surname><given-names>F</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>R</given-names></name><etal/></person-group><article-title>LPCAT1 promotes brain metastasis of lung adenocarcinoma by up-regulating PI3K/AKT/MYC pathway</article-title><source>J Exp Clin Cancer Res</source><year>2019</year><volume>38</volume><fpage>95</fpage><pub-id pub-id-type="doi">10.1186/s13046-019-1092-4</pub-id><pub-id pub-id-type="pmid">30791942</pub-id>
</element-citation><mixed-citation id="mc-CR106" publication-type="journal">Wei C, Dong X, Lu H, Tong F, Chen L, Zhang R, et al. LPCAT1 promotes brain metastasis of lung adenocarcinoma by up-regulating PI3K/AKT/MYC pathway. J Exp Clin Cancer Res. 2019;38:95. 10.1186/s13046-019-1092-4.<pub-id pub-id-type="pmid">30791942</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR107"><label>107.</label><citation-alternatives><element-citation id="ec-CR107" publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>J</given-names></name><name><surname>Lu</surname><given-names>Y</given-names></name><name><surname>Chu</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Xu</surname><given-names>C</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><etal/></person-group><article-title>Anti-EGFR ScFv functionalized exosomes delivering LPCAT1 specific siRNAs for inhibition of lung cancer brain metastases</article-title><source>J Nanobiotechnology</source><year>2024</year><volume>22</volume><fpage>159</fpage><pub-id pub-id-type="doi">10.1186/s12951-024-02414-7</pub-id><pub-id pub-id-type="pmid">38589859</pub-id>
</element-citation><mixed-citation id="mc-CR107" publication-type="journal">Jiang J, Lu Y, Chu J, Zhang X, Xu C, Liu S, et al. Anti-EGFR ScFv functionalized exosomes delivering LPCAT1 specific siRNAs for inhibition of lung cancer brain metastases. J Nanobiotechnology. 2024;22:159. 10.1186/s12951-024-02414-7.<pub-id pub-id-type="pmid">38589859</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR108"><label>108.</label><citation-alternatives><element-citation id="ec-CR108" publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>N</given-names></name><name><surname>Kim</surname><given-names>HK</given-names></name><name><surname>Lee</surname><given-names>K</given-names></name><name><surname>Hong</surname><given-names>Y</given-names></name><name><surname>Cho</surname><given-names>JH</given-names></name><name><surname>Choi</surname><given-names>JW</given-names></name><etal/></person-group><article-title>Single-cell RNA sequencing demonstrates the molecular and cellular reprogramming of metastatic lung adenocarcinoma</article-title><source>Nat Commun</source><year>2020</year><volume>11</volume><fpage>2285</fpage><pub-id pub-id-type="doi">10.1038/s41467-020-16164-1</pub-id><pub-id pub-id-type="pmid">32385277</pub-id>
</element-citation><mixed-citation id="mc-CR108" publication-type="journal">Kim N, Kim HK, Lee K, Hong Y, Cho JH, Choi JW, et al. Single-cell RNA sequencing demonstrates the molecular and cellular reprogramming of metastatic lung adenocarcinoma. Nat Commun. 2020;11:2285. 10.1038/s41467-020-16164-1.<pub-id pub-id-type="pmid">32385277</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR109"><label>109.</label><citation-alternatives><element-citation id="ec-CR109" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Chang</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>P</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><etal/></person-group><article-title>Single-cell transcriptomic analyses provide insights into the cellular origins and drivers of brain metastasis from lung adenocarcinoma</article-title><source>Neuro Oncol</source><year>2023</year><volume>25</volume><fpage>1262</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1093/neuonc/noad017</pub-id><pub-id pub-id-type="pmid">36656750</pub-id>
</element-citation><mixed-citation id="mc-CR109" publication-type="journal">Wang Z, Wang Y, Chang M, Wang Y, Liu P, Wu J, et al. Single-cell transcriptomic analyses provide insights into the cellular origins and drivers of brain metastasis from lung adenocarcinoma. Neuro Oncol. 2023;25:1262&#x02013;74. 10.1093/neuonc/noad017.<pub-id pub-id-type="pmid">36656750</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR110"><label>110.</label><citation-alternatives><element-citation id="ec-CR110" publication-type="journal"><person-group person-group-type="author"><name><surname>Gonzalez</surname><given-names>H</given-names></name><name><surname>Mei</surname><given-names>W</given-names></name><name><surname>Robles</surname><given-names>I</given-names></name><name><surname>Hagerling</surname><given-names>C</given-names></name><name><surname>Allen</surname><given-names>BM</given-names></name><name><surname>Hauge Okholm</surname><given-names>TL</given-names></name><etal/></person-group><article-title>Cellular architecture of human brain metastases</article-title><source>Cell</source><year>2022</year><volume>185</volume><fpage>729</fpage><lpage>45 e20</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2021.12.043</pub-id><pub-id pub-id-type="pmid">35063085</pub-id>
</element-citation><mixed-citation id="mc-CR110" publication-type="journal">Gonzalez H, Mei W, Robles I, Hagerling C, Allen BM, Hauge Okholm TL, et al. Cellular architecture of human brain metastases. Cell. 2022;185:729-45 e20. 10.1016/j.cell.2021.12.043.<pub-id pub-id-type="pmid">35063085</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR111"><label>111.</label><citation-alternatives><element-citation id="ec-CR111" publication-type="journal"><person-group person-group-type="author"><name><surname>Friebel</surname><given-names>E</given-names></name><name><surname>Kapolou</surname><given-names>K</given-names></name><name><surname>Unger</surname><given-names>S</given-names></name><name><surname>Nunez</surname><given-names>NG</given-names></name><name><surname>Utz</surname><given-names>S</given-names></name><name><surname>Rushing</surname><given-names>EJ</given-names></name><etal/></person-group><article-title>Single-cell mapping of human brain cancer reveals tumor-specific instruction of tissue-invading leukocytes</article-title><source>Cell</source><year>2020</year><volume>181</volume><fpage>1626</fpage><lpage>42 e20</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.04.055</pub-id><pub-id pub-id-type="pmid">32470397</pub-id>
</element-citation><mixed-citation id="mc-CR111" publication-type="journal">Friebel E, Kapolou K, Unger S, Nunez NG, Utz S, Rushing EJ, et al. Single-cell mapping of human brain cancer reveals tumor-specific instruction of tissue-invading leukocytes. Cell. 2020;181:1626-42 e20. 10.1016/j.cell.2020.04.055.<pub-id pub-id-type="pmid">32470397</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR112"><label>112.</label><citation-alternatives><element-citation id="ec-CR112" publication-type="journal"><person-group person-group-type="author"><name><surname>Klemm</surname><given-names>F</given-names></name><name><surname>Maas</surname><given-names>RR</given-names></name><name><surname>Bowman</surname><given-names>RL</given-names></name><name><surname>Kornete</surname><given-names>M</given-names></name><name><surname>Soukup</surname><given-names>K</given-names></name><name><surname>Nassiri</surname><given-names>S</given-names></name><etal/></person-group><article-title>Interrogation of the microenvironmental landscape in brain tumors reveals disease-specific alterations of immune cells</article-title><source>Cell</source><year>2020</year><volume>181</volume><fpage>1643</fpage><lpage>60 e17</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.05.007</pub-id><pub-id pub-id-type="pmid">32470396</pub-id>
</element-citation><mixed-citation id="mc-CR112" publication-type="journal">Klemm F, Maas RR, Bowman RL, Kornete M, Soukup K, Nassiri S, et al. Interrogation of the microenvironmental landscape in brain tumors reveals disease-specific alterations of immune cells. Cell. 2020;181:1643-60 e17. 10.1016/j.cell.2020.05.007.<pub-id pub-id-type="pmid">32470396</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR113"><label>113.</label><citation-alternatives><element-citation id="ec-CR113" publication-type="journal"><person-group person-group-type="author"><name><surname>Karimi</surname><given-names>E</given-names></name><name><surname>Yu</surname><given-names>MW</given-names></name><name><surname>Maritan</surname><given-names>SM</given-names></name><name><surname>Perus</surname><given-names>LJM</given-names></name><name><surname>Rezanejad</surname><given-names>M</given-names></name><name><surname>Sorin</surname><given-names>M</given-names></name><etal/></person-group><article-title>Single-cell spatial immune landscapes of primary and metastatic brain tumours</article-title><source>Nature</source><year>2023</year><volume>614</volume><fpage>555</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1038/s41586-022-05680-3</pub-id><pub-id pub-id-type="pmid">36725935</pub-id>
</element-citation><mixed-citation id="mc-CR113" publication-type="journal">Karimi E, Yu MW, Maritan SM, Perus LJM, Rezanejad M, Sorin M, et al. Single-cell spatial immune landscapes of primary and metastatic brain tumours. Nature. 2023;614:555&#x02013;63. 10.1038/s41586-022-05680-3.<pub-id pub-id-type="pmid">36725935</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR114"><label>114.</label><citation-alternatives><element-citation id="ec-CR114" publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>Q</given-names></name><name><surname>Ruiz</surname><given-names>J</given-names></name><name><surname>Xing</surname><given-names>F</given-names></name><name><surname>Lo</surname><given-names>HW</given-names></name><name><surname>Craddock</surname><given-names>L</given-names></name><name><surname>Pullikuth</surname><given-names>AK</given-names></name><etal/></person-group><article-title>Single-cell sequencing reveals the landscape of the human brain metastatic microenvironment</article-title><source>Commun Biol</source><year>2023</year><volume>6</volume><fpage>760</fpage><pub-id pub-id-type="doi">10.1038/s42003-023-05124-2</pub-id><pub-id pub-id-type="pmid">37479733</pub-id>
</element-citation><mixed-citation id="mc-CR114" publication-type="journal">Song Q, Ruiz J, Xing F, Lo HW, Craddock L, Pullikuth AK, et al. Single-cell sequencing reveals the landscape of the human brain metastatic microenvironment. Commun Biol. 2023;6:760. 10.1038/s42003-023-05124-2.<pub-id pub-id-type="pmid">37479733</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR115"><label>115.</label><citation-alternatives><element-citation id="ec-CR115" publication-type="journal"><person-group person-group-type="author"><name><surname>Xiao</surname><given-names>Y</given-names></name><name><surname>Hu</surname><given-names>F</given-names></name><name><surname>Chi</surname><given-names>Q</given-names></name></person-group><article-title>Single-cell RNA sequencing and spatial transcriptome reveal potential molecular mechanisms of lung cancer brain metastasis</article-title><source>Int Immunopharmacol</source><year>2024</year><volume>140</volume><fpage>112804</fpage><pub-id pub-id-type="doi">10.1016/j.intimp.2024.112804</pub-id><pub-id pub-id-type="pmid">39079345</pub-id>
</element-citation><mixed-citation id="mc-CR115" publication-type="journal">Xiao Y, Hu F, Chi Q. Single-cell RNA sequencing and spatial transcriptome reveal potential molecular mechanisms of lung cancer brain metastasis. Int Immunopharmacol. 2024;140:112804. 10.1016/j.intimp.2024.112804.<pub-id pub-id-type="pmid">39079345</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR116"><label>116.</label><citation-alternatives><element-citation id="ec-CR116" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Abdo</surname><given-names>R</given-names></name><name><surname>Iosef</surname><given-names>C</given-names></name><name><surname>Kaneko</surname><given-names>T</given-names></name><name><surname>Cecchini</surname><given-names>M</given-names></name><name><surname>Han</surname><given-names>VK</given-names></name><etal/></person-group><article-title>The spatial transcriptomic landscape of non-small cell lung cancer brain metastasis</article-title><source>Nat Commun</source><year>2022</year><volume>13</volume><fpage>5983</fpage><pub-id pub-id-type="doi">10.1038/s41467-022-33365-y</pub-id><pub-id pub-id-type="pmid">36216799</pub-id>
</element-citation><mixed-citation id="mc-CR116" publication-type="journal">Zhang Q, Abdo R, Iosef C, Kaneko T, Cecchini M, Han VK, et al. The spatial transcriptomic landscape of non-small cell lung cancer brain metastasis. Nat Commun. 2022;13:5983. 10.1038/s41467-022-33365-y.<pub-id pub-id-type="pmid">36216799</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR117"><label>117.</label><citation-alternatives><element-citation id="ec-CR117" publication-type="journal"><person-group person-group-type="author"><name><surname>Barker</surname><given-names>FG</given-names><suffix>2nd</suffix></name></person-group><article-title>Craniotomy for the resection of metastatic brain tumors in the U.S., 1988-2000: decreasing mortality and the effect of provider caseload</article-title><source>Cancer</source><year>2004</year><volume>100</volume><fpage>999</fpage><lpage>1007</lpage><pub-id pub-id-type="doi">10.1002/cncr.20058</pub-id><pub-id pub-id-type="pmid">14983496</pub-id>
</element-citation><mixed-citation id="mc-CR117" publication-type="journal">Barker FG 2nd. Craniotomy for the resection of metastatic brain tumors in the U.S., 1988-2000: decreasing mortality and the effect of provider caseload. Cancer. 2004;100:999&#x02013;1007. 10.1002/cncr.20058.<pub-id pub-id-type="pmid">14983496</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR118"><label>118.</label><citation-alternatives><element-citation id="ec-CR118" publication-type="journal"><person-group person-group-type="author"><name><surname>Hatiboglu</surname><given-names>MA</given-names></name><name><surname>Wildrick</surname><given-names>DM</given-names></name><name><surname>Sawaya</surname><given-names>R</given-names></name></person-group><article-title>The role of surgical resection in patients with brain metastases</article-title><source>Ecancermedicalscience</source><year>2013</year><volume>7</volume><fpage>308</fpage><pub-id pub-id-type="doi">10.3332/ecancer.2013.308</pub-id><pub-id pub-id-type="pmid">23634178</pub-id>
</element-citation><mixed-citation id="mc-CR118" publication-type="journal">Hatiboglu MA, Wildrick DM, Sawaya R. The role of surgical resection in patients with brain metastases. Ecancermedicalscience. 2013;7:308. 10.3332/ecancer.2013.308.<pub-id pub-id-type="pmid">23634178</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR119"><label>119.</label><citation-alternatives><element-citation id="ec-CR119" publication-type="journal"><person-group person-group-type="author"><name><surname>Takeshima</surname><given-names>H</given-names></name><name><surname>Kuratsu</surname><given-names>J</given-names></name><name><surname>Nishi</surname><given-names>T</given-names></name><name><surname>Ushio</surname><given-names>Y</given-names></name></person-group><article-title>Prognostic factors in patients who survived more than 10 years after undergoing surgery for metastatic brain tumors: report of 5 cases and review of the literature</article-title><source>Surg Neurol</source><year>2002</year><volume>58</volume><fpage>118</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1016/s0090-3019(02)00753-x</pub-id><pub-id pub-id-type="pmid">12453648</pub-id>
</element-citation><mixed-citation id="mc-CR119" publication-type="journal">Takeshima H, Kuratsu J, Nishi T, Ushio Y. Prognostic factors in patients who survived more than 10 years after undergoing surgery for metastatic brain tumors: report of 5 cases and review of the literature. Surg Neurol. 2002;58:118&#x02013;23. 10.1016/s0090-3019(02)00753-x. discussion 23.<pub-id pub-id-type="pmid">12453648</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR120"><label>120.</label><citation-alternatives><element-citation id="ec-CR120" publication-type="journal"><person-group person-group-type="author"><name><surname>Kanou</surname><given-names>T</given-names></name><name><surname>Okami</surname><given-names>J</given-names></name><name><surname>Tokunaga</surname><given-names>T</given-names></name><name><surname>Fujiwara</surname><given-names>A</given-names></name><name><surname>Ishida</surname><given-names>D</given-names></name><name><surname>Kuno</surname><given-names>H</given-names></name><etal/></person-group><article-title>Prognosis associated with surgery for non-small cell lung cancer and synchronous brain metastasis</article-title><source>Surg Today</source><year>2014</year><volume>44</volume><fpage>1321</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1007/s00595-014-0895-3</pub-id><pub-id pub-id-type="pmid">24748535</pub-id>
</element-citation><mixed-citation id="mc-CR120" publication-type="journal">Kanou T, Okami J, Tokunaga T, Fujiwara A, Ishida D, Kuno H, et al. Prognosis associated with surgery for non-small cell lung cancer and synchronous brain metastasis. Surg Today. 2014;44:1321&#x02013;7. 10.1007/s00595-014-0895-3.<pub-id pub-id-type="pmid">24748535</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR121"><label>121.</label><citation-alternatives><element-citation id="ec-CR121" publication-type="journal"><person-group person-group-type="author"><name><surname>Fuchs</surname><given-names>J</given-names></name><name><surname>Fruh</surname><given-names>M</given-names></name><name><surname>Papachristofilou</surname><given-names>A</given-names></name><name><surname>Bubendorf</surname><given-names>L</given-names></name><name><surname>Hauptle</surname><given-names>P</given-names></name><name><surname>Jost</surname><given-names>L</given-names></name><etal/></person-group><article-title>Resection of isolated brain metastases in non-small cell lung cancer (NSCLC) patients - evaluation of outcome and prognostic factors: a retrospective multicenter study</article-title><source>PLoS ONE</source><year>2021</year><volume>16</volume><fpage>e0253601</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0253601</pub-id><pub-id pub-id-type="pmid">34181677</pub-id>
</element-citation><mixed-citation id="mc-CR121" publication-type="journal">Fuchs J, Fruh M, Papachristofilou A, Bubendorf L, Hauptle P, Jost L, et al. Resection of isolated brain metastases in non-small cell lung cancer (NSCLC) patients - evaluation of outcome and prognostic factors: a retrospective multicenter study. PLoS ONE. 2021;16:e0253601. 10.1371/journal.pone.0253601.<pub-id pub-id-type="pmid">34181677</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR122"><label>122.</label><citation-alternatives><element-citation id="ec-CR122" publication-type="journal"><person-group person-group-type="author"><name><surname>Bernhardt</surname><given-names>D</given-names></name><name><surname>Adeberg</surname><given-names>S</given-names></name><name><surname>Bozorgmehr</surname><given-names>F</given-names></name><name><surname>Opfermann</surname><given-names>N</given-names></name><name><surname>Hoerner-Rieber</surname><given-names>J</given-names></name><name><surname>Konig</surname><given-names>L</given-names></name><etal/></person-group><article-title>Outcome and prognostic factors in patients with brain metastases from small-cell lung cancer treated with whole brain radiotherapy</article-title><source>J Neurooncol</source><year>2017</year><volume>134</volume><fpage>205</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1007/s11060-017-2510-0</pub-id><pub-id pub-id-type="pmid">28560661</pub-id>
</element-citation><mixed-citation id="mc-CR122" publication-type="journal">Bernhardt D, Adeberg S, Bozorgmehr F, Opfermann N, Hoerner-Rieber J, Konig L, et al. Outcome and prognostic factors in patients with brain metastases from small-cell lung cancer treated with whole brain radiotherapy. J Neurooncol. 2017;134:205&#x02013;12. 10.1007/s11060-017-2510-0.<pub-id pub-id-type="pmid">28560661</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR123"><label>123.</label><citation-alternatives><element-citation id="ec-CR123" publication-type="journal"><person-group person-group-type="author"><name><surname>Sas-Korczynska</surname><given-names>B</given-names></name><name><surname>Rucinska</surname><given-names>M</given-names></name></person-group><article-title>WBRT for brain metastases from non-small cell lung cancer: for whom and when?-Contemporary point of view</article-title><source>J Thorac Dis</source><year>2021</year><volume>13</volume><fpage>3246</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.21037/jtd-2019-rbmlc-06</pub-id><pub-id pub-id-type="pmid">34164217</pub-id>
</element-citation><mixed-citation id="mc-CR123" publication-type="journal">Sas-Korczynska B, Rucinska M. WBRT for brain metastases from non-small cell lung cancer: for whom and when?-Contemporary point of view. J Thorac Dis. 2021;13:3246&#x02013;57. 10.21037/jtd-2019-rbmlc-06.<pub-id pub-id-type="pmid">34164217</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR124"><label>124.</label><citation-alternatives><element-citation id="ec-CR124" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhen</surname><given-names>J</given-names></name><name><surname>Wen</surname><given-names>L</given-names></name><name><surname>Lai</surname><given-names>M</given-names></name><name><surname>Zhou</surname><given-names>Z</given-names></name><name><surname>Shan</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><etal/></person-group><article-title>Whole brain radiotherapy (WBRT) for leptomeningeal metastasis from NSCLC in the era of targeted therapy: a retrospective study</article-title><source>Radiat Oncol</source><year>2020</year><volume>15</volume><fpage>185</fpage><pub-id pub-id-type="doi">10.1186/s13014-020-01627-y</pub-id><pub-id pub-id-type="pmid">32736566</pub-id>
</element-citation><mixed-citation id="mc-CR124" publication-type="journal">Zhen J, Wen L, Lai M, Zhou Z, Shan C, Li S, et al. Whole brain radiotherapy (WBRT) for leptomeningeal metastasis from NSCLC in the era of targeted therapy: a retrospective study. Radiat Oncol. 2020;15:185. 10.1186/s13014-020-01627-y.<pub-id pub-id-type="pmid">32736566</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR125"><label>125.</label><citation-alternatives><element-citation id="ec-CR125" publication-type="journal"><person-group person-group-type="author"><name><surname>Qin</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Jiang</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Ruan</surname><given-names>Z</given-names></name></person-group><article-title>Patients with single brain metastasis from non-small cell lung cancer equally benefit from stereotactic radiosurgery and surgery: a systematic review</article-title><source>Med Sci Monit</source><year>2015</year><volume>21</volume><fpage>144</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.12659/MSM.892405</pub-id><pub-id pub-id-type="pmid">25579245</pub-id>
</element-citation><mixed-citation id="mc-CR125" publication-type="journal">Qin H, Wang C, Jiang Y, Zhang X, Zhang Y, Ruan Z. Patients with single brain metastasis from non-small cell lung cancer equally benefit from stereotactic radiosurgery and surgery: a systematic review. Med Sci Monit. 2015;21:144&#x02013;52. 10.12659/MSM.892405.<pub-id pub-id-type="pmid">25579245</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR126"><label>126.</label><citation-alternatives><element-citation id="ec-CR126" publication-type="journal"><person-group person-group-type="author"><name><surname>Yomo</surname><given-names>S</given-names></name><name><surname>Hayashi</surname><given-names>M</given-names></name></person-group><article-title>Is stereotactic radiosurgery a rational treatment option for brain metastases from small cell lung cancer? A retrospective analysis of 70 consecutive patients</article-title><source>BMC Cancer</source><year>2015</year><volume>15</volume><fpage>95</fpage><pub-id pub-id-type="doi">10.1186/s12885-015-1103-6</pub-id><pub-id pub-id-type="pmid">25879433</pub-id>
</element-citation><mixed-citation id="mc-CR126" publication-type="journal">Yomo S, Hayashi M. Is stereotactic radiosurgery a rational treatment option for brain metastases from small cell lung cancer? A retrospective analysis of 70 consecutive patients. BMC Cancer. 2015;15:95. 10.1186/s12885-015-1103-6.<pub-id pub-id-type="pmid">25879433</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR127"><label>127.</label><citation-alternatives><element-citation id="ec-CR127" publication-type="journal"><person-group person-group-type="author"><name><surname>Viani</surname><given-names>GA</given-names></name><name><surname>Gouveia</surname><given-names>AG</given-names></name><name><surname>Louie</surname><given-names>AV</given-names></name><name><surname>Moraes</surname><given-names>FY</given-names></name></person-group><article-title>Stereotactic radiosurgery for brain metastases from small cell lung cancer without prior whole-brain radiotherapy: a meta-analysis</article-title><source>Radiother Oncol</source><year>2021</year><volume>162</volume><fpage>45</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1016/j.radonc.2021.06.026</pub-id><pub-id pub-id-type="pmid">34171453</pub-id>
</element-citation><mixed-citation id="mc-CR127" publication-type="journal">Viani GA, Gouveia AG, Louie AV, Moraes FY. Stereotactic radiosurgery for brain metastases from small cell lung cancer without prior whole-brain radiotherapy: a meta-analysis. Radiother Oncol. 2021;162:45&#x02013;51. 10.1016/j.radonc.2021.06.026.<pub-id pub-id-type="pmid">34171453</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR128"><label>128.</label><citation-alternatives><element-citation id="ec-CR128" publication-type="journal"><person-group person-group-type="author"><name><surname>Halasz</surname><given-names>LM</given-names></name><name><surname>Uno</surname><given-names>H</given-names></name><name><surname>Hughes</surname><given-names>M</given-names></name><name><surname>D'Amico</surname><given-names>T</given-names></name><name><surname>Dexter</surname><given-names>EU</given-names></name><name><surname>Edge</surname><given-names>SB</given-names></name><etal/></person-group><article-title>Comparative effectiveness of stereotactic radiosurgery versus whole-brain radiation therapy for patients with brain metastases from breast or non-small cell lung cancer</article-title><source>Cancer</source><year>2016</year><volume>122</volume><fpage>2091</fpage><lpage>100</lpage><pub-id pub-id-type="doi">10.1002/cncr.30009</pub-id><pub-id pub-id-type="pmid">27088755</pub-id>
</element-citation><mixed-citation id="mc-CR128" publication-type="journal">Halasz LM, Uno H, Hughes M, D&#x02019;Amico T, Dexter EU, Edge SB, et al. Comparative effectiveness of stereotactic radiosurgery versus whole-brain radiation therapy for patients with brain metastases from breast or non-small cell lung cancer. Cancer. 2016;122:2091&#x02013;100. 10.1002/cncr.30009.<pub-id pub-id-type="pmid">27088755</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR129"><label>129.</label><citation-alternatives><element-citation id="ec-CR129" publication-type="journal"><person-group person-group-type="author"><name><surname>Nikitas</surname><given-names>J</given-names></name><name><surname>Roach</surname><given-names>M</given-names></name><name><surname>Robinson</surname><given-names>C</given-names></name><name><surname>Bradley</surname><given-names>J</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Perkins</surname><given-names>S</given-names></name><etal/></person-group><article-title>Treatment of oligometastatic lung cancer with brain metastases using stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT)</article-title><source>Clin Transl Radiat Oncol</source><year>2020</year><volume>21</volume><fpage>32</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1016/j.ctro.2019.12.001</pub-id><pub-id pub-id-type="pmid">31956701</pub-id>
</element-citation><mixed-citation id="mc-CR129" publication-type="journal">Nikitas J, Roach M, Robinson C, Bradley J, Huang J, Perkins S, et al. Treatment of oligometastatic lung cancer with brain metastases using stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT). Clin Transl Radiat Oncol. 2020;21:32&#x02013;5. 10.1016/j.ctro.2019.12.001.<pub-id pub-id-type="pmid">31956701</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR130"><label>130.</label><citation-alternatives><element-citation id="ec-CR130" publication-type="journal"><person-group person-group-type="author"><name><surname>Nakazaki</surname><given-names>K</given-names></name><name><surname>Higuchi</surname><given-names>Y</given-names></name><name><surname>Nagano</surname><given-names>O</given-names></name><name><surname>Serizawa</surname><given-names>T</given-names></name></person-group><article-title>Efficacy and limitations of salvage gamma knife radiosurgery for brain metastases of small-cell lung cancer after whole-brain radiotherapy</article-title><source>Acta Neurochir (Wien)</source><year>2013</year><volume>155</volume><fpage>107</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1007/s00701-012-1520-0</pub-id><pub-id pub-id-type="pmid">23065044</pub-id>
</element-citation><mixed-citation id="mc-CR130" publication-type="journal">Nakazaki K, Higuchi Y, Nagano O, Serizawa T. Efficacy and limitations of salvage gamma knife radiosurgery for brain metastases of small-cell lung cancer after whole-brain radiotherapy. Acta Neurochir (Wien). 2013;155:107&#x02013;13. 10.1007/s00701-012-1520-0. discussion 13-4.<pub-id pub-id-type="pmid">23065044</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR131"><label>131.</label><citation-alternatives><element-citation id="ec-CR131" publication-type="journal"><person-group person-group-type="author"><name><surname>Harris</surname><given-names>S</given-names></name><name><surname>Chan</surname><given-names>MD</given-names></name><name><surname>Lovato</surname><given-names>JF</given-names></name><name><surname>Ellis</surname><given-names>TL</given-names></name><name><surname>Tatter</surname><given-names>SB</given-names></name><name><surname>Bourland</surname><given-names>JD</given-names></name><etal/></person-group><article-title>Gamma knife stereotactic radiosurgery as salvage therapy after failure of whole-brain radiotherapy in patients with small-cell lung cancer</article-title><source>Int J Radiat Oncol Biol Phys</source><year>2012</year><volume>83</volume><fpage>e53</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.ijrobp.2011.11.059</pub-id><pub-id pub-id-type="pmid">22342297</pub-id>
</element-citation><mixed-citation id="mc-CR131" publication-type="journal">Harris S, Chan MD, Lovato JF, Ellis TL, Tatter SB, Bourland JD, et al. Gamma knife stereotactic radiosurgery as salvage therapy after failure of whole-brain radiotherapy in patients with small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2012;83:e53-9. 10.1016/j.ijrobp.2011.11.059.<pub-id pub-id-type="pmid">22342297</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR132"><label>132.</label><citation-alternatives><element-citation id="ec-CR132" publication-type="journal"><person-group person-group-type="author"><name><surname>Andrews</surname><given-names>DW</given-names></name><name><surname>Scott</surname><given-names>CB</given-names></name><name><surname>Sperduto</surname><given-names>PW</given-names></name><name><surname>Flanders</surname><given-names>AE</given-names></name><name><surname>Gaspar</surname><given-names>LE</given-names></name><name><surname>Schell</surname><given-names>MC</given-names></name><etal/></person-group><article-title>Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial</article-title><source>Lancet</source><year>2004</year><volume>363</volume><fpage>1665</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(04)16250-8</pub-id><pub-id pub-id-type="pmid">15158627</pub-id>
</element-citation><mixed-citation id="mc-CR132" publication-type="journal">Andrews DW, Scott CB, Sperduto PW, Flanders AE, Gaspar LE, Schell MC, et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet. 2004;363:1665&#x02013;72. 10.1016/S0140-6736(04)16250-8.<pub-id pub-id-type="pmid">15158627</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR133"><label>133.</label><citation-alternatives><element-citation id="ec-CR133" publication-type="journal"><person-group person-group-type="author"><name><surname>Le Rhun</surname><given-names>E</given-names></name><name><surname>Guckenberger</surname><given-names>M</given-names></name><name><surname>Smits</surname><given-names>M</given-names></name><name><surname>Dummer</surname><given-names>R</given-names></name><name><surname>Bachelot</surname><given-names>T</given-names></name><name><surname>Sahm</surname><given-names>F</given-names></name><etal/></person-group><article-title>EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours</article-title><source>Ann Oncol</source><year>2021</year><volume>32</volume><fpage>1332</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1016/j.annonc.2021.07.016</pub-id><pub-id pub-id-type="pmid">34364998</pub-id>
</element-citation><mixed-citation id="mc-CR133" publication-type="journal">Le Rhun E, Guckenberger M, Smits M, Dummer R, Bachelot T, Sahm F, et al. EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours. Ann Oncol. 2021;32:1332&#x02013;47. 10.1016/j.annonc.2021.07.016.<pub-id pub-id-type="pmid">34364998</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR134"><label>134.</label><citation-alternatives><element-citation id="ec-CR134" publication-type="journal"><person-group person-group-type="author"><name><surname>Abbott</surname><given-names>NJ</given-names></name></person-group><article-title>Blood-brain barrier structure and function and the challenges for CNS drug delivery</article-title><source>J Inherit Metab Dis</source><year>2013</year><volume>36</volume><fpage>437</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.1007/s10545-013-9608-0</pub-id><pub-id pub-id-type="pmid">23609350</pub-id>
</element-citation><mixed-citation id="mc-CR134" publication-type="journal">Abbott NJ. Blood-brain barrier structure and function and the challenges for CNS drug delivery. J Inherit Metab Dis. 2013;36:437&#x02013;49. 10.1007/s10545-013-9608-0.<pub-id pub-id-type="pmid">23609350</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR135"><label>135.</label><citation-alternatives><element-citation id="ec-CR135" publication-type="journal"><person-group person-group-type="author"><name><surname>Sweeney</surname><given-names>MD</given-names></name><name><surname>Zhao</surname><given-names>Z</given-names></name><name><surname>Montagne</surname><given-names>A</given-names></name><name><surname>Nelson</surname><given-names>AR</given-names></name><name><surname>Zlokovic</surname><given-names>BV</given-names></name></person-group><article-title>Blood-brain barrier: from physiology to disease and back</article-title><source>Physiol Rev</source><year>2019</year><volume>99</volume><fpage>21</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.1152/physrev.00050.2017</pub-id><pub-id pub-id-type="pmid">30280653</pub-id>
</element-citation><mixed-citation id="mc-CR135" publication-type="journal">Sweeney MD, Zhao Z, Montagne A, Nelson AR, Zlokovic BV. Blood-brain barrier: from physiology to disease and back. Physiol Rev. 2019;99:21&#x02013;78. 10.1152/physrev.00050.2017.<pub-id pub-id-type="pmid">30280653</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR136"><label>136.</label><citation-alternatives><element-citation id="ec-CR136" publication-type="journal"><person-group person-group-type="author"><name><surname>Abbott</surname><given-names>NJ</given-names></name><name><surname>Patabendige</surname><given-names>AA</given-names></name><name><surname>Dolman</surname><given-names>DE</given-names></name><name><surname>Yusof</surname><given-names>SR</given-names></name><name><surname>Begley</surname><given-names>DJ</given-names></name></person-group><article-title>Structure and function of the blood-brain barrier</article-title><source>Neurobiol Dis</source><year>2010</year><volume>37</volume><fpage>13</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1016/j.nbd.2009.07.030</pub-id><pub-id pub-id-type="pmid">19664713</pub-id>
</element-citation><mixed-citation id="mc-CR136" publication-type="journal">Abbott NJ, Patabendige AA, Dolman DE, Yusof SR, Begley DJ. Structure and function of the blood-brain barrier. Neurobiol Dis. 2010;37:13&#x02013;25. 10.1016/j.nbd.2009.07.030.<pub-id pub-id-type="pmid">19664713</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR137"><label>137.</label><citation-alternatives><element-citation id="ec-CR137" publication-type="journal"><person-group person-group-type="author"><name><surname>Vanlandewijck</surname><given-names>M</given-names></name><name><surname>He</surname><given-names>L</given-names></name><name><surname>Mae</surname><given-names>MA</given-names></name><name><surname>Andrae</surname><given-names>J</given-names></name><name><surname>Ando</surname><given-names>K</given-names></name><name><surname>Del Gaudio</surname><given-names>F</given-names></name><etal/></person-group><article-title>A molecular atlas of cell types and zonation in the brain vasculature</article-title><source>Nature</source><year>2018</year><volume>554</volume><fpage>475</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1038/nature25739</pub-id><pub-id pub-id-type="pmid">29443965</pub-id>
</element-citation><mixed-citation id="mc-CR137" publication-type="journal">Vanlandewijck M, He L, Mae MA, Andrae J, Ando K, Del Gaudio F, et al. A molecular atlas of cell types and zonation in the brain vasculature. Nature. 2018;554:475&#x02013;80. 10.1038/nature25739.<pub-id pub-id-type="pmid">29443965</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR138"><label>138.</label><citation-alternatives><element-citation id="ec-CR138" publication-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>Y</given-names></name><name><surname>Jin</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Yuan</surname><given-names>X</given-names></name></person-group><article-title>Advances in Lung cancer driver genes associated with brain metastasis</article-title><source>Front Oncol</source><year>2020</year><volume>10</volume><fpage>606300</fpage><pub-id pub-id-type="doi">10.3389/fonc.2020.606300</pub-id><pub-id pub-id-type="pmid">33537237</pub-id>
</element-citation><mixed-citation id="mc-CR138" publication-type="journal">Kang Y, Jin Y, Li Q, Yuan X. Advances in Lung cancer driver genes associated with brain metastasis. Front Oncol. 2020;10:606300. 10.3389/fonc.2020.606300.<pub-id pub-id-type="pmid">33537237</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR139"><label>139.</label><citation-alternatives><element-citation id="ec-CR139" publication-type="journal"><person-group person-group-type="author"><name><surname>Alvarez-Breckenridge</surname><given-names>C</given-names></name><name><surname>Remon</surname><given-names>J</given-names></name><name><surname>Pina</surname><given-names>Y</given-names></name><name><surname>Nieblas-Bedolla</surname><given-names>E</given-names></name><name><surname>Forsyth</surname><given-names>P</given-names></name><name><surname>Hendriks</surname><given-names>L</given-names></name><etal/></person-group><article-title>Emerging systemic treatment perspectives on brain metastases: moving toward a better outlook for patients</article-title><source>Am Soc Clin Oncol Educ Book</source><year>2022</year><volume>42</volume><fpage>1</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.1200/EDBK_352320</pub-id><pub-id pub-id-type="pmid">35522917</pub-id>
</element-citation><mixed-citation id="mc-CR139" publication-type="journal">Alvarez-Breckenridge C, Remon J, Pina Y, Nieblas-Bedolla E, Forsyth P, Hendriks L, et al. Emerging systemic treatment perspectives on brain metastases: moving toward a better outlook for patients. Am Soc Clin Oncol Educ Book. 2022;42:1&#x02013;19. 10.1200/EDBK_352320.<pub-id pub-id-type="pmid">35522917</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR140"><label>140.</label><citation-alternatives><element-citation id="ec-CR140" publication-type="journal"><person-group person-group-type="author"><name><surname>Iuchi</surname><given-names>T</given-names></name><name><surname>Shingyoji</surname><given-names>M</given-names></name><name><surname>Sakaida</surname><given-names>T</given-names></name><name><surname>Hatano</surname><given-names>K</given-names></name><name><surname>Nagano</surname><given-names>O</given-names></name><name><surname>Itakura</surname><given-names>M</given-names></name><etal/></person-group><article-title>Phase II trial of gefitinib alone without radiation therapy for Japanese patients with brain metastases from EGFR-mutant lung adenocarcinoma</article-title><source>Lung Cancer</source><year>2013</year><volume>82</volume><fpage>282</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1016/j.lungcan.2013.08.016</pub-id><pub-id pub-id-type="pmid">24021541</pub-id>
</element-citation><mixed-citation id="mc-CR140" publication-type="journal">Iuchi T, Shingyoji M, Sakaida T, Hatano K, Nagano O, Itakura M, et al. Phase II trial of gefitinib alone without radiation therapy for Japanese patients with brain metastases from EGFR-mutant lung adenocarcinoma. Lung Cancer. 2013;82:282&#x02013;7. 10.1016/j.lungcan.2013.08.016.<pub-id pub-id-type="pmid">24021541</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR141"><label>141.</label><citation-alternatives><element-citation id="ec-CR141" publication-type="journal"><person-group person-group-type="author"><name><surname>Ballard</surname><given-names>P</given-names></name><name><surname>Yates</surname><given-names>JW</given-names></name><name><surname>Yang</surname><given-names>Z</given-names></name><name><surname>Kim</surname><given-names>DW</given-names></name><name><surname>Yang</surname><given-names>JC</given-names></name><name><surname>Cantarini</surname><given-names>M</given-names></name><etal/></person-group><article-title>Preclinical comparison of osimertinib with other EGFR-TKIs in EGFR-mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activity</article-title><source>Clin Cancer Res</source><year>2016</year><volume>22</volume><fpage>5130</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-16-0399</pub-id><pub-id pub-id-type="pmid">27435396</pub-id>
</element-citation><mixed-citation id="mc-CR141" publication-type="journal">Ballard P, Yates JW, Yang Z, Kim DW, Yang JC, Cantarini M, et al. Preclinical comparison of osimertinib with other EGFR-TKIs in EGFR-mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activity. Clin Cancer Res. 2016;22:5130&#x02013;40. 10.1158/1078-0432.CCR-16-0399.<pub-id pub-id-type="pmid">27435396</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR142"><label>142.</label><citation-alternatives><element-citation id="ec-CR142" publication-type="journal"><person-group person-group-type="author"><name><surname>Costa</surname><given-names>DB</given-names></name><name><surname>Shaw</surname><given-names>AT</given-names></name><name><surname>Ou</surname><given-names>SH</given-names></name><name><surname>Solomon</surname><given-names>BJ</given-names></name><name><surname>Riely</surname><given-names>GJ</given-names></name><name><surname>Ahn</surname><given-names>MJ</given-names></name><etal/></person-group><article-title>Clinical experience with crizotinib in patients with advanced ALK-rearranged non-small-cell lung cancer and brain metastases</article-title><source>J Clin Oncol</source><year>2015</year><volume>33</volume><fpage>1881</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1200/JCO.2014.59.0539</pub-id><pub-id pub-id-type="pmid">25624436</pub-id>
</element-citation><mixed-citation id="mc-CR142" publication-type="journal">Costa DB, Shaw AT, Ou SH, Solomon BJ, Riely GJ, Ahn MJ, et al. Clinical experience with crizotinib in patients with advanced ALK-rearranged non-small-cell lung cancer and brain metastases. J Clin Oncol. 2015;33:1881&#x02013;8. 10.1200/JCO.2014.59.0539.<pub-id pub-id-type="pmid">25624436</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR143"><label>143.</label><citation-alternatives><element-citation id="ec-CR143" publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>YW</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>WJ</given-names></name></person-group><article-title>Targeted drugs for systemic therapy of lung cancer with brain metastases</article-title><source>Oncotarget</source><year>2018</year><volume>9</volume><fpage>5459</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.23616</pub-id><pub-id pub-id-type="pmid">29435193</pub-id>
</element-citation><mixed-citation id="mc-CR143" publication-type="journal">Sun YW, Xu J, Zhou J, Liu WJ. Targeted drugs for systemic therapy of lung cancer with brain metastases. Oncotarget. 2018;9:5459&#x02013;72. 10.18632/oncotarget.23616.<pub-id pub-id-type="pmid">29435193</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR144"><label>144.</label><citation-alternatives><element-citation id="ec-CR144" publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>DW</given-names></name><name><surname>Tiseo</surname><given-names>M</given-names></name><name><surname>Ahn</surname><given-names>MJ</given-names></name><name><surname>Reckamp</surname><given-names>KL</given-names></name><name><surname>Hansen</surname><given-names>KH</given-names></name><name><surname>Kim</surname><given-names>SW</given-names></name><etal/></person-group><article-title>Brigatinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-small-cell lung cancer: a randomized, multicenter phase II trial</article-title><source>J Clin Oncol</source><year>2017</year><volume>35</volume><fpage>2490</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1200/JCO.2016.71.5904</pub-id><pub-id pub-id-type="pmid">28475456</pub-id>
</element-citation><mixed-citation id="mc-CR144" publication-type="journal">Kim DW, Tiseo M, Ahn MJ, Reckamp KL, Hansen KH, Kim SW, et al. Brigatinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-small-cell lung cancer: a randomized, multicenter phase II trial. J Clin Oncol. 2017;35:2490&#x02013;8. 10.1200/JCO.2016.71.5904.<pub-id pub-id-type="pmid">28475456</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR145"><label>145.</label><citation-alternatives><element-citation id="ec-CR145" publication-type="journal"><person-group person-group-type="author"><name><surname>Solomon</surname><given-names>BJ</given-names></name><name><surname>Bauer</surname><given-names>TM</given-names></name><name><surname>Ignatius Ou</surname><given-names>SH</given-names></name><name><surname>Liu</surname><given-names>G</given-names></name><name><surname>Hayashi</surname><given-names>H</given-names></name><name><surname>Bearz</surname><given-names>A</given-names></name><etal/></person-group><article-title>Post Hoc analysis of Lorlatinib intracranial efficacy and safety in patients with ALK-positive advanced non-small-cell lung cancer from the phase III CROWN study</article-title><source>J Clin Oncol</source><year>2022</year><volume>40</volume><fpage>3593</fpage><lpage>602</lpage><pub-id pub-id-type="doi">10.1200/JCO.21.02278</pub-id><pub-id pub-id-type="pmid">35605188</pub-id>
</element-citation><mixed-citation id="mc-CR145" publication-type="journal">Solomon BJ, Bauer TM, Ignatius Ou SH, Liu G, Hayashi H, Bearz A, et al. Post Hoc analysis of Lorlatinib intracranial efficacy and safety in patients with ALK-positive advanced non-small-cell lung cancer from the phase III CROWN study. J Clin Oncol. 2022;40:3593&#x02013;602. 10.1200/JCO.21.02278.<pub-id pub-id-type="pmid">35605188</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR146"><label>146.</label><citation-alternatives><element-citation id="ec-CR146" publication-type="journal"><person-group person-group-type="author"><name><surname>Roys</surname><given-names>A</given-names></name><name><surname>Chang</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>X</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Zuo</surname><given-names>D</given-names></name></person-group><article-title>Resistance mechanisms and potent-targeted therapies of ROS1-positive lung cancer</article-title><source>Cancer Chemother Pharmacol</source><year>2019</year><volume>84</volume><fpage>679</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1007/s00280-019-03902-6</pub-id><pub-id pub-id-type="pmid">31256210</pub-id>
</element-citation><mixed-citation id="mc-CR146" publication-type="journal">Roys A, Chang X, Liu Y, Xu X, Wu Y, Zuo D. Resistance mechanisms and potent-targeted therapies of ROS1-positive lung cancer. Cancer Chemother Pharmacol. 2019;84:679&#x02013;88. 10.1007/s00280-019-03902-6.<pub-id pub-id-type="pmid">31256210</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR147"><label>147.</label><citation-alternatives><element-citation id="ec-CR147" publication-type="journal"><person-group person-group-type="author"><name><surname>Sabari</surname><given-names>JK</given-names></name><name><surname>Velcheti</surname><given-names>V</given-names></name><name><surname>Shimizu</surname><given-names>K</given-names></name><name><surname>Strickland</surname><given-names>MR</given-names></name><name><surname>Heist</surname><given-names>RS</given-names></name><name><surname>Singh</surname><given-names>M</given-names></name><etal/></person-group><article-title>Activity of Adagrasib (MRTX849) in brain metastases: preclinical models and clinical data from patients with KRASG12C-mutant non-small cell lung cancer</article-title><source>Clin Cancer Res</source><year>2022</year><volume>28</volume><fpage>3318</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-22-0383</pub-id><pub-id pub-id-type="pmid">35404402</pub-id>
</element-citation><mixed-citation id="mc-CR147" publication-type="journal">Sabari JK, Velcheti V, Shimizu K, Strickland MR, Heist RS, Singh M, et al. Activity of Adagrasib (MRTX849) in brain metastases: preclinical models and clinical data from patients with KRASG12C-mutant non-small cell lung cancer. Clin Cancer Res. 2022;28:3318&#x02013;28. 10.1158/1078-0432.CCR-22-0383.<pub-id pub-id-type="pmid">35404402</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR148"><label>148.</label><citation-alternatives><element-citation id="ec-CR148" publication-type="journal"><person-group person-group-type="author"><name><surname>Santarpia</surname><given-names>M</given-names></name><name><surname>Massafra</surname><given-names>M</given-names></name><name><surname>Gebbia</surname><given-names>V</given-names></name><name><surname>D&#x02019;Aquino</surname><given-names>A</given-names></name><name><surname>Garipoli</surname><given-names>C</given-names></name><name><surname>Altavilla</surname><given-names>G</given-names></name><etal/></person-group><article-title>A narrative review of MET inhibitors in non-small cell lung cancer with MET exon 14 skipping mutations</article-title><source>Transl Lung Cancer Res</source><year>2021</year><volume>10</volume><fpage>1536</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.21037/tlcr-20-1113</pub-id><pub-id pub-id-type="pmid">33889528</pub-id>
</element-citation><mixed-citation id="mc-CR148" publication-type="journal">Santarpia M, Massafra M, Gebbia V, D&#x02019;Aquino A, Garipoli C, Altavilla G, et al. A narrative review of MET inhibitors in non-small cell lung cancer with MET exon 14 skipping mutations. Transl Lung Cancer Res. 2021;10:1536&#x02013;56. 10.21037/tlcr-20-1113.<pub-id pub-id-type="pmid">33889528</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR149"><label>149.</label><citation-alternatives><element-citation id="ec-CR149" publication-type="journal"><person-group person-group-type="author"><name><surname>Ansari</surname><given-names>J</given-names></name><name><surname>Palmer</surname><given-names>DH</given-names></name><name><surname>Rea</surname><given-names>DW</given-names></name><name><surname>Hussain</surname><given-names>SA</given-names></name></person-group><article-title>Role of tyrosine kinase inhibitors in lung cancer</article-title><source>Anticancer Agents Med Chem</source><year>2009</year><volume>9</volume><fpage>569</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.2174/187152009788451879</pub-id><pub-id pub-id-type="pmid">19519298</pub-id>
</element-citation><mixed-citation id="mc-CR149" publication-type="journal">Ansari J, Palmer DH, Rea DW, Hussain SA. Role of tyrosine kinase inhibitors in lung cancer. Anticancer Agents Med Chem. 2009;9:569&#x02013;75. 10.2174/187152009788451879.<pub-id pub-id-type="pmid">19519298</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR150"><label>150.</label><citation-alternatives><element-citation id="ec-CR150" publication-type="journal"><person-group person-group-type="author"><name><surname>Venur</surname><given-names>VA</given-names></name><name><surname>Ahluwalia</surname><given-names>MS</given-names></name></person-group><article-title>Targeted therapy in brain metastases: ready for primetime?</article-title><source>Am Soc Clin Oncol Educ Book</source><year>2016</year><volume>35</volume><fpage>e123</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1200/EDBK_100006</pub-id><pub-id pub-id-type="pmid">27249714</pub-id>
</element-citation><mixed-citation id="mc-CR150" publication-type="journal">Venur VA, Ahluwalia MS. Targeted therapy in brain metastases: ready for primetime? Am Soc Clin Oncol Educ Book. 2016;35:e123-30. 10.1200/EDBK_100006.<pub-id pub-id-type="pmid">27249714</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR151"><label>151.</label><citation-alternatives><element-citation id="ec-CR151" publication-type="journal"><person-group person-group-type="author"><name><surname>Peters</surname><given-names>S</given-names></name><name><surname>Camidge</surname><given-names>DR</given-names></name><name><surname>Shaw</surname><given-names>AT</given-names></name><name><surname>Gadgeel</surname><given-names>S</given-names></name><name><surname>Ahn</surname><given-names>JS</given-names></name><name><surname>Kim</surname><given-names>DW</given-names></name><etal/></person-group><article-title>Alectinib versus Crizotinib in untreated ALK-positive non-small-cell lung cancer</article-title><source>N Engl J Med</source><year>2017</year><volume>377</volume><fpage>829</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1704795</pub-id><pub-id pub-id-type="pmid">28586279</pub-id>
</element-citation><mixed-citation id="mc-CR151" publication-type="journal">Peters S, Camidge DR, Shaw AT, Gadgeel S, Ahn JS, Kim DW, et al. Alectinib versus Crizotinib in untreated ALK-positive non-small-cell lung cancer. N Engl J Med. 2017;377:829&#x02013;38. 10.1056/NEJMoa1704795.<pub-id pub-id-type="pmid">28586279</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR152"><label>152.</label><citation-alternatives><element-citation id="ec-CR152" publication-type="journal"><person-group person-group-type="author"><name><surname>Mok</surname><given-names>TS</given-names></name><name><surname>Wu</surname><given-names>YL</given-names></name><name><surname>Ahn</surname><given-names>MJ</given-names></name><name><surname>Garassino</surname><given-names>MC</given-names></name><name><surname>Kim</surname><given-names>HR</given-names></name><name><surname>Ramalingam</surname><given-names>SS</given-names></name><etal/></person-group><article-title>Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer</article-title><source>N Engl J Med</source><year>2017</year><volume>376</volume><fpage>629</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1612674</pub-id><pub-id pub-id-type="pmid">27959700</pub-id>
</element-citation><mixed-citation id="mc-CR152" publication-type="journal">Mok TS, Wu YL, Ahn MJ, Garassino MC, Kim HR, Ramalingam SS, et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med. 2017;376:629&#x02013;40. 10.1056/NEJMoa1612674.<pub-id pub-id-type="pmid">27959700</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR153"><label>153.</label><citation-alternatives><element-citation id="ec-CR153" publication-type="journal"><person-group person-group-type="author"><name><surname>Lamba</surname><given-names>N</given-names></name><name><surname>Wen</surname><given-names>PY</given-names></name><name><surname>Aizer</surname><given-names>AA</given-names></name></person-group><article-title>Epidemiology of brain metastases and leptomeningeal disease</article-title><source>Neuro Oncol</source><year>2021</year><volume>23</volume><fpage>1447</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1093/neuonc/noab101</pub-id><pub-id pub-id-type="pmid">33908612</pub-id>
</element-citation><mixed-citation id="mc-CR153" publication-type="journal">Lamba N, Wen PY, Aizer AA. Epidemiology of brain metastases and leptomeningeal disease. Neuro Oncol. 2021;23:1447&#x02013;56. 10.1093/neuonc/noab101.<pub-id pub-id-type="pmid">33908612</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR154"><label>154.</label><citation-alternatives><element-citation id="ec-CR154" publication-type="journal"><person-group person-group-type="author"><name><surname>Angeli</surname><given-names>E</given-names></name><name><surname>Bousquet</surname><given-names>G</given-names></name></person-group><article-title>Brain metastasis treatment: the place of tyrosine kinase inhibitors and how to facilitate their diffusion across the blood-brain barrier</article-title><source>Pharmaceutics</source><year>2021</year><volume>13</volume><fpage>1446</fpage><pub-id pub-id-type="doi">10.3390/pharmaceutics13091446</pub-id><pub-id pub-id-type="pmid">34575525</pub-id>
</element-citation><mixed-citation id="mc-CR154" publication-type="journal">Angeli E, Bousquet G. Brain metastasis treatment: the place of tyrosine kinase inhibitors and how to facilitate their diffusion across the blood-brain barrier. Pharmaceutics. 2021;13:1446. 10.3390/pharmaceutics13091446.<pub-id pub-id-type="pmid">34575525</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR155"><label>155.</label><citation-alternatives><element-citation id="ec-CR155" publication-type="journal"><person-group person-group-type="author"><name><surname>Ahn</surname><given-names>MJ</given-names></name><name><surname>Kim</surname><given-names>DW</given-names></name><name><surname>Cho</surname><given-names>BC</given-names></name><name><surname>Kim</surname><given-names>SW</given-names></name><name><surname>Lee</surname><given-names>JS</given-names></name><name><surname>Ahn</surname><given-names>JS</given-names></name><etal/></person-group><article-title>Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study</article-title><source>Lancet Respir Med</source><year>2017</year><volume>5</volume><fpage>891</fpage><lpage>902</lpage><pub-id pub-id-type="doi">10.1016/S2213-2600(17)30378-8</pub-id><pub-id pub-id-type="pmid">29056570</pub-id>
</element-citation><mixed-citation id="mc-CR155" publication-type="journal">Ahn MJ, Kim DW, Cho BC, Kim SW, Lee JS, Ahn JS, et al. Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study. Lancet Respir Med. 2017;5:891&#x02013;902. 10.1016/S2213-2600(17)30378-8.<pub-id pub-id-type="pmid">29056570</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR156"><label>156.</label><citation-alternatives><element-citation id="ec-CR156" publication-type="journal"><person-group person-group-type="author"><name><surname>Das</surname><given-names>M</given-names></name></person-group><article-title>Brigatinib effective in ALK-positive non-small-cell lung cancer</article-title><source>Lancet Oncol</source><year>2017</year><volume>18</volume><fpage>e310</fpage><pub-id pub-id-type="doi">10.1016/S1470-2045(17)30342-X</pub-id><pub-id pub-id-type="pmid">28506557</pub-id>
</element-citation><mixed-citation id="mc-CR156" publication-type="journal">Das M. Brigatinib effective in ALK-positive non-small-cell lung cancer. Lancet Oncol. 2017;18:e310. 10.1016/S1470-2045(17)30342-X.<pub-id pub-id-type="pmid">28506557</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR157"><label>157.</label><citation-alternatives><element-citation id="ec-CR157" publication-type="journal"><person-group person-group-type="author"><name><surname>Solomon</surname><given-names>BJ</given-names></name><name><surname>Bauer</surname><given-names>TM</given-names></name><name><surname>Mok</surname><given-names>TSK</given-names></name><name><surname>Liu</surname><given-names>G</given-names></name><name><surname>Mazieres</surname><given-names>J</given-names></name><name><surname>de Marinis</surname><given-names>F</given-names></name><etal/></person-group><article-title>Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study</article-title><source>Lancet Respir Med</source><year>2023</year><volume>11</volume><fpage>354</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1016/S2213-2600(22)00437-4</pub-id><pub-id pub-id-type="pmid">36535300</pub-id>
</element-citation><mixed-citation id="mc-CR157" publication-type="journal">Solomon BJ, Bauer TM, Mok TSK, Liu G, Mazieres J, de Marinis F, et al. Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study. Lancet Respir Med. 2023;11:354&#x02013;66. 10.1016/S2213-2600(22)00437-4.<pub-id pub-id-type="pmid">36535300</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR158"><label>158.</label><citation-alternatives><element-citation id="ec-CR158" publication-type="journal"><person-group person-group-type="author"><name><surname>Camidge</surname><given-names>DR</given-names></name><name><surname>Kim</surname><given-names>HR</given-names></name><name><surname>Ahn</surname><given-names>MJ</given-names></name><name><surname>Yang</surname><given-names>JCH</given-names></name><name><surname>Han</surname><given-names>JY</given-names></name><name><surname>Hochmair</surname><given-names>MJ</given-names></name><etal/></person-group><article-title>Brigatinib versus crizotinib in alk inhibitor-naive advanced ALK-positive NSCLC: final results of phase 3 ALTA-1L trial</article-title><source>J Thorac Oncol</source><year>2021</year><volume>16</volume><fpage>2091</fpage><lpage>108</lpage><pub-id pub-id-type="doi">10.1016/j.jtho.2021.07.035</pub-id><pub-id pub-id-type="pmid">34537440</pub-id>
</element-citation><mixed-citation id="mc-CR158" publication-type="journal">Camidge DR, Kim HR, Ahn MJ, Yang JCH, Han JY, Hochmair MJ, et al. Brigatinib versus crizotinib in alk inhibitor-naive advanced ALK-positive NSCLC: final results of phase 3 ALTA-1L trial. J Thorac Oncol. 2021;16:2091&#x02013;108. 10.1016/j.jtho.2021.07.035.<pub-id pub-id-type="pmid">34537440</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR159"><label>159.</label><citation-alternatives><element-citation id="ec-CR159" publication-type="journal"><person-group person-group-type="author"><name><surname>Shaw</surname><given-names>AT</given-names></name><name><surname>Bauer</surname><given-names>TM</given-names></name><name><surname>de Marinis</surname><given-names>F</given-names></name><name><surname>Felip</surname><given-names>E</given-names></name><name><surname>Goto</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>G</given-names></name><etal/></person-group><article-title>First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer</article-title><source>N Engl J Med</source><year>2020</year><volume>383</volume><fpage>2018</fpage><lpage>29</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2027187</pub-id><pub-id pub-id-type="pmid">33207094</pub-id>
</element-citation><mixed-citation id="mc-CR159" publication-type="journal">Shaw AT, Bauer TM, de Marinis F, Felip E, Goto Y, Liu G, et al. First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer. N Engl J Med. 2020;383:2018&#x02013;29. 10.1056/NEJMoa2027187.<pub-id pub-id-type="pmid">33207094</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR160"><label>160.</label><citation-alternatives><element-citation id="ec-CR160" publication-type="journal"><person-group person-group-type="author"><name><surname>Felip</surname><given-names>E</given-names></name><name><surname>Shaw</surname><given-names>AT</given-names></name><name><surname>Bearz</surname><given-names>A</given-names></name><name><surname>Camidge</surname><given-names>DR</given-names></name><name><surname>Solomon</surname><given-names>BJ</given-names></name><name><surname>Bauman</surname><given-names>JR</given-names></name><etal/></person-group><article-title>Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer previously treated with second-generation ALK TKIs</article-title><source>Ann Oncol</source><year>2021</year><volume>32</volume><fpage>620</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1016/j.annonc.2021.02.012</pub-id><pub-id pub-id-type="pmid">33639216</pub-id>
</element-citation><mixed-citation id="mc-CR160" publication-type="journal">Felip E, Shaw AT, Bearz A, Camidge DR, Solomon BJ, Bauman JR, et al. Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer previously treated with second-generation ALK TKIs. Ann Oncol. 2021;32:620&#x02013;30. 10.1016/j.annonc.2021.02.012.<pub-id pub-id-type="pmid">33639216</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR161"><label>161.</label><citation-alternatives><element-citation id="ec-CR161" publication-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>AC</given-names></name><name><surname>Itchins</surname><given-names>M</given-names></name><name><surname>Khasraw</surname><given-names>M</given-names></name></person-group><article-title>Brain metastases in lung cancers with emerging targetable fusion drivers</article-title><source>Int J Mol Sci</source><year>2020</year><volume>21</volume><fpage>1416</fpage><pub-id pub-id-type="doi">10.3390/ijms21041416</pub-id><pub-id pub-id-type="pmid">32093103</pub-id>
</element-citation><mixed-citation id="mc-CR161" publication-type="journal">Tan AC, Itchins M, Khasraw M. Brain metastases in lung cancers with emerging targetable fusion drivers. Int J Mol Sci. 2020;21:1416. 10.3390/ijms21041416.<pub-id pub-id-type="pmid">32093103</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR162"><label>162.</label><citation-alternatives><element-citation id="ec-CR162" publication-type="journal"><person-group person-group-type="author"><name><surname>Schram</surname><given-names>AM</given-names></name><name><surname>O&#x02019;Reilly</surname><given-names>EM</given-names></name><name><surname>Somwar</surname><given-names>R</given-names></name><name><surname>Benayed</surname><given-names>R</given-names></name><name><surname>Shameem</surname><given-names>S</given-names></name><name><surname>Chauhan</surname><given-names>T</given-names></name><etal/></person-group><article-title>Abstract PR02: Clinical proof of concept for MCLA-128, a bispecific HER2/3 antibody therapy, in NRG1 fusion-positive cancers</article-title><source>Mol Cancer Ther</source><year>2019</year><volume>18</volume><fpage>PR02</fpage><pub-id pub-id-type="doi">10.1158/1535-7163.Targ-19-pr02</pub-id></element-citation><mixed-citation id="mc-CR162" publication-type="journal">Schram AM, O&#x02019;Reilly EM, Somwar R, Benayed R, Shameem S, Chauhan T, et al. Abstract PR02: Clinical proof of concept for MCLA-128, a bispecific HER2/3 antibody therapy, in NRG1 fusion-positive cancers. Mol Cancer Ther. 2019;18:PR02. 10.1158/1535-7163.Targ-19-pr02.</mixed-citation></citation-alternatives></ref><ref id="CR163"><label>163.</label><citation-alternatives><element-citation id="ec-CR163" publication-type="journal"><person-group person-group-type="author"><name><surname>Bohn</surname><given-names>KA</given-names></name><name><surname>Adkins</surname><given-names>CE</given-names></name><name><surname>Nounou</surname><given-names>MI</given-names></name><name><surname>Lockman</surname><given-names>PR</given-names></name></person-group><article-title>Inhibition of VEGF and angiopoietin-2 to reduce brain metastases of breast cancer burden</article-title><source>Front Pharmacol</source><year>2017</year><volume>8</volume><fpage>193</fpage><pub-id pub-id-type="doi">10.3389/fphar.2017.00193</pub-id><pub-id pub-id-type="pmid">28443023</pub-id>
</element-citation><mixed-citation id="mc-CR163" publication-type="journal">Bohn KA, Adkins CE, Nounou MI, Lockman PR. Inhibition of VEGF and angiopoietin-2 to reduce brain metastases of breast cancer burden. Front Pharmacol. 2017;8:193. 10.3389/fphar.2017.00193.<pub-id pub-id-type="pmid">28443023</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR164"><label>164.</label><citation-alternatives><element-citation id="ec-CR164" publication-type="journal"><person-group person-group-type="author"><name><surname>Kovalchuk</surname><given-names>B</given-names></name><name><surname>Berghoff</surname><given-names>AS</given-names></name><name><surname>Karreman</surname><given-names>MA</given-names></name><name><surname>Frey</surname><given-names>K</given-names></name><name><surname>Piechutta</surname><given-names>M</given-names></name><name><surname>Fischer</surname><given-names>M</given-names></name><etal/></person-group><article-title>Nintedanib and a bi-specific anti-VEGF/Ang2 nanobody selectively prevent brain metastases of lung adenocarcinoma cells</article-title><source>Clin Exp Metastasis</source><year>2020</year><volume>37</volume><fpage>637</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1007/s10585-020-10055-x</pub-id><pub-id pub-id-type="pmid">32918638</pub-id>
</element-citation><mixed-citation id="mc-CR164" publication-type="journal">Kovalchuk B, Berghoff AS, Karreman MA, Frey K, Piechutta M, Fischer M, et al. Nintedanib and a bi-specific anti-VEGF/Ang2 nanobody selectively prevent brain metastases of lung adenocarcinoma cells. Clin Exp Metastasis. 2020;37:637&#x02013;48. 10.1007/s10585-020-10055-x.<pub-id pub-id-type="pmid">32918638</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR165"><label>165.</label><citation-alternatives><element-citation id="ec-CR165" publication-type="journal"><person-group person-group-type="author"><name><surname>Brastianos</surname><given-names>PK</given-names></name><name><surname>Kim</surname><given-names>AE</given-names></name><name><surname>Wang</surname><given-names>N</given-names></name><name><surname>Lee</surname><given-names>EQ</given-names></name><name><surname>Ligibel</surname><given-names>J</given-names></name><name><surname>Cohen</surname><given-names>JV</given-names></name><etal/></person-group><article-title>Palbociclib demonstrates intracranial activity in progressive brain metastases harboring cyclin-dependent kinase pathway alterations</article-title><source>Nat Cancer</source><year>2021</year><volume>2</volume><fpage>498</fpage><lpage>502</lpage><pub-id pub-id-type="doi">10.1038/s43018-021-00198-5</pub-id><pub-id pub-id-type="pmid">35122016</pub-id>
</element-citation><mixed-citation id="mc-CR165" publication-type="journal">Brastianos PK, Kim AE, Wang N, Lee EQ, Ligibel J, Cohen JV, et al. Palbociclib demonstrates intracranial activity in progressive brain metastases harboring cyclin-dependent kinase pathway alterations. Nat Cancer. 2021;2:498&#x02013;502. 10.1038/s43018-021-00198-5.<pub-id pub-id-type="pmid">35122016</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR166"><label>166.</label><citation-alternatives><element-citation id="ec-CR166" publication-type="journal"><person-group person-group-type="author"><name><surname>Peddi</surname><given-names>PF</given-names></name><name><surname>Hurvitz</surname><given-names>SA</given-names></name></person-group><article-title>PI3K pathway inhibitors for the treatment of brain metastases with a focus on HER2+ breast cancer</article-title><source>J Neurooncol</source><year>2014</year><volume>117</volume><fpage>7</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1007/s11060-014-1369-6</pub-id><pub-id pub-id-type="pmid">24469856</pub-id>
</element-citation><mixed-citation id="mc-CR166" publication-type="journal">Peddi PF, Hurvitz SA. PI3K pathway inhibitors for the treatment of brain metastases with a focus on HER2+ breast cancer. J Neurooncol. 2014;117:7&#x02013;13. 10.1007/s11060-014-1369-6.<pub-id pub-id-type="pmid">24469856</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR167"><label>167.</label><citation-alternatives><element-citation id="ec-CR167" publication-type="journal"><person-group person-group-type="author"><name><surname>Boussiotis</surname><given-names>VA</given-names></name></person-group><article-title>Molecular and biochemical aspects of the PD-1 checkpoint pathway</article-title><source>N Engl J Med</source><year>2016</year><volume>375</volume><fpage>1767</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.1056/NEJMra1514296</pub-id><pub-id pub-id-type="pmid">27806234</pub-id>
</element-citation><mixed-citation id="mc-CR167" publication-type="journal">Boussiotis VA. Molecular and biochemical aspects of the PD-1 checkpoint pathway. N Engl J Med. 2016;375:1767&#x02013;78. 10.1056/NEJMra1514296.<pub-id pub-id-type="pmid">27806234</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR168"><label>168.</label><citation-alternatives><element-citation id="ec-CR168" publication-type="journal"><person-group person-group-type="author"><name><surname>Berghoff</surname><given-names>AS</given-names></name><name><surname>Venur</surname><given-names>VA</given-names></name><name><surname>Preusser</surname><given-names>M</given-names></name><name><surname>Ahluwalia</surname><given-names>MS</given-names></name></person-group><article-title>Immune checkpoint inhibitors in brain metastases: from biology to treatment</article-title><source>Am Soc Clin Oncol Educ Book</source><year>2016</year><volume>35</volume><fpage>e116</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1200/EDBK_100005</pub-id><pub-id pub-id-type="pmid">27249713</pub-id>
</element-citation><mixed-citation id="mc-CR168" publication-type="journal">Berghoff AS, Venur VA, Preusser M, Ahluwalia MS. Immune checkpoint inhibitors in brain metastases: from biology to treatment. Am Soc Clin Oncol Educ Book. 2016;35:e116-22. 10.1200/EDBK_100005.<pub-id pub-id-type="pmid">27249713</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR169"><label>169.</label><citation-alternatives><element-citation id="ec-CR169" publication-type="journal"><person-group person-group-type="author"><name><surname>Tawbi</surname><given-names>HA</given-names></name><name><surname>Forsyth</surname><given-names>PA</given-names></name><name><surname>Algazi</surname><given-names>A</given-names></name><name><surname>Hamid</surname><given-names>O</given-names></name><name><surname>Hodi</surname><given-names>FS</given-names></name><name><surname>Moschos</surname><given-names>SJ</given-names></name><etal/></person-group><article-title>Combined nivolumab and ipilimumab in melanoma metastatic to the brain</article-title><source>N Engl J Med</source><year>2018</year><volume>379</volume><fpage>722</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1805453</pub-id><pub-id pub-id-type="pmid">30134131</pub-id>
</element-citation><mixed-citation id="mc-CR169" publication-type="journal">Tawbi HA, Forsyth PA, Algazi A, Hamid O, Hodi FS, Moschos SJ, et al. Combined nivolumab and ipilimumab in melanoma metastatic to the brain. N Engl J Med. 2018;379:722&#x02013;30. 10.1056/NEJMoa1805453.<pub-id pub-id-type="pmid">30134131</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR170"><label>170.</label><citation-alternatives><element-citation id="ec-CR170" publication-type="journal"><person-group person-group-type="author"><name><surname>Long</surname><given-names>GV</given-names></name><name><surname>Atkinson</surname><given-names>V</given-names></name><name><surname>Lo</surname><given-names>S</given-names></name><name><surname>Sandhu</surname><given-names>S</given-names></name><name><surname>Guminski</surname><given-names>AD</given-names></name><name><surname>Brown</surname><given-names>MP</given-names></name><etal/></person-group><article-title>Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study</article-title><source>Lancet Oncol</source><year>2018</year><volume>19</volume><fpage>672</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(18)30139-6</pub-id><pub-id pub-id-type="pmid">29602646</pub-id>
</element-citation><mixed-citation id="mc-CR170" publication-type="journal">Long GV, Atkinson V, Lo S, Sandhu S, Guminski AD, Brown MP, et al. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. Lancet Oncol. 2018;19:672&#x02013;81. 10.1016/S1470-2045(18)30139-6.<pub-id pub-id-type="pmid">29602646</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR171"><label>171.</label><citation-alternatives><element-citation id="ec-CR171" publication-type="journal"><person-group person-group-type="author"><name><surname>Tawbi</surname><given-names>HA</given-names></name><name><surname>Forsyth</surname><given-names>PA</given-names></name><name><surname>Hodi</surname><given-names>FS</given-names></name><name><surname>Algazi</surname><given-names>AP</given-names></name><name><surname>Hamid</surname><given-names>O</given-names></name><name><surname>Lao</surname><given-names>CD</given-names></name><etal/></person-group><article-title>Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study</article-title><source>Lancet Oncol</source><year>2021</year><volume>22</volume><fpage>1692</fpage><lpage>704</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(21)00545-3</pub-id><pub-id pub-id-type="pmid">34774225</pub-id>
</element-citation><mixed-citation id="mc-CR171" publication-type="journal">Tawbi HA, Forsyth PA, Hodi FS, Algazi AP, Hamid O, Lao CD, et al. Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study. Lancet Oncol. 2021;22:1692&#x02013;704. 10.1016/S1470-2045(21)00545-3.<pub-id pub-id-type="pmid">34774225</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR172"><label>172.</label><citation-alternatives><element-citation id="ec-CR172" publication-type="journal"><person-group person-group-type="author"><name><surname>Hendriks</surname><given-names>LEL</given-names></name><name><surname>Henon</surname><given-names>C</given-names></name><name><surname>Auclin</surname><given-names>E</given-names></name><name><surname>Mezquita</surname><given-names>L</given-names></name><name><surname>Ferrara</surname><given-names>R</given-names></name><name><surname>Audigier-Valette</surname><given-names>C</given-names></name><etal/></person-group><article-title>Outcome of patients with non-small cell lung cancer and brain metastases treated with checkpoint inhibitors</article-title><source>J Thorac Oncol</source><year>2019</year><volume>14</volume><fpage>1244</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1016/j.jtho.2019.02.009</pub-id><pub-id pub-id-type="pmid">30780002</pub-id>
</element-citation><mixed-citation id="mc-CR172" publication-type="journal">Hendriks LEL, Henon C, Auclin E, Mezquita L, Ferrara R, Audigier-Valette C, et al. Outcome of patients with non-small cell lung cancer and brain metastases treated with checkpoint inhibitors. J Thorac Oncol. 2019;14:1244&#x02013;54. 10.1016/j.jtho.2019.02.009.<pub-id pub-id-type="pmid">30780002</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR173"><label>173.</label><citation-alternatives><element-citation id="ec-CR173" publication-type="journal"><person-group person-group-type="author"><name><surname>Shaverdian</surname><given-names>N</given-names></name><name><surname>Lisberg</surname><given-names>AE</given-names></name><name><surname>Bornazyan</surname><given-names>K</given-names></name><name><surname>Veruttipong</surname><given-names>D</given-names></name><name><surname>Goldman</surname><given-names>JW</given-names></name><name><surname>Formenti</surname><given-names>SC</given-names></name><etal/></person-group><article-title>Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial</article-title><source>Lancet Oncol</source><year>2017</year><volume>18</volume><fpage>895</fpage><lpage>903</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(17)30380-7</pub-id><pub-id pub-id-type="pmid">28551359</pub-id>
</element-citation><mixed-citation id="mc-CR173" publication-type="journal">Shaverdian N, Lisberg AE, Bornazyan K, Veruttipong D, Goldman JW, Formenti SC, et al. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial. Lancet Oncol. 2017;18:895&#x02013;903. 10.1016/S1470-2045(17)30380-7.<pub-id pub-id-type="pmid">28551359</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR174"><label>174.</label><citation-alternatives><element-citation id="ec-CR174" publication-type="journal"><person-group person-group-type="author"><name><surname>Antonia</surname><given-names>SJ</given-names></name><name><surname>Villegas</surname><given-names>A</given-names></name><name><surname>Daniel</surname><given-names>D</given-names></name><name><surname>Vicente</surname><given-names>D</given-names></name><name><surname>Murakami</surname><given-names>S</given-names></name><name><surname>Hui</surname><given-names>R</given-names></name><etal/></person-group><article-title>Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer</article-title><source>N Engl J Med</source><year>2017</year><volume>377</volume><fpage>1919</fpage><lpage>29</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1709937</pub-id><pub-id pub-id-type="pmid">28885881</pub-id>
</element-citation><mixed-citation id="mc-CR174" publication-type="journal">Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med. 2017;377:1919&#x02013;29. 10.1056/NEJMoa1709937.<pub-id pub-id-type="pmid">28885881</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR175"><label>175.</label><citation-alternatives><element-citation id="ec-CR175" publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Deng</surname><given-names>L</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>T</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><etal/></person-group><article-title>Efficacy and safety of combined brain radiotherapy and immunotherapy in non-small-cell lung cancer with brain metastases: a systematic review and meta-analysis</article-title><source>Clin Lung Cancer</source><year>2022</year><volume>23</volume><fpage>95</fpage><lpage>107</lpage><pub-id pub-id-type="doi">10.1016/j.cllc.2021.06.009</pub-id><pub-id pub-id-type="pmid">34284948</pub-id>
</element-citation><mixed-citation id="mc-CR175" publication-type="journal">Yang Y, Deng L, Yang Y, Zhang T, Wu Y, Wang L, et al. Efficacy and safety of combined brain radiotherapy and immunotherapy in non-small-cell lung cancer with brain metastases: a systematic review and meta-analysis. Clin Lung Cancer. 2022;23:95&#x02013;107. 10.1016/j.cllc.2021.06.009.<pub-id pub-id-type="pmid">34284948</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR176"><label>176.</label><citation-alternatives><element-citation id="ec-CR176" publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>H</given-names></name><name><surname>Xu</surname><given-names>ZY</given-names></name><name><surname>Zhu</surname><given-names>Q</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Jiang</surname><given-names>SC</given-names></name><name><surname>Zheng</surname><given-names>JH</given-names></name></person-group><article-title>Brain metastases status and immunotherapy efficacy in advanced lung cancer: a systematic review and meta-analysis</article-title><source>Front Immunol</source><year>2021</year><volume>12</volume><fpage>669398</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2021.669398</pub-id><pub-id pub-id-type="pmid">34335570</pub-id>
</element-citation><mixed-citation id="mc-CR176" publication-type="journal">Hu H, Xu ZY, Zhu Q, Liu X, Jiang SC, Zheng JH. Brain metastases status and immunotherapy efficacy in advanced lung cancer: a systematic review and meta-analysis. Front Immunol. 2021;12:669398. 10.3389/fimmu.2021.669398.<pub-id pub-id-type="pmid">34335570</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR177"><label>177.</label><citation-alternatives><element-citation id="ec-CR177" publication-type="journal"><person-group person-group-type="author"><name><surname>Barlesi</surname><given-names>F</given-names></name><name><surname>Tomasini</surname><given-names>P</given-names></name></person-group><article-title>Non-small-cell lung cancer brain metastases and PD-(L)1 immune checkpoint inhibitors</article-title><source>Lancet Oncol</source><year>2020</year><volume>21</volume><fpage>607</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(20)30207-2</pub-id><pub-id pub-id-type="pmid">32251624</pub-id>
</element-citation><mixed-citation id="mc-CR177" publication-type="journal">Barlesi F, Tomasini P. Non-small-cell lung cancer brain metastases and PD-(L)1 immune checkpoint inhibitors. Lancet Oncol. 2020;21:607&#x02013;8. 10.1016/S1470-2045(20)30207-2.<pub-id pub-id-type="pmid">32251624</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR178"><label>178.</label><citation-alternatives><element-citation id="ec-CR178" publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>J</given-names></name><name><surname>Jing</surname><given-names>X</given-names></name><name><surname>Hua</surname><given-names>Y</given-names></name><name><surname>Geng</surname><given-names>K</given-names></name><name><surname>Li</surname><given-names>R</given-names></name><name><surname>Lu</surname><given-names>S</given-names></name><etal/></person-group><article-title>Programmed cell death 1 pathway inhibitors improve the overall survival of small cell lung cancer patients with brain metastases</article-title><source>J Cancer Res Clin Oncol</source><year>2023</year><volume>149</volume><fpage>1825</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1007/s00432-022-04121-y</pub-id><pub-id pub-id-type="pmid">35737093</pub-id>
</element-citation><mixed-citation id="mc-CR178" publication-type="journal">Chang J, Jing X, Hua Y, Geng K, Li R, Lu S, et al. Programmed cell death 1 pathway inhibitors improve the overall survival of small cell lung cancer patients with brain metastases. J Cancer Res Clin Oncol. 2023;149:1825&#x02013;33. 10.1007/s00432-022-04121-y.<pub-id pub-id-type="pmid">35737093</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR179"><label>179.</label><citation-alternatives><element-citation id="ec-CR179" publication-type="journal"><person-group person-group-type="author"><name><surname>Thust</surname><given-names>SC</given-names></name><name><surname>van den Bent</surname><given-names>MJ</given-names></name><name><surname>Smits</surname><given-names>M</given-names></name></person-group><article-title>Pseudoprogression of brain tumors</article-title><source>J Magn Reson Imaging</source><year>2018</year><volume>48</volume><fpage>571</fpage><lpage>89</lpage><pub-id pub-id-type="doi">10.1002/jmri.26171</pub-id><pub-id pub-id-type="pmid">29734497</pub-id>
</element-citation><mixed-citation id="mc-CR179" publication-type="journal">Thust SC, van den Bent MJ, Smits M. Pseudoprogression of brain tumors. J Magn Reson Imaging. 2018;48:571&#x02013;89. 10.1002/jmri.26171.<pub-id pub-id-type="pmid">29734497</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR180"><label>180.</label><citation-alternatives><element-citation id="ec-CR180" publication-type="journal"><person-group person-group-type="author"><name><surname>Xie</surname><given-names>J</given-names></name><name><surname>Shen</surname><given-names>Z</given-names></name><name><surname>Anraku</surname><given-names>Y</given-names></name><name><surname>Kataoka</surname><given-names>K</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name></person-group><article-title>Nanomaterial-based blood-brain-barrier (BBB) crossing strategies</article-title><source>Biomaterials</source><year>2019</year><volume>224</volume><fpage>119491</fpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2019.119491</pub-id><pub-id pub-id-type="pmid">31546096</pub-id>
</element-citation><mixed-citation id="mc-CR180" publication-type="journal">Xie J, Shen Z, Anraku Y, Kataoka K, Chen X. Nanomaterial-based blood-brain-barrier (BBB) crossing strategies. Biomaterials. 2019;224:119491. 10.1016/j.biomaterials.2019.119491.<pub-id pub-id-type="pmid">31546096</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR181"><label>181.</label><citation-alternatives><element-citation id="ec-CR181" publication-type="journal"><person-group person-group-type="author"><name><surname>Terstappen</surname><given-names>GC</given-names></name><name><surname>Meyer</surname><given-names>AH</given-names></name><name><surname>Bell</surname><given-names>RD</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name></person-group><article-title>Strategies for delivering therapeutics across the blood-brain barrier</article-title><source>Nat Rev Drug Discov</source><year>2021</year><volume>20</volume><fpage>362</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1038/s41573-021-00139-y</pub-id><pub-id pub-id-type="pmid">33649582</pub-id>
</element-citation><mixed-citation id="mc-CR181" publication-type="journal">Terstappen GC, Meyer AH, Bell RD, Zhang W. Strategies for delivering therapeutics across the blood-brain barrier. Nat Rev Drug Discov. 2021;20:362&#x02013;83. 10.1038/s41573-021-00139-y.<pub-id pub-id-type="pmid">33649582</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR182"><label>182.</label><citation-alternatives><element-citation id="ec-CR182" publication-type="journal"><person-group person-group-type="author"><name><surname>Kumthekar</surname><given-names>P</given-names></name><name><surname>Tang</surname><given-names>SC</given-names></name><name><surname>Brenner</surname><given-names>AJ</given-names></name><name><surname>Kesari</surname><given-names>S</given-names></name><name><surname>Piccioni</surname><given-names>DE</given-names></name><name><surname>Anders</surname><given-names>C</given-names></name><etal/></person-group><article-title>ANG1005, a brain-penetrating peptide-drug conjugate, shows activity in patients with breast cancer with leptomeningeal carcinomatosis and recurrent brain metastases</article-title><source>Clin Cancer Res</source><year>2020</year><volume>26</volume><fpage>2789</fpage><lpage>99</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-19-3258</pub-id><pub-id pub-id-type="pmid">31969331</pub-id>
</element-citation><mixed-citation id="mc-CR182" publication-type="journal">Kumthekar P, Tang SC, Brenner AJ, Kesari S, Piccioni DE, Anders C, et al. ANG1005, a brain-penetrating peptide-drug conjugate, shows activity in patients with breast cancer with leptomeningeal carcinomatosis and recurrent brain metastases. Clin Cancer Res. 2020;26:2789&#x02013;99. 10.1158/1078-0432.CCR-19-3258.<pub-id pub-id-type="pmid">31969331</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR183"><label>183.</label><citation-alternatives><element-citation id="ec-CR183" publication-type="journal"><person-group person-group-type="author"><name><surname>Quader</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Mi</surname><given-names>P</given-names></name><name><surname>Chida</surname><given-names>T</given-names></name><name><surname>Ishii</surname><given-names>T</given-names></name><etal/></person-group><article-title>cRGD peptide-installed epirubicin-loaded polymeric micelles for effective targeted therapy against brain tumors</article-title><source>J Control Release</source><year>2017</year><volume>258</volume><fpage>56</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2017.04.033</pub-id><pub-id pub-id-type="pmid">28483513</pub-id>
</element-citation><mixed-citation id="mc-CR183" publication-type="journal">Quader S, Liu X, Chen Y, Mi P, Chida T, Ishii T, et al. cRGD peptide-installed epirubicin-loaded polymeric micelles for effective targeted therapy against brain tumors. J Control Release. 2017;258:56&#x02013;66. 10.1016/j.jconrel.2017.04.033.<pub-id pub-id-type="pmid">28483513</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR184"><label>184.</label><citation-alternatives><element-citation id="ec-CR184" publication-type="journal"><person-group person-group-type="author"><name><surname>Pardridge</surname><given-names>WM</given-names></name></person-group><article-title>Molecular biology of the blood-brain barrier</article-title><source>Mol Biotechnol</source><year>2005</year><volume>30</volume><fpage>57</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1385/MB:30:1:057</pub-id><pub-id pub-id-type="pmid">15805577</pub-id>
</element-citation><mixed-citation id="mc-CR184" publication-type="journal">Pardridge WM. Molecular biology of the blood-brain barrier. Mol Biotechnol. 2005;30:57&#x02013;70. 10.1385/MB:30:1:057.<pub-id pub-id-type="pmid">15805577</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR185"><label>185.</label><citation-alternatives><element-citation id="ec-CR185" publication-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Ying</surname><given-names>M</given-names></name><name><surname>Lu</surname><given-names>W</given-names></name></person-group><article-title>Brain tumor-targeted drug delivery strategies</article-title><source>Acta Pharm Sin B</source><year>2014</year><volume>4</volume><fpage>193</fpage><lpage>201</lpage><pub-id pub-id-type="doi">10.1016/j.apsb.2014.03.001</pub-id><pub-id pub-id-type="pmid">26579383</pub-id>
</element-citation><mixed-citation id="mc-CR185" publication-type="journal">Wei X, Chen X, Ying M, Lu W. Brain tumor-targeted drug delivery strategies. Acta Pharm Sin B. 2014;4:193&#x02013;201. 10.1016/j.apsb.2014.03.001.<pub-id pub-id-type="pmid">26579383</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR186"><label>186.</label><citation-alternatives><element-citation id="ec-CR186" publication-type="journal"><person-group person-group-type="author"><name><surname>Foley</surname><given-names>CP</given-names></name><name><surname>Rubin</surname><given-names>DG</given-names></name><name><surname>Santillan</surname><given-names>A</given-names></name><name><surname>Sondhi</surname><given-names>D</given-names></name><name><surname>Dyke</surname><given-names>JP</given-names></name><name><surname>Crystal</surname><given-names>RG</given-names></name><etal/></person-group><article-title>Intra-arterial delivery of AAV vectors to the mouse brain after mannitol mediated blood brain barrier disruption</article-title><source>J Control Release</source><year>2014</year><volume>196</volume><fpage>71</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2014.09.018</pub-id><pub-id pub-id-type="pmid">25270115</pub-id>
</element-citation><mixed-citation id="mc-CR186" publication-type="journal">Foley CP, Rubin DG, Santillan A, Sondhi D, Dyke JP, Crystal RG, et al. Intra-arterial delivery of AAV vectors to the mouse brain after mannitol mediated blood brain barrier disruption. J Control Release. 2014;196:71&#x02013;8. 10.1016/j.jconrel.2014.09.018.<pub-id pub-id-type="pmid">25270115</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR187"><label>187.</label><citation-alternatives><element-citation id="ec-CR187" publication-type="journal"><person-group person-group-type="author"><name><surname>Boockvar</surname><given-names>JA</given-names></name><name><surname>Tsiouris</surname><given-names>AJ</given-names></name><name><surname>Hofstetter</surname><given-names>CP</given-names></name><name><surname>Kovanlikaya</surname><given-names>I</given-names></name><name><surname>Fralin</surname><given-names>S</given-names></name><name><surname>Kesavabhotla</surname><given-names>K</given-names></name><etal/></person-group><article-title>Safety and maximum tolerated dose of superselective intraarterial cerebral infusion of bevacizumab after osmotic blood-brain barrier disruption for recurrent malignant glioma. Clinical article</article-title><source>J Neurosurg</source><year>2011</year><volume>114</volume><fpage>624</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.3171/2010.9.JNS101223</pub-id><pub-id pub-id-type="pmid">20964595</pub-id>
</element-citation><mixed-citation id="mc-CR187" publication-type="journal">Boockvar JA, Tsiouris AJ, Hofstetter CP, Kovanlikaya I, Fralin S, Kesavabhotla K, et al. Safety and maximum tolerated dose of superselective intraarterial cerebral infusion of bevacizumab after osmotic blood-brain barrier disruption for recurrent malignant glioma. Clinical article. J Neurosurg. 2011;114:624&#x02013;32. 10.3171/2010.9.JNS101223.<pub-id pub-id-type="pmid">20964595</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR188"><label>188.</label><citation-alternatives><element-citation id="ec-CR188" publication-type="journal"><person-group person-group-type="author"><name><surname>Allhenn</surname><given-names>D</given-names></name><name><surname>Boushehri</surname><given-names>MA</given-names></name><name><surname>Lamprecht</surname><given-names>A</given-names></name></person-group><article-title>Drug delivery strategies for the treatment of malignant gliomas</article-title><source>Int J Pharm</source><year>2012</year><volume>436</volume><fpage>299</fpage><lpage>310</lpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2012.06.025</pub-id><pub-id pub-id-type="pmid">22721856</pub-id>
</element-citation><mixed-citation id="mc-CR188" publication-type="journal">Allhenn D, Boushehri MA, Lamprecht A. Drug delivery strategies for the treatment of malignant gliomas. Int J Pharm. 2012;436:299&#x02013;310. 10.1016/j.ijpharm.2012.06.025.<pub-id pub-id-type="pmid">22721856</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR189"><label>189.</label><citation-alternatives><element-citation id="ec-CR189" publication-type="journal"><person-group person-group-type="author"><name><surname>Bobo</surname><given-names>RH</given-names></name><name><surname>Laske</surname><given-names>DW</given-names></name><name><surname>Akbasak</surname><given-names>A</given-names></name><name><surname>Morrison</surname><given-names>PF</given-names></name><name><surname>Dedrick</surname><given-names>RL</given-names></name><name><surname>Oldfield</surname><given-names>EH</given-names></name></person-group><article-title>Convection-enhanced delivery of macromolecules in the brain</article-title><source>Proc Natl Acad Sci U S A</source><year>1994</year><volume>91</volume><fpage>2076</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1073/pnas.91.6.2076</pub-id><pub-id pub-id-type="pmid">8134351</pub-id>
</element-citation><mixed-citation id="mc-CR189" publication-type="journal">Bobo RH, Laske DW, Akbasak A, Morrison PF, Dedrick RL, Oldfield EH. Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci U S A. 1994;91:2076&#x02013;80. 10.1073/pnas.91.6.2076.<pub-id pub-id-type="pmid">8134351</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR190"><label>190.</label><citation-alternatives><element-citation id="ec-CR190" publication-type="journal"><person-group person-group-type="author"><name><surname>Yin</surname><given-names>D</given-names></name><name><surname>Forsayeth</surname><given-names>J</given-names></name><name><surname>Bankiewicz</surname><given-names>KS</given-names></name></person-group><article-title>Optimized cannula design and placement for convection-enhanced delivery in rat striatum</article-title><source>J Neurosci Methods</source><year>2010</year><volume>187</volume><fpage>46</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1016/j.jneumeth.2009.12.008</pub-id><pub-id pub-id-type="pmid">20026357</pub-id>
</element-citation><mixed-citation id="mc-CR190" publication-type="journal">Yin D, Forsayeth J, Bankiewicz KS. Optimized cannula design and placement for convection-enhanced delivery in rat striatum. J Neurosci Methods. 2010;187:46&#x02013;51. 10.1016/j.jneumeth.2009.12.008.<pub-id pub-id-type="pmid">20026357</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR191"><label>191.</label><citation-alternatives><element-citation id="ec-CR191" publication-type="journal"><person-group person-group-type="author"><name><surname>Sonabend</surname><given-names>AM</given-names></name><name><surname>Carminucci</surname><given-names>AS</given-names></name><name><surname>Amendolara</surname><given-names>B</given-names></name><name><surname>Bansal</surname><given-names>M</given-names></name><name><surname>Leung</surname><given-names>R</given-names></name><name><surname>Lei</surname><given-names>L</given-names></name><etal/></person-group><article-title>Convection-enhanced delivery of etoposide is effective against murine proneural glioblastoma</article-title><source>Neuro Oncol</source><year>2014</year><volume>16</volume><fpage>1210</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1093/neuonc/nou026</pub-id><pub-id pub-id-type="pmid">24637229</pub-id>
</element-citation><mixed-citation id="mc-CR191" publication-type="journal">Sonabend AM, Carminucci AS, Amendolara B, Bansal M, Leung R, Lei L, et al. Convection-enhanced delivery of etoposide is effective against murine proneural glioblastoma. Neuro Oncol. 2014;16:1210&#x02013;9. 10.1093/neuonc/nou026.<pub-id pub-id-type="pmid">24637229</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR192"><label>192.</label><citation-alternatives><element-citation id="ec-CR192" publication-type="journal"><person-group person-group-type="author"><name><surname>Astary</surname><given-names>GW</given-names></name><name><surname>Kantorovich</surname><given-names>S</given-names></name><name><surname>Carney</surname><given-names>PR</given-names></name><name><surname>Mareci</surname><given-names>TH</given-names></name><name><surname>Sarntinoranont</surname><given-names>M</given-names></name></person-group><article-title>Regional convection-enhanced delivery of gadolinium-labeled albumin in the rat hippocampus in vivo</article-title><source>J Neurosci Methods</source><year>2010</year><volume>187</volume><fpage>129</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1016/j.jneumeth.2010.01.002</pub-id><pub-id pub-id-type="pmid">20067808</pub-id>
</element-citation><mixed-citation id="mc-CR192" publication-type="journal">Astary GW, Kantorovich S, Carney PR, Mareci TH, Sarntinoranont M. Regional convection-enhanced delivery of gadolinium-labeled albumin in the rat hippocampus in vivo. J Neurosci Methods. 2010;187:129&#x02013;37. 10.1016/j.jneumeth.2010.01.002.<pub-id pub-id-type="pmid">20067808</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR193"><label>193.</label><citation-alternatives><element-citation id="ec-CR193" publication-type="journal"><person-group person-group-type="author"><name><surname>Patel</surname><given-names>SJ</given-names></name><name><surname>Shapiro</surname><given-names>WR</given-names></name><name><surname>Laske</surname><given-names>DW</given-names></name><name><surname>Jensen</surname><given-names>RL</given-names></name><name><surname>Asher</surname><given-names>AL</given-names></name><name><surname>Wessels</surname><given-names>BW</given-names></name><etal/></person-group><article-title>Safety and feasibility of convection-enhanced delivery of Cotara for the treatment of malignant glioma: initial experience in 51 patients</article-title><source>Neurosurgery</source><year>2005</year><volume>56</volume><fpage>1243</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1227/01.neu.0000159649.71890.30</pub-id><pub-id pub-id-type="pmid">15918940</pub-id>
</element-citation><mixed-citation id="mc-CR193" publication-type="journal">Patel SJ, Shapiro WR, Laske DW, Jensen RL, Asher AL, Wessels BW, et al. Safety and feasibility of convection-enhanced delivery of Cotara for the treatment of malignant glioma: initial experience in 51 patients. Neurosurgery. 2005;56:1243&#x02013;52. 10.1227/01.neu.0000159649.71890.30. discussion 52-3.<pub-id pub-id-type="pmid">15918940</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR194"><label>194.</label><citation-alternatives><element-citation id="ec-CR194" publication-type="journal"><person-group person-group-type="author"><name><surname>Allard</surname><given-names>E</given-names></name><name><surname>Passirani</surname><given-names>C</given-names></name><name><surname>Benoit</surname><given-names>JP</given-names></name></person-group><article-title>Convection-enhanced delivery of nanocarriers for the treatment of brain tumors</article-title><source>Biomaterials</source><year>2009</year><volume>30</volume><fpage>2302</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2009.01.003</pub-id><pub-id pub-id-type="pmid">19168213</pub-id>
</element-citation><mixed-citation id="mc-CR194" publication-type="journal">Allard E, Passirani C, Benoit JP. Convection-enhanced delivery of nanocarriers for the treatment of brain tumors. Biomaterials. 2009;30:2302&#x02013;18. 10.1016/j.biomaterials.2009.01.003.<pub-id pub-id-type="pmid">19168213</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR195"><label>195.</label><citation-alternatives><element-citation id="ec-CR195" publication-type="journal"><person-group person-group-type="author"><name><surname>Bernal</surname><given-names>GM</given-names></name><name><surname>LaRiviere</surname><given-names>MJ</given-names></name><name><surname>Mansour</surname><given-names>N</given-names></name><name><surname>Pytel</surname><given-names>P</given-names></name><name><surname>Cahill</surname><given-names>KE</given-names></name><name><surname>Voce</surname><given-names>DJ</given-names></name><etal/></person-group><article-title>Convection-enhanced delivery and in vivo imaging of polymeric nanoparticles for the treatment of malignant glioma</article-title><source>Nanomedicine</source><year>2014</year><volume>10</volume><fpage>149</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.1016/j.nano.2013.07.003</pub-id><pub-id pub-id-type="pmid">23891990</pub-id>
</element-citation><mixed-citation id="mc-CR195" publication-type="journal">Bernal GM, LaRiviere MJ, Mansour N, Pytel P, Cahill KE, Voce DJ, et al. Convection-enhanced delivery and in vivo imaging of polymeric nanoparticles for the treatment of malignant glioma. Nanomedicine. 2014;10:149&#x02013;57. 10.1016/j.nano.2013.07.003.<pub-id pub-id-type="pmid">23891990</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR196"><label>196.</label><citation-alternatives><element-citation id="ec-CR196" publication-type="journal"><person-group person-group-type="author"><name><surname>Engelhard</surname><given-names>HH</given-names></name></person-group><article-title>The role of interstitial BCNU chemotherapy in the treatment of malignant glioma</article-title><source>Surg Neurol</source><year>2000</year><volume>53</volume><fpage>458</fpage><lpage>464</lpage><pub-id pub-id-type="doi">10.1016/s0090-3019(00)00211-1</pub-id><pub-id pub-id-type="pmid">10874145</pub-id>
</element-citation><mixed-citation id="mc-CR196" publication-type="journal">Engelhard HH. The role of interstitial BCNU chemotherapy in the treatment of malignant glioma. Surg Neurol. 2000;53:458&#x02013;64. 10.1016/s0090-3019(00)00211-1.<pub-id pub-id-type="pmid">10874145</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR197"><label>197.</label><citation-alternatives><element-citation id="ec-CR197" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Xiong</surname><given-names>G</given-names></name><name><surname>Tsang</surname><given-names>WC</given-names></name><name><surname>Schatzlein</surname><given-names>AG</given-names></name><name><surname>Uchegbu</surname><given-names>IF</given-names></name></person-group><article-title>Nose-to-brain delivery</article-title><source>J Pharmacol Exp Ther</source><year>2019</year><volume>370</volume><fpage>593</fpage><lpage>601</lpage><pub-id pub-id-type="doi">10.1124/jpet.119.258152</pub-id><pub-id pub-id-type="pmid">31126978</pub-id>
</element-citation><mixed-citation id="mc-CR197" publication-type="journal">Wang Z, Xiong G, Tsang WC, Schatzlein AG, Uchegbu IF. Nose-to-brain delivery. J Pharmacol Exp Ther. 2019;370:593&#x02013;601. 10.1124/jpet.119.258152.<pub-id pub-id-type="pmid">31126978</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR198"><label>198.</label><citation-alternatives><element-citation id="ec-CR198" publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>SY</given-names></name><name><surname>Kim</surname><given-names>TW</given-names></name></person-group><article-title>Current challenges in the implementation of precision oncology for the management of metastatic colorectal cancer</article-title><source>ESMO Open</source><year>2020</year><volume>5</volume><fpage>e000634 </fpage><pub-id pub-id-type="doi">10.1136/esmoopen-2019-000634</pub-id><pub-id pub-id-type="pmid">32188714</pub-id>
</element-citation><mixed-citation id="mc-CR198" publication-type="journal">Kim SY, Kim TW. Current challenges in the implementation of precision oncology for the management of metastatic colorectal cancer. ESMO Open. 2020;5:e000634. 10.1136/esmoopen-2019-000634.<pub-id pub-id-type="pmid">32188714</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR199"><label>199.</label><citation-alternatives><element-citation id="ec-CR199" publication-type="journal"><person-group person-group-type="author"><name><surname>Kallingal</surname><given-names>A</given-names></name><name><surname>Olszewski</surname><given-names>M</given-names></name><name><surname>Maciejewska</surname><given-names>N</given-names></name><name><surname>Brankiewicz</surname><given-names>W</given-names></name><name><surname>Baginski</surname><given-names>M</given-names></name></person-group><article-title>Cancer immune escape: the role of antigen presentation machinery</article-title><source>J Cancer Res Clin Oncol</source><year>2023</year><volume>149</volume><fpage>8131</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1007/s00432-023-04737-8</pub-id><pub-id pub-id-type="pmid">37031434</pub-id>
</element-citation><mixed-citation id="mc-CR199" publication-type="journal">Kallingal A, Olszewski M, Maciejewska N, Brankiewicz W, Baginski M. Cancer immune escape: the role of antigen presentation machinery. J Cancer Res Clin Oncol. 2023;149:8131&#x02013;41. 10.1007/s00432-023-04737-8.<pub-id pub-id-type="pmid">37031434</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR200"><label>200.</label><citation-alternatives><element-citation id="ec-CR200" publication-type="journal"><person-group person-group-type="author"><name><surname>Nakamura</surname><given-names>K</given-names></name><name><surname>Smyth</surname><given-names>MJ</given-names></name></person-group><article-title>Myeloid immunosuppression and immune checkpoints in the tumor microenvironment</article-title><source>Cell Mol Immunol</source><year>2020</year><volume>17</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1038/s41423-019-0306-1</pub-id><pub-id pub-id-type="pmid">31611651</pub-id>
</element-citation><mixed-citation id="mc-CR200" publication-type="journal">Nakamura K, Smyth MJ. Myeloid immunosuppression and immune checkpoints in the tumor microenvironment. Cell Mol Immunol. 2020;17:1&#x02013;12. 10.1038/s41423-019-0306-1.<pub-id pub-id-type="pmid">31611651</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR201"><label>201.</label><citation-alternatives><element-citation id="ec-CR201" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Gong</surname><given-names>R</given-names></name><name><surname>Zhao</surname><given-names>C</given-names></name><name><surname>Lei</surname><given-names>K</given-names></name><name><surname>Sun</surname><given-names>X</given-names></name><name><surname>Ren</surname><given-names>H</given-names></name></person-group><article-title>Human FOXP3 and tumour microenvironment</article-title><source>Immunology</source><year>2023</year><volume>168</volume><fpage>248</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1111/imm.13520</pub-id><pub-id pub-id-type="pmid">35689826</pub-id>
</element-citation><mixed-citation id="mc-CR201" publication-type="journal">Wang J, Gong R, Zhao C, Lei K, Sun X, Ren H. Human FOXP3 and tumour microenvironment. Immunology. 2023;168:248&#x02013;55. 10.1111/imm.13520.<pub-id pub-id-type="pmid">35689826</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR202"><label>202.</label><citation-alternatives><element-citation id="ec-CR202" publication-type="journal"><person-group person-group-type="author"><name><surname>Ganesh</surname><given-names>K</given-names></name><name><surname>Stadler</surname><given-names>ZK</given-names></name><name><surname>Cercek</surname><given-names>A</given-names></name><name><surname>Mendelsohn</surname><given-names>RB</given-names></name><name><surname>Shia</surname><given-names>J</given-names></name><name><surname>Segal</surname><given-names>NH</given-names></name><etal/></person-group><article-title>Immunotherapy in colorectal cancer: rationale, challenges and potential</article-title><source>Nat Rev Gastroenterol Hepatol</source><year>2019</year><volume>16</volume><fpage>361</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1038/s41575-019-0126-x</pub-id><pub-id pub-id-type="pmid">30886395</pub-id>
</element-citation><mixed-citation id="mc-CR202" publication-type="journal">Ganesh K, Stadler ZK, Cercek A, Mendelsohn RB, Shia J, Segal NH, et al. Immunotherapy in colorectal cancer: rationale, challenges and potential. Nat Rev Gastroenterol Hepatol. 2019;16:361&#x02013;75. 10.1038/s41575-019-0126-x.<pub-id pub-id-type="pmid">30886395</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR203"><label>203.</label><citation-alternatives><element-citation id="ec-CR203" publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Mayes</surname><given-names>PA</given-names></name><name><surname>Eastman</surname><given-names>S</given-names></name><name><surname>Shi</surname><given-names>H</given-names></name><name><surname>Yadavilli</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>T</given-names></name><etal/></person-group><article-title>The BRAF and MEK inhibitors dabrafenib and trametinib: effects on immune function and in combination with immunomodulatory antibodies targeting PD-1, PD-L1, and CTLA-4</article-title><source>Clin Cancer Res</source><year>2015</year><volume>21</volume><fpage>1639</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-14-2339</pub-id><pub-id pub-id-type="pmid">25589619</pub-id>
</element-citation><mixed-citation id="mc-CR203" publication-type="journal">Liu L, Mayes PA, Eastman S, Shi H, Yadavilli S, Zhang T, et al. The BRAF and MEK inhibitors dabrafenib and trametinib: effects on immune function and in combination with immunomodulatory antibodies targeting PD-1, PD-L1, and CTLA-4. Clin Cancer Res. 2015;21:1639&#x02013;51. 10.1158/1078-0432.CCR-14-2339.<pub-id pub-id-type="pmid">25589619</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR204"><label>204.</label><citation-alternatives><element-citation id="ec-CR204" publication-type="journal"><person-group person-group-type="author"><name><surname>Boni</surname><given-names>A</given-names></name><name><surname>Cogdill</surname><given-names>AP</given-names></name><name><surname>Dang</surname><given-names>P</given-names></name><name><surname>Udayakumar</surname><given-names>D</given-names></name><name><surname>Njauw</surname><given-names>CN</given-names></name><name><surname>Sloss</surname><given-names>CM</given-names></name><etal/></person-group><article-title>Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function</article-title><source>Cancer Res</source><year>2010</year><volume>70</volume><fpage>5213</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-10-0118</pub-id><pub-id pub-id-type="pmid">20551059</pub-id>
</element-citation><mixed-citation id="mc-CR204" publication-type="journal">Boni A, Cogdill AP, Dang P, Udayakumar D, Njauw CN, Sloss CM, et al. Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res. 2010;70:5213&#x02013;9. 10.1158/0008-5472.CAN-10-0118.<pub-id pub-id-type="pmid">20551059</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR205"><label>205.</label><citation-alternatives><element-citation id="ec-CR205" publication-type="journal"><person-group person-group-type="author"><name><surname>Knight</surname><given-names>DA</given-names></name><name><surname>Ngiow</surname><given-names>SF</given-names></name><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Parmenter</surname><given-names>T</given-names></name><name><surname>Mok</surname><given-names>S</given-names></name><name><surname>Cass</surname><given-names>A</given-names></name><etal/></person-group><article-title>Host immunity contributes to the anti-melanoma activity of BRAF inhibitors</article-title><source>J Clin Invest</source><year>2013</year><volume>123</volume><fpage>1371</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1172/JCI66236</pub-id><pub-id pub-id-type="pmid">23454771</pub-id>
</element-citation><mixed-citation id="mc-CR205" publication-type="journal">Knight DA, Ngiow SF, Li M, Parmenter T, Mok S, Cass A, et al. Host immunity contributes to the anti-melanoma activity of BRAF inhibitors. J Clin Invest. 2013;123:1371&#x02013;81. 10.1172/JCI66236.<pub-id pub-id-type="pmid">23454771</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR206"><label>206.</label><citation-alternatives><element-citation id="ec-CR206" publication-type="journal"><person-group person-group-type="author"><name><surname>Steinberg</surname><given-names>SM</given-names></name><name><surname>Zhang</surname><given-names>P</given-names></name><name><surname>Malik</surname><given-names>BT</given-names></name><name><surname>Boni</surname><given-names>A</given-names></name><name><surname>Shabaneh</surname><given-names>TB</given-names></name><name><surname>Byrne</surname><given-names>KT</given-names></name><etal/></person-group><article-title>BRAF inhibition alleviates immune suppression in murine autochthonous melanoma</article-title><source>Cancer Immunol Res</source><year>2014</year><volume>2</volume><fpage>1044</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1158/2326-6066.CIR-14-0074</pub-id><pub-id pub-id-type="pmid">25183499</pub-id>
</element-citation><mixed-citation id="mc-CR206" publication-type="journal">Steinberg SM, Zhang P, Malik BT, Boni A, Shabaneh TB, Byrne KT, et al. BRAF inhibition alleviates immune suppression in murine autochthonous melanoma. Cancer Immunol Res. 2014;2:1044&#x02013;50. 10.1158/2326-6066.CIR-14-0074.<pub-id pub-id-type="pmid">25183499</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR207"><label>207.</label><citation-alternatives><element-citation id="ec-CR207" publication-type="journal"><person-group person-group-type="author"><name><surname>Hu-Lieskovan</surname><given-names>S</given-names></name><name><surname>Mok</surname><given-names>S</given-names></name><name><surname>Homet Moreno</surname><given-names>B</given-names></name><name><surname>Tsoi</surname><given-names>J</given-names></name><name><surname>Robert</surname><given-names>L</given-names></name><name><surname>Goedert</surname><given-names>L</given-names></name><etal/></person-group><article-title>Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma</article-title><source>Sci Transl Med</source><year>2015</year><volume>7</volume><fpage>279ra41</fpage><pub-id pub-id-type="doi">10.1126/scitranslmed.aaa4691</pub-id><pub-id pub-id-type="pmid">25787767</pub-id>
</element-citation><mixed-citation id="mc-CR207" publication-type="journal">Hu-Lieskovan S, Mok S, Homet Moreno B, Tsoi J, Robert L, Goedert L, et al. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma. Sci Transl Med. 2015;7:279ra41. 10.1126/scitranslmed.aaa4691.<pub-id pub-id-type="pmid">25787767</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR208"><label>208.</label><citation-alternatives><element-citation id="ec-CR208" publication-type="journal"><person-group person-group-type="author"><name><surname>Deng</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>ES</given-names></name><name><surname>Jenkins</surname><given-names>RW</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Dries</surname><given-names>R</given-names></name><name><surname>Yates</surname><given-names>K</given-names></name><etal/></person-group><article-title>CDK4/6 inhibition augments antitumor immunity by enhancing T-cell activation</article-title><source>Cancer Discov</source><year>2018</year><volume>8</volume><fpage>216</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-17-0915</pub-id><pub-id pub-id-type="pmid">29101163</pub-id>
</element-citation><mixed-citation id="mc-CR208" publication-type="journal">Deng J, Wang ES, Jenkins RW, Li S, Dries R, Yates K, et al. CDK4/6 inhibition augments antitumor immunity by enhancing T-cell activation. Cancer Discov. 2018;8:216&#x02013;33. 10.1158/2159-8290.CD-17-0915.<pub-id pub-id-type="pmid">29101163</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR209"><label>209.</label><citation-alternatives><element-citation id="ec-CR209" publication-type="journal"><person-group person-group-type="author"><name><surname>Ding</surname><given-names>L</given-names></name><name><surname>Kim</surname><given-names>HJ</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Kearns</surname><given-names>M</given-names></name><name><surname>Jiang</surname><given-names>T</given-names></name><name><surname>Ohlson</surname><given-names>CE</given-names></name><etal/></person-group><article-title>PARP inhibition elicits STING-dependent antitumor immunity in Brca1-deficient ovarian cancer</article-title><source>Cell Rep</source><year>2018</year><volume>25</volume><fpage>2972</fpage><lpage>80 e5</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2018.11.054</pub-id><pub-id pub-id-type="pmid">30540933</pub-id>
</element-citation><mixed-citation id="mc-CR209" publication-type="journal">Ding L, Kim HJ, Wang Q, Kearns M, Jiang T, Ohlson CE, et al. PARP inhibition elicits STING-dependent antitumor immunity in Brca1-deficient ovarian cancer. Cell Rep. 2018;25:2972-80 e5. 10.1016/j.celrep.2018.11.054.<pub-id pub-id-type="pmid">30540933</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR210"><label>210.</label><citation-alternatives><element-citation id="ec-CR210" publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>J</given-names></name><name><surname>Zhao</surname><given-names>W</given-names></name><name><surname>Ju</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Peng</surname><given-names>Y</given-names></name><name><surname>Labrie</surname><given-names>M</given-names></name><etal/></person-group><article-title>PARPi triggers the STING-dependent immune response and enhances the therapeutic efficacy of immune checkpoint blockade independent of BRCAness</article-title><source>Cancer Res</source><year>2019</year><volume>79</volume><fpage>311</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-18-1003</pub-id><pub-id pub-id-type="pmid">30482774</pub-id>
</element-citation><mixed-citation id="mc-CR210" publication-type="journal">Shen J, Zhao W, Ju Z, Wang L, Peng Y, Labrie M, et al. PARPi triggers the STING-dependent immune response and enhances the therapeutic efficacy of immune checkpoint blockade independent of BRCAness. Cancer Res. 2019;79:311&#x02013;9. 10.1158/0008-5472.CAN-18-1003.<pub-id pub-id-type="pmid">30482774</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR211"><label>211.</label><citation-alternatives><element-citation id="ec-CR211" publication-type="journal"><person-group person-group-type="author"><name><surname>Sen</surname><given-names>T</given-names></name><name><surname>Rodriguez</surname><given-names>BL</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Corte</surname><given-names>CMD</given-names></name><name><surname>Morikawa</surname><given-names>N</given-names></name><name><surname>Fujimoto</surname><given-names>J</given-names></name><etal/></person-group><article-title>Targeting DNA damage response promotes antitumor immunity through STING-mediated T-cell activation in small cell lung cancer</article-title><source>Cancer Discov</source><year>2019</year><volume>9</volume><fpage>646</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-18-1020</pub-id><pub-id pub-id-type="pmid">30777870</pub-id>
</element-citation><mixed-citation id="mc-CR211" publication-type="journal">Sen T, Rodriguez BL, Chen L, Corte CMD, Morikawa N, Fujimoto J, et al. Targeting DNA damage response promotes antitumor immunity through STING-mediated T-cell activation in small cell lung cancer. Cancer Discov. 2019;9:646&#x02013;61. 10.1158/2159-8290.CD-18-1020.<pub-id pub-id-type="pmid">30777870</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR212"><label>212.</label><citation-alternatives><element-citation id="ec-CR212" publication-type="journal"><person-group person-group-type="author"><name><surname>Ding</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Xu</surname><given-names>X</given-names></name><name><surname>Qian</surname><given-names>Y</given-names></name><name><surname>Liang</surname><given-names>G</given-names></name><name><surname>Yao</surname><given-names>F</given-names></name><etal/></person-group><article-title>PARP1 suppresses the transcription of PD-L1 by Poly(ADP-Ribosyl)ating STAT3</article-title><source>Cancer Immunol Res</source><year>2019</year><volume>7</volume><fpage>136</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.1158/2326-6066.CIR-18-0071</pub-id><pub-id pub-id-type="pmid">30401677</pub-id>
</element-citation><mixed-citation id="mc-CR212" publication-type="journal">Ding L, Chen X, Xu X, Qian Y, Liang G, Yao F, et al. PARP1 suppresses the transcription of PD-L1 by Poly(ADP-Ribosyl)ating STAT3. Cancer Immunol Res. 2019;7:136&#x02013;49. 10.1158/2326-6066.CIR-18-0071.<pub-id pub-id-type="pmid">30401677</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR213"><label>213.</label><citation-alternatives><element-citation id="ec-CR213" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Sun</surname><given-names>K</given-names></name><name><surname>Xiao</surname><given-names>Y</given-names></name><name><surname>Feng</surname><given-names>B</given-names></name><name><surname>Mikule</surname><given-names>K</given-names></name><name><surname>Ma</surname><given-names>X</given-names></name><etal/></person-group><article-title>Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models</article-title><source>Sci Rep</source><year>2019</year><volume>9</volume><fpage>1853</fpage><pub-id pub-id-type="doi">10.1038/s41598-019-38534-6</pub-id><pub-id pub-id-type="pmid">30755715</pub-id>
</element-citation><mixed-citation id="mc-CR213" publication-type="journal">Wang Z, Sun K, Xiao Y, Feng B, Mikule K, Ma X, et al. Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models. Sci Rep. 2019;9:1853. 10.1038/s41598-019-38534-6.<pub-id pub-id-type="pmid">30755715</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR214"><label>214.</label><citation-alternatives><element-citation id="ec-CR214" publication-type="journal"><person-group person-group-type="author"><name><surname>Parkes</surname><given-names>EE</given-names></name><name><surname>Walker</surname><given-names>SM</given-names></name><name><surname>Taggart</surname><given-names>LE</given-names></name><name><surname>McCabe</surname><given-names>N</given-names></name><name><surname>Knight</surname><given-names>LA</given-names></name><name><surname>Wilkinson</surname><given-names>R</given-names></name><etal/></person-group><article-title>Activation of STING-dependent innate immune signaling by S-phase-specific DNA damage in breast cancer</article-title><source>J Natl Cancer Inst</source><year>2017</year><volume>109</volume><fpage>djw199</fpage><pub-id pub-id-type="doi">10.1093/jnci/djw199</pub-id><pub-id pub-id-type="pmid">27707838</pub-id>
</element-citation><mixed-citation id="mc-CR214" publication-type="journal">Parkes EE, Walker SM, Taggart LE, McCabe N, Knight LA, Wilkinson R, et al. Activation of STING-dependent innate immune signaling by S-phase-specific DNA damage in breast cancer. J Natl Cancer Inst. 2017;109:djw199. 10.1093/jnci/djw199.<pub-id pub-id-type="pmid">27707838</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR215"><label>215.</label><mixed-citation publication-type="other">Masuda C, Onishi S, Yorozu K, Kurasawa M, Morinaga M, Wakita D, et al. PD-L1 and VEGF dual blockade enhances anti-tumor effect on brain metastasis in hematogenous metastasis model. Clin Exp Metastasis. 2024. 10.1007/s10585-024-10309-y.</mixed-citation></ref><ref id="CR216"><label>216.</label><citation-alternatives><element-citation id="ec-CR216" publication-type="journal"><person-group person-group-type="author"><name><surname>Fu</surname><given-names>M</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Sheng</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Qiu</surname><given-names>F</given-names></name><etal/></person-group><article-title>Overcoming tyrosine kinase inhibitor resistance in lung cancer brain metastasis with CTLA4 blockade</article-title><source>Cancer Cell</source><year>2024</year><volume>42</volume><fpage>1882</fpage><lpage>97 e7</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2024.09.012</pub-id><pub-id pub-id-type="pmid">39423817</pub-id>
</element-citation><mixed-citation id="mc-CR216" publication-type="journal">Fu M, Zhao J, Zhang L, Sheng Z, Li X, Qiu F, et al. Overcoming tyrosine kinase inhibitor resistance in lung cancer brain metastasis with CTLA4 blockade. Cancer Cell. 2024;42:1882-97 e7. 10.1016/j.ccell.2024.09.012.<pub-id pub-id-type="pmid">39423817</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR217"><label>217.</label><citation-alternatives><element-citation id="ec-CR217" publication-type="journal"><person-group person-group-type="author"><name><surname>Ferraro</surname><given-names>GB</given-names></name><name><surname>Ali</surname><given-names>A</given-names></name><name><surname>Luengo</surname><given-names>A</given-names></name><name><surname>Kodack</surname><given-names>DP</given-names></name><name><surname>Deik</surname><given-names>A</given-names></name><name><surname>Abbott</surname><given-names>KL</given-names></name><etal/></person-group><article-title>Fatty acid synthesis is required for breast cancer brain metastasis</article-title><source>Nat Cancer</source><year>2021</year><volume>2</volume><fpage>414</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1038/s43018-021-00183-y</pub-id><pub-id pub-id-type="pmid">34179825</pub-id>
</element-citation><mixed-citation id="mc-CR217" publication-type="journal">Ferraro GB, Ali A, Luengo A, Kodack DP, Deik A, Abbott KL, et al. Fatty acid synthesis is required for breast cancer brain metastasis. Nat Cancer. 2021;2:414&#x02013;28. 10.1038/s43018-021-00183-y.<pub-id pub-id-type="pmid">34179825</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR218"><label>218.</label><citation-alternatives><element-citation id="ec-CR218" publication-type="journal"><person-group person-group-type="author"><name><surname>Arrieta</surname><given-names>O</given-names></name><name><surname>Barron</surname><given-names>F</given-names></name><name><surname>Padilla</surname><given-names>MS</given-names></name><name><surname>Aviles-Salas</surname><given-names>A</given-names></name><name><surname>Ramirez-Tirado</surname><given-names>LA</given-names></name><name><surname>Arguelles Jimenez</surname><given-names>MJ</given-names></name><etal/></person-group><article-title>Effect of metformin plus tyrosine kinase inhibitors compared with tyrosine kinase inhibitors alone in patients with epidermal growth factor receptor-mutated lung adenocarcinoma: a phase 2 randomized clinical trial</article-title><source>JAMA Oncol</source><year>2019</year><volume>5</volume><fpage>e192553</fpage><pub-id pub-id-type="doi">10.1001/jamaoncol.2019.2553</pub-id><pub-id pub-id-type="pmid">31486833</pub-id>
</element-citation><mixed-citation id="mc-CR218" publication-type="journal">Arrieta O, Barron F, Padilla MS, Aviles-Salas A, Ramirez-Tirado LA, Arguelles Jimenez MJ, et al. Effect of metformin plus tyrosine kinase inhibitors compared with tyrosine kinase inhibitors alone in patients with epidermal growth factor receptor-mutated lung adenocarcinoma: a phase 2 randomized clinical trial. JAMA Oncol. 2019;5:e192553. 10.1001/jamaoncol.2019.2553.<pub-id pub-id-type="pmid">31486833</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR219"><label>219.</label><citation-alternatives><element-citation id="ec-CR219" publication-type="journal"><person-group person-group-type="author"><name><surname>Dalton</surname><given-names>KM</given-names></name><name><surname>Lochmann</surname><given-names>TL</given-names></name><name><surname>Floros</surname><given-names>KV</given-names></name><name><surname>Calbert</surname><given-names>ML</given-names></name><name><surname>Kurupi</surname><given-names>R</given-names></name><name><surname>Stein</surname><given-names>GT</given-names></name><etal/></person-group><article-title>Catastrophic ATP loss underlies a metabolic combination therapy tailored for MYCN-amplified neuroblastoma</article-title><source>Proc Natl Acad Sci U S A</source><year>2021</year><volume>118</volume><fpage>20</fpage><lpage>e2009620118</lpage><pub-id pub-id-type="doi">10.1073/pnas.2009620118</pub-id></element-citation><mixed-citation id="mc-CR219" publication-type="journal">Dalton KM, Lochmann TL, Floros KV, Calbert ML, Kurupi R, Stein GT, et al. Catastrophic ATP loss underlies a metabolic combination therapy tailored for MYCN-amplified neuroblastoma. Proc Natl Acad Sci U S A. 2021;118:20-e2009620118. 10.1073/pnas.2009620118.</mixed-citation></citation-alternatives></ref><ref id="CR220"><label>220.</label><citation-alternatives><element-citation id="ec-CR220" publication-type="journal"><person-group person-group-type="author"><name><surname>Fischer</surname><given-names>GM</given-names></name><name><surname>Jalali</surname><given-names>A</given-names></name><name><surname>Kircher</surname><given-names>DA</given-names></name><name><surname>Lee</surname><given-names>WC</given-names></name><name><surname>McQuade</surname><given-names>JL</given-names></name><name><surname>Haydu</surname><given-names>LE</given-names></name><etal/></person-group><article-title>Molecular profiling reveals unique immune and metabolic features of melanoma brain metastases</article-title><source>Cancer Discov</source><year>2019</year><volume>9</volume><fpage>628</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-18-1489</pub-id><pub-id pub-id-type="pmid">30787016</pub-id>
</element-citation><mixed-citation id="mc-CR220" publication-type="journal">Fischer GM, Jalali A, Kircher DA, Lee WC, McQuade JL, Haydu LE, et al. Molecular profiling reveals unique immune and metabolic features of melanoma brain metastases. Cancer Discov. 2019;9:628&#x02013;45. 10.1158/2159-8290.CD-18-1489.<pub-id pub-id-type="pmid">30787016</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR221"><label>221.</label><citation-alternatives><element-citation id="ec-CR221" publication-type="journal"><person-group person-group-type="author"><name><surname>Marin-Valencia</surname><given-names>I</given-names></name><name><surname>Yang</surname><given-names>C</given-names></name><name><surname>Mashimo</surname><given-names>T</given-names></name><name><surname>Cho</surname><given-names>S</given-names></name><name><surname>Baek</surname><given-names>H</given-names></name><name><surname>Yang</surname><given-names>XL</given-names></name><etal/></person-group><article-title>Analysis of tumor metabolism reveals mitochondrial glucose oxidation in genetically diverse human glioblastomas in the mouse brain in vivo</article-title><source>Cell Metab</source><year>2012</year><volume>15</volume><fpage>827</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2012.05.001</pub-id><pub-id pub-id-type="pmid">22682223</pub-id>
</element-citation><mixed-citation id="mc-CR221" publication-type="journal">Marin-Valencia I, Yang C, Mashimo T, Cho S, Baek H, Yang XL, et al. Analysis of tumor metabolism reveals mitochondrial glucose oxidation in genetically diverse human glioblastomas in the mouse brain in vivo. Cell Metab. 2012;15:827&#x02013;37. 10.1016/j.cmet.2012.05.001.<pub-id pub-id-type="pmid">22682223</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR222"><label>222.</label><citation-alternatives><element-citation id="ec-CR222" publication-type="journal"><person-group person-group-type="author"><name><surname>Bonnet</surname><given-names>S</given-names></name><name><surname>Archer</surname><given-names>SL</given-names></name><name><surname>Allalunis-Turner</surname><given-names>J</given-names></name><name><surname>Haromy</surname><given-names>A</given-names></name><name><surname>Beaulieu</surname><given-names>C</given-names></name><name><surname>Thompson</surname><given-names>R</given-names></name><etal/></person-group><article-title>A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth</article-title><source>Cancer Cell</source><year>2007</year><volume>11</volume><fpage>37</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2006.10.020</pub-id><pub-id pub-id-type="pmid">17222789</pub-id>
</element-citation><mixed-citation id="mc-CR222" publication-type="journal">Bonnet S, Archer SL, Allalunis-Turner J, Haromy A, Beaulieu C, Thompson R, et al. A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell. 2007;11:37&#x02013;51. 10.1016/j.ccr.2006.10.020.<pub-id pub-id-type="pmid">17222789</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR223"><label>223.</label><citation-alternatives><element-citation id="ec-CR223" publication-type="journal"><person-group person-group-type="author"><name><surname>Stacpoole</surname><given-names>PW</given-names></name><name><surname>Kerr</surname><given-names>DS</given-names></name><name><surname>Barnes</surname><given-names>C</given-names></name><name><surname>Bunch</surname><given-names>ST</given-names></name><name><surname>Carney</surname><given-names>PR</given-names></name><name><surname>Fennell</surname><given-names>EM</given-names></name><etal/></person-group><article-title>Controlled clinical trial of dichloroacetate for treatment of congenital lactic acidosis in children</article-title><source>Pediatrics</source><year>2006</year><volume>117</volume><fpage>1519</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1542/peds.2005-1226</pub-id><pub-id pub-id-type="pmid">16651305</pub-id>
</element-citation><mixed-citation id="mc-CR223" publication-type="journal">Stacpoole PW, Kerr DS, Barnes C, Bunch ST, Carney PR, Fennell EM, et al. Controlled clinical trial of dichloroacetate for treatment of congenital lactic acidosis in children. Pediatrics. 2006;117:1519&#x02013;31. 10.1542/peds.2005-1226.<pub-id pub-id-type="pmid">16651305</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR224"><label>224.</label><citation-alternatives><element-citation id="ec-CR224" publication-type="journal"><person-group person-group-type="author"><name><surname>Kinnaird</surname><given-names>A</given-names></name><name><surname>Dromparis</surname><given-names>P</given-names></name><name><surname>Saleme</surname><given-names>B</given-names></name><name><surname>Gurtu</surname><given-names>V</given-names></name><name><surname>Watson</surname><given-names>K</given-names></name><name><surname>Paulin</surname><given-names>R</given-names></name><etal/></person-group><article-title>Metabolic modulation of clear-cell renal cell carcinoma with dichloroacetate, an inhibitor of pyruvate dehydrogenase kinase</article-title><source>Eur Urol</source><year>2016</year><volume>69</volume><fpage>734</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1016/j.eururo.2015.09.014</pub-id><pub-id pub-id-type="pmid">26433571</pub-id>
</element-citation><mixed-citation id="mc-CR224" publication-type="journal">Kinnaird A, Dromparis P, Saleme B, Gurtu V, Watson K, Paulin R, et al. Metabolic modulation of clear-cell renal cell carcinoma with dichloroacetate, an inhibitor of pyruvate dehydrogenase kinase. Eur Urol. 2016;69:734&#x02013;44. 10.1016/j.eururo.2015.09.014.<pub-id pub-id-type="pmid">26433571</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR225"><label>225.</label><citation-alternatives><element-citation id="ec-CR225" publication-type="journal"><person-group person-group-type="author"><name><surname>Preusser</surname><given-names>M</given-names></name><name><surname>Winkler</surname><given-names>F</given-names></name><name><surname>Valiente</surname><given-names>M</given-names></name><name><surname>Manegold</surname><given-names>C</given-names></name><name><surname>Moyal</surname><given-names>E</given-names></name><name><surname>Widhalm</surname><given-names>G</given-names></name><etal/></person-group><article-title>Recent advances in the biology and treatment of brain metastases of non-small cell lung cancer: summary of a multidisciplinary roundtable discussion</article-title><source>ESMO Open</source><year>2018</year><volume>3</volume><fpage>e000262</fpage><pub-id pub-id-type="doi">10.1136/esmoopen-2017-000262</pub-id><pub-id pub-id-type="pmid">29387475</pub-id>
</element-citation><mixed-citation id="mc-CR225" publication-type="journal">Preusser M, Winkler F, Valiente M, Manegold C, Moyal E, Widhalm G, et al. Recent advances in the biology and treatment of brain metastases of non-small cell lung cancer: summary of a multidisciplinary roundtable discussion. ESMO Open. 2018;3:e000262. 10.1136/esmoopen-2017-000262.<pub-id pub-id-type="pmid">29387475</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR226"><label>226.</label><citation-alternatives><element-citation id="ec-CR226" publication-type="journal"><person-group person-group-type="author"><name><surname>Bauml</surname><given-names>J</given-names></name><name><surname>Mick</surname><given-names>R</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Watt</surname><given-names>CD</given-names></name><name><surname>Vachani</surname><given-names>A</given-names></name><name><surname>Aggarwal</surname><given-names>C</given-names></name><etal/></person-group><article-title>Frequency of EGFR and KRAS mutations in patients with non small cell lung cancer by racial background: do disparities exist?</article-title><source>Lung Cancer</source><year>2013</year><volume>81</volume><fpage>347</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1016/j.lungcan.2013.05.011</pub-id><pub-id pub-id-type="pmid">23806795</pub-id>
</element-citation><mixed-citation id="mc-CR226" publication-type="journal">Bauml J, Mick R, Zhang Y, Watt CD, Vachani A, Aggarwal C, et al. Frequency of EGFR and KRAS mutations in patients with non small cell lung cancer by racial background: do disparities exist? Lung Cancer. 2013;81:347&#x02013;53. 10.1016/j.lungcan.2013.05.011.<pub-id pub-id-type="pmid">23806795</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR227"><label>227.</label><citation-alternatives><element-citation id="ec-CR227" publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>Y</given-names></name><name><surname>Au</surname><given-names>JS</given-names></name><name><surname>Thongprasert</surname><given-names>S</given-names></name><name><surname>Srinivasan</surname><given-names>S</given-names></name><name><surname>Tsai</surname><given-names>CM</given-names></name><name><surname>Khoa</surname><given-names>MT</given-names></name><etal/></person-group><article-title>A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER)</article-title><source>J Thorac Oncol</source><year>2014</year><volume>9</volume><fpage>154</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.1097/JTO.0000000000000033</pub-id><pub-id pub-id-type="pmid">24419411</pub-id>
</element-citation><mixed-citation id="mc-CR227" publication-type="journal">Shi Y, Au JS, Thongprasert S, Srinivasan S, Tsai CM, Khoa MT, et al. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). J Thorac Oncol. 2014;9:154&#x02013;62. 10.1097/JTO.0000000000000033.<pub-id pub-id-type="pmid">24419411</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR228"><label>228.</label><citation-alternatives><element-citation id="ec-CR228" publication-type="journal"><person-group person-group-type="author"><name><surname>Soda</surname><given-names>M</given-names></name><name><surname>Choi</surname><given-names>YL</given-names></name><name><surname>Enomoto</surname><given-names>M</given-names></name><name><surname>Takada</surname><given-names>S</given-names></name><name><surname>Yamashita</surname><given-names>Y</given-names></name><name><surname>Ishikawa</surname><given-names>S</given-names></name><etal/></person-group><article-title>Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer</article-title><source>Nature</source><year>2007</year><volume>448</volume><fpage>561</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1038/nature05945</pub-id><pub-id pub-id-type="pmid">17625570</pub-id>
</element-citation><mixed-citation id="mc-CR228" publication-type="journal">Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448:561&#x02013;6. 10.1038/nature05945.<pub-id pub-id-type="pmid">17625570</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR229"><label>229.</label><citation-alternatives><element-citation id="ec-CR229" publication-type="journal"><person-group person-group-type="author"><name><surname>Preusser</surname><given-names>M</given-names></name><name><surname>Berghoff</surname><given-names>AS</given-names></name><name><surname>Ilhan-Mutlu</surname><given-names>A</given-names></name><name><surname>Magerle</surname><given-names>M</given-names></name><name><surname>Dinhof</surname><given-names>C</given-names></name><name><surname>Widhalm</surname><given-names>G</given-names></name><etal/></person-group><article-title>ALK gene translocations and amplifications in brain metastases of non-small cell lung cancer</article-title><source>Lung Cancer</source><year>2013</year><volume>80</volume><fpage>278</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1016/j.lungcan.2013.01.019</pub-id><pub-id pub-id-type="pmid">23453647</pub-id>
</element-citation><mixed-citation id="mc-CR229" publication-type="journal">Preusser M, Berghoff AS, Ilhan-Mutlu A, Magerle M, Dinhof C, Widhalm G, et al. ALK gene translocations and amplifications in brain metastases of non-small cell lung cancer. Lung Cancer. 2013;80:278&#x02013;83. 10.1016/j.lungcan.2013.01.019.<pub-id pub-id-type="pmid">23453647</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR230"><label>230.</label><citation-alternatives><element-citation id="ec-CR230" publication-type="journal"><person-group person-group-type="author"><name><surname>Novello</surname><given-names>S</given-names></name><name><surname>Mazieres</surname><given-names>J</given-names></name><name><surname>Oh</surname><given-names>IJ</given-names></name><name><surname>de Castro</surname><given-names>J</given-names></name><name><surname>Migliorino</surname><given-names>MR</given-names></name><name><surname>Helland</surname><given-names>A</given-names></name><etal/></person-group><article-title>Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study</article-title><source>Ann Oncol</source><year>2018</year><volume>29</volume><fpage>1409</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdy121</pub-id><pub-id pub-id-type="pmid">29668860</pub-id>
</element-citation><mixed-citation id="mc-CR230" publication-type="journal">Novello S, Mazieres J, Oh IJ, de Castro J, Migliorino MR, Helland A, et al. Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study. Ann Oncol. 2018;29:1409&#x02013;16. 10.1093/annonc/mdy121.<pub-id pub-id-type="pmid">29668860</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR231"><label>231.</label><citation-alternatives><element-citation id="ec-CR231" publication-type="journal"><person-group person-group-type="author"><name><surname>Solomon</surname><given-names>BJ</given-names></name><name><surname>Besse</surname><given-names>B</given-names></name><name><surname>Bauer</surname><given-names>TM</given-names></name><name><surname>Felip</surname><given-names>E</given-names></name><name><surname>Soo</surname><given-names>RA</given-names></name><name><surname>Camidge</surname><given-names>DR</given-names></name><etal/></person-group><article-title>Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study</article-title><source>Lancet Oncol</source><year>2018</year><volume>19</volume><fpage>1654</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(18)30649-1</pub-id><pub-id pub-id-type="pmid">30413378</pub-id>
</element-citation><mixed-citation id="mc-CR231" publication-type="journal">Solomon BJ, Besse B, Bauer TM, Felip E, Soo RA, Camidge DR, et al. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. Lancet Oncol. 2018;19:1654&#x02013;67. 10.1016/S1470-2045(18)30649-1.<pub-id pub-id-type="pmid">30413378</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR232"><label>232.</label><citation-alternatives><element-citation id="ec-CR232" publication-type="journal"><person-group person-group-type="author"><name><surname>Camidge</surname><given-names>DR</given-names></name><name><surname>Kim</surname><given-names>HR</given-names></name><name><surname>Ahn</surname><given-names>MJ</given-names></name><name><surname>Yang</surname><given-names>JC</given-names></name><name><surname>Han</surname><given-names>JY</given-names></name><name><surname>Lee</surname><given-names>JS</given-names></name><etal/></person-group><article-title>Brigatinib versus Crizotinib in ALK-positive non-small-cell lung cancer</article-title><source>N Engl J Med</source><year>2018</year><volume>379</volume><fpage>2027</fpage><lpage>39</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1810171</pub-id><pub-id pub-id-type="pmid">30280657</pub-id>
</element-citation><mixed-citation id="mc-CR232" publication-type="journal">Camidge DR, Kim HR, Ahn MJ, Yang JC, Han JY, Lee JS, et al. Brigatinib versus Crizotinib in ALK-positive non-small-cell lung cancer. N Engl J Med. 2018;379:2027&#x02013;39. 10.1056/NEJMoa1810171.<pub-id pub-id-type="pmid">30280657</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR233"><label>233.</label><citation-alternatives><element-citation id="ec-CR233" publication-type="journal"><person-group person-group-type="author"><name><surname>Chiari</surname><given-names>R</given-names></name><name><surname>Buttitta</surname><given-names>F</given-names></name><name><surname>Iacono</surname><given-names>D</given-names></name><name><surname>Bennati</surname><given-names>C</given-names></name><name><surname>Metro</surname><given-names>G</given-names></name><name><surname>Di Lorito</surname><given-names>A</given-names></name><etal/></person-group><article-title>Dramatic response to crizotinib in ROS1 fluorescent in situ hybridization- and immunohistochemistry-positive lung adenocarcinoma: a case series</article-title><source>Clin Lung Cancer</source><year>2014</year><volume>15</volume><fpage>470</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.1016/j.cllc.2014.06.004</pub-id><pub-id pub-id-type="pmid">25087901</pub-id>
</element-citation><mixed-citation id="mc-CR233" publication-type="journal">Chiari R, Buttitta F, Iacono D, Bennati C, Metro G, Di Lorito A, et al. Dramatic response to crizotinib in ROS1 fluorescent in situ hybridization- and immunohistochemistry-positive lung adenocarcinoma: a case series. Clin Lung Cancer. 2014;15:470&#x02013;4. 10.1016/j.cllc.2014.06.004.<pub-id pub-id-type="pmid">25087901</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR234"><label>234.</label><citation-alternatives><element-citation id="ec-CR234" publication-type="journal"><person-group person-group-type="author"><name><surname>Preusser</surname><given-names>M</given-names></name><name><surname>Streubel</surname><given-names>B</given-names></name><name><surname>Birner</surname><given-names>P</given-names></name></person-group><article-title>ROS1 translocations and amplifications in lung cancer brain metastases</article-title><source>J Neurooncol</source><year>2014</year><volume>118</volume><fpage>425</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1007/s11060-014-1446-x</pub-id><pub-id pub-id-type="pmid">24760415</pub-id>
</element-citation><mixed-citation id="mc-CR234" publication-type="journal">Preusser M, Streubel B, Birner P. ROS1 translocations and amplifications in lung cancer brain metastases. J Neurooncol. 2014;118:425&#x02013;6. 10.1007/s11060-014-1446-x.<pub-id pub-id-type="pmid">24760415</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR235"><label>235.</label><citation-alternatives><element-citation id="ec-CR235" publication-type="journal"><person-group person-group-type="author"><name><surname>Baschnagel</surname><given-names>AM</given-names></name><name><surname>Kaushik</surname><given-names>S</given-names></name><name><surname>Durmaz</surname><given-names>A</given-names></name><name><surname>Goldstein</surname><given-names>S</given-names></name><name><surname>Ong</surname><given-names>IM</given-names></name><name><surname>Abel</surname><given-names>L</given-names></name><etal/></person-group><article-title>Development and characterization of patient-derived xenografts from non-small cell lung cancer brain metastases</article-title><source>Sci Rep</source><year>2021</year><volume>11</volume><fpage>2520</fpage><pub-id pub-id-type="doi">10.1038/s41598-021-81832-1</pub-id><pub-id pub-id-type="pmid">33510214</pub-id>
</element-citation><mixed-citation id="mc-CR235" publication-type="journal">Baschnagel AM, Kaushik S, Durmaz A, Goldstein S, Ong IM, Abel L, et al. Development and characterization of patient-derived xenografts from non-small cell lung cancer brain metastases. Sci Rep. 2021;11:2520. 10.1038/s41598-021-81832-1.<pub-id pub-id-type="pmid">33510214</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR236"><label>236.</label><citation-alternatives><element-citation id="ec-CR236" publication-type="journal"><person-group person-group-type="author"><name><surname>Friese-Hamim</surname><given-names>M</given-names></name><name><surname>Clark</surname><given-names>A</given-names></name><name><surname>Perrin</surname><given-names>D</given-names></name><name><surname>Crowley</surname><given-names>L</given-names></name><name><surname>Reusch</surname><given-names>C</given-names></name><name><surname>Bogatyrova</surname><given-names>O</given-names></name><etal/></person-group><article-title>Brain penetration and efficacy of tepotinib in orthotopic patient-derived xenograft models of MET-driven non-small cell lung cancer brain metastases</article-title><source>Lung Cancer</source><year>2022</year><volume>163</volume><fpage>77</fpage><lpage>86</lpage><pub-id pub-id-type="doi">10.1016/j.lungcan.2021.11.020</pub-id><pub-id pub-id-type="pmid">34942492</pub-id>
</element-citation><mixed-citation id="mc-CR236" publication-type="journal">Friese-Hamim M, Clark A, Perrin D, Crowley L, Reusch C, Bogatyrova O, et al. Brain penetration and efficacy of tepotinib in orthotopic patient-derived xenograft models of MET-driven non-small cell lung cancer brain metastases. Lung Cancer. 2022;163:77&#x02013;86. 10.1016/j.lungcan.2021.11.020.<pub-id pub-id-type="pmid">34942492</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR237"><label>237.</label><citation-alternatives><element-citation id="ec-CR237" publication-type="journal"><person-group person-group-type="author"><name><surname>Guillen</surname><given-names>KP</given-names></name><name><surname>Fujita</surname><given-names>M</given-names></name><name><surname>Butterfield</surname><given-names>AJ</given-names></name><name><surname>Scherer</surname><given-names>SD</given-names></name><name><surname>Bailey</surname><given-names>MH</given-names></name><name><surname>Chu</surname><given-names>Z</given-names></name><etal/></person-group><article-title>A human breast cancer-derived xenograft and organoid platform for drug discovery and precision oncology</article-title><source>Nat Cancer</source><year>2022</year><volume>3</volume><fpage>232</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1038/s43018-022-00337-6</pub-id><pub-id pub-id-type="pmid">35221336</pub-id>
</element-citation><mixed-citation id="mc-CR237" publication-type="journal">Guillen KP, Fujita M, Butterfield AJ, Scherer SD, Bailey MH, Chu Z, et al. A human breast cancer-derived xenograft and organoid platform for drug discovery and precision oncology. Nat Cancer. 2022;3:232&#x02013;50. 10.1038/s43018-022-00337-6.<pub-id pub-id-type="pmid">35221336</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR238"><label>238.</label><citation-alternatives><element-citation id="ec-CR238" publication-type="journal"><person-group person-group-type="author"><name><surname>Faria</surname><given-names>CC</given-names></name><name><surname>Cascao</surname><given-names>R</given-names></name><name><surname>Custodia</surname><given-names>C</given-names></name><name><surname>Paisana</surname><given-names>E</given-names></name><name><surname>Carvalho</surname><given-names>T</given-names></name><name><surname>Pereira</surname><given-names>P</given-names></name><etal/></person-group><article-title>Patient-derived models of brain metastases recapitulate human disseminated disease</article-title><source>Cell Rep Med</source><year>2022</year><volume>3</volume><fpage>100623</fpage><pub-id pub-id-type="doi">10.1016/j.xcrm.2022.100623</pub-id><pub-id pub-id-type="pmid">35584628</pub-id>
</element-citation><mixed-citation id="mc-CR238" publication-type="journal">Faria CC, Cascao R, Custodia C, Paisana E, Carvalho T, Pereira P, et al. Patient-derived models of brain metastases recapitulate human disseminated disease. Cell Rep Med. 2022;3:100623. 10.1016/j.xcrm.2022.100623.<pub-id pub-id-type="pmid">35584628</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR239"><label>239.</label><citation-alternatives><element-citation id="ec-CR239" publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>H</given-names></name><name><surname>Cao</surname><given-names>S</given-names></name><name><surname>Mashl</surname><given-names>RJ</given-names></name><name><surname>Mo</surname><given-names>CK</given-names></name><name><surname>Zaccaria</surname><given-names>S</given-names></name><name><surname>Wendl</surname><given-names>MC</given-names></name><etal/></person-group><article-title>Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidatesfor targeted treatment</article-title><source>Nat Commun</source><year>2021</year><volume>12</volume><fpage>5086</fpage><pub-id pub-id-type="doi">10.1038/s41467-021-25177-3</pub-id><pub-id pub-id-type="pmid">34429404</pub-id>
</element-citation><mixed-citation id="mc-CR239" publication-type="journal">Sun H, Cao S, Mashl RJ, Mo CK, Zaccaria S, Wendl MC, et al. Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidatesfor targeted treatment. Nat Commun. 2021;12:5086. 10.1038/s41467-021-25177-3.<pub-id pub-id-type="pmid">34429404</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR240"><label>240.</label><citation-alternatives><element-citation id="ec-CR240" publication-type="journal"><person-group person-group-type="author"><name><surname>Nadal</surname><given-names>E</given-names></name><name><surname>Rodriguez-Abreu</surname><given-names>D</given-names></name><name><surname>Simo</surname><given-names>M</given-names></name><name><surname>Massuti</surname><given-names>B</given-names></name><name><surname>Juan</surname><given-names>O</given-names></name><name><surname>Huidobro</surname><given-names>G</given-names></name><etal/></person-group><article-title>Phase II trial of Atezolizumab combined with carboplatin and pemetrexed for patients with advanced nonsquamous non-small-cell lung cancer with untreated brain metastases (Atezo-Brain, GECP17/05)</article-title><source>J Clin Oncol</source><year>2023</year><volume>41</volume><fpage>4478</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.1200/JCO.22.02561</pub-id><pub-id pub-id-type="pmid">37603816</pub-id>
</element-citation><mixed-citation id="mc-CR240" publication-type="journal">Nadal E, Rodriguez-Abreu D, Simo M, Massuti B, Juan O, Huidobro G, et al. Phase II trial of Atezolizumab combined with carboplatin and pemetrexed for patients with advanced nonsquamous non-small-cell lung cancer with untreated brain metastases (Atezo-Brain, GECP17/05). J Clin Oncol. 2023;41:4478&#x02013;85. 10.1200/JCO.22.02561.<pub-id pub-id-type="pmid">37603816</pub-id>
</mixed-citation></citation-alternatives></ref></ref-list></back></article>